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Red blood cells are the most numerous cell in the body, and clinical measures used to 
describe them (RBC traits) are highly polygenic. Hundreds of loci have been identified using 
traditional genome-wide association study methods. However, the majority of association studies 
have been performed in European- or East Asian-ancestry populations, and heritability estimates 
suggest that additional associations remain to be identified. Rare variants, which GWAS are 
typically underpowered to detect, have been considered as potential contributors to this missing 
heritability. Of note, European-ancestry populations have both the lowest genetic diversity and 
the fewest rare variants compared to other ancestry groups. 
Both the identification of previously unreported loci and the characterization of known 
loci for complex quantitative traits benefit from inclusive study populations and recently 
developed association study methods. The objective of this study was to evaluate genetic 
associations with seven RBC traits in an ancestrally diverse study population by applying two 
different methods—a combined-phenotype approach to evaluating common variants that may 
affect multiple RBC traits, and a gene-based approach that improves power to detect groups of 
rare variants acting on a single genetic transcript. We utilized data from a large, multi-ethnic 
study population from across the United States, including genotypes and data from seven RBC 
traits: hematocrit, hemoglobin concentration, mean corpuscular hemoglobin, mean corpuscular 
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hemoglobin concentration, mean corpuscular volume, red blood cell count, and red cell 
distribution width. 
Our findings confirm the high polygenicity of RBC traits and the applicability of 
previously reported RBC trait loci to populations of all ancestries. We identified four previously 
unreported genes associated with one or more RBC traits. Additionally, using a combined-
phenotype method we identified twenty independent association signals within seven loci, 
several of which had lead variants only present in African- or American-ancestry populations. 
Our work shows the importance of performing association studies in populations of all 
ancestries, while also calling for increased representation of genetic variation from diverse 
populations in publicly available resources such as eQTL databases. Continued efforts into the 
bioinformatic characterization of RBC trait loci will pave the way for molecular work that 
improves our understanding of RBC physiology and may lead to pharmaceutical innovations for 
genetically or environmentally induced RBC disorders.
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SPTA1  Spectrin, alpha, erythrocytic 1 
SPTB  Spectrin, beta, erythrocytic 
STX11  Syntaxin 11 
STXBP2 STX-binding protein 2 
TF  Transferrin 
TFR2  Transferrin receptor 2 
TRFC  Transferrin receptor 
THRB  Thyroid hormone receptor beta 
TMPRSS6 Transmembrane protease, serine 6 
UNC13D UNC13 homolog D (C. elegans) 
UROD  Uroporphyrinogen decarboxylase 






 OVERVIEW AND RATIONALE 
 
Red blood cell (RBC) traits capture the molecular properties of red blood cells, which are 
required to transport oxygen to tissues throughout the body. RBC traits are complex, quantitative 
measures obtained from a complete blood count (CBC), including three primary traits—
hematocrit (HCT), hemoglobin (HGB), and RBC count—and four derived indices—mean 
corpuscular hemoglobin (MCH), MCH concentration (MCHC), mean corpuscular volume 
(MCV), and RBC distribution width (RDW). In combination, these correlated traits are used to 
describe RBC physiology and diagnose RBC disorders. Additionally, population-level variation 
in these traits has been associated with a wide array of diseases, ranging from chronic kidney 
disease to autoimmune disorders1-14.  
RBC traits are quantitative and tightly regulated, suggesting that a high number of genes 
contribute to each trait. A large body of literature has identified and characterized RBC trait-
associated genes over the past several decades, particularly in the genome-wide association 
studies (GWAS) era. Several hundred loci have been identified through genetic-association 
studies; however, effects from these loci explain only a small proportion of the broad-sense 
variability expected to be attributed to genetics (referred to as "heritability" or h2)15-31.  
Several factors contribute to the fact that genetic loci very likely remain to be discovered, 
which will be examined in the proposed work. First, RBC trait GWAS have included primarily 
European- and East Asian-ancestry populations, creating a biased view of human variation 




are globally rare or population-specific; furthermore, inclusion of ancestrally diverse study 
populations is necessary for equitable genomics research 32-40.  
Second, previous RBC GWAS have examined RBC traits separately despite evidence of 
shared molecular pathways, common genetic underpinnings, and statistical innovations enabling 
examination of multiple traits in aggregate. For example, several loci have been consistently 
associated with multiple RBC traits in GWAS—including HBS1L/MYB, PRKCE, and RCL1—
suggesting that studies that leverage evidence of correlation between RBC traits to increase 
statistical power may help identify additional novel loci. Such “combined phenotype” studies are 
enabled by statistical and genomic developments, as well as the improved assessment of genetic 
variation in racial/ethnic minority populations. Together, these suggest that the time is right to 
perform a combined-phenotype examination of RBC traits34; 41; 42. 
Finally, improved coverage of rare variants via innovations in imputation and genome 
measurement, as well as a vast array of functional annotations, are now available facilitate fine-
mapping and functional characterization of RBC trait association signals. Diverse populations 
are also more likely to have an increased quantity of rare variants when compared with European 
populations. The interrogation of rare variants in a large study population, particularly one 
exhibiting ancestral diversity, may thus be beneficial in identifying additional novel loci that are 
relevant for RBC traits across all ancestries, as has been demonstrated in rare-variant studies of 
other complex traits43-48.  
Innovative, recently developed methods and the availability of GWAS and phenotype 
data in the large, ancestrally diverse Population Architecture Using Genomics in Epidemiology 
(PAGE) consortium uniquely position us to detect and characterize RBC trait genetic 




participants. Continued identification of such associations can help clarify the genetic 
architecture of RBC traits and elucidate mechanisms of RBC trait biology. An improved 
understanding of the suite of genes contributing to RBC traits will benefit both basic science and 
translational research as they pertain to blood diseases as well as phenotypes strongly associated 





 SPECIFIC AIMS 
 
2.1. Aim 1: Leverage evidence of pleiotropy to identify and characterize RBC trait loci. 
Aim 1a. Estimate trans-ethnic and ancestry-specific univariate genome-wide genetic 
associations in approximately 68,000 African American, European American, and 
Hispanic/Latino PAGE participants between approximately 25 million variants (effective 
heterozygosity >35 by study population) and seven RBC traits (HCT, HGB, RBCC, RDW, 
MCH, MCHC, and MCV) using SUGEN software.  
Aim 1b. Using summary statistics from Aim 1a, apply the adaptive sum of powered score 
(aSPU) test, which integrates evidence of association across multiple correlated traits, to identify 
potentially pleiotropic loci.  
Aim 1c. Using summary statistics from Aim 1a, perform iterative conditional analysis, 
which will identify independent leads SNPs within association signals and determine the 
presence of secondary signals, i.e., physically proximal or overlapping association signals with 
independent index variants. Sensitivity analyses will be performed by race-ethnicity at multi-
ethnic combined-phenotype lead SNPs. 
Aim 1d. Annotate (novel and previously identified) association signals from Aim 1a and 
1b using the ENCODE Variant Expression Predictor (VEP) and GTEx eQTL database to assess 
potential functional significance of candidate variants. 
2.2. Aim 2: Identify rare variants associated with RBC traits via gene-based analysis. 




American, Asian American, and Native American MEGA-genotyped PAGE Study participants, 
perform univariate gene-based testing using SKAT-O—a combined burden and variance-
component test—for approximately 25,000 genes in each of seven RBC traits (HCT, HGB, 
RBCC, RDW, MCH, MCHC, and MCV).  
Aim 2b. Annotate the ontology of candidate genes identified in Aim 2a using publicly 
available databases to determine biological pathways that are well-represented among genome-
wide-significant (GWS, Bonferroni-corrected alpha = 2.87x10-7) findings for one or more RBC 
traits. 
Aim 2c. Annotate the most significant variant for each significant transcript identified in 
Aim 2c using publicly available databases—including VEP and Blueprint—to identify globally 





 BACKGROUND AND SIGNIFICANCE 
 
3.1. Historical background  
Red blood cells have been recognized as a crucial contributor to human physiology for 
millennia: as far back as 3000 BCE, Egyptian physicians were cognizant of the connection 
between the heart and circulatory system, although the physiologic functions of this system were 
not elucidated until much later49-52. From the medical practices of ancient Greek and Islamic 
physicians through the European Middle Ages, blood was considered one of the four primary 
“humors” and the main contributor to the “sanguine temperament”—concordantly, blood-letting 
was a common treatment for disease states associated with "excessive blood humor", such as 
insanity, heart and vascular disease, and menstrual disorders53-55. Although the concept of 
humors fell out of favor in medicine during the 19th century (upon the acceptance of Virchow’s 
cell theory and, subsequently, germ theory), the practice of blood-letting remained widespread in 
the Western world into the 20th century56-60. When the discovery was made in the mid-17th 
century that all living organisms comprised one or more cells, red blood cells were among the 
earliest to be characterized given their ready availability from human and animal subjects60. By 
the mid-20th century, the importance of hemoglobin—the RBC-specific protein responsible for 
the oxygenation of all bodily tissues—was recognized as contributing to several prevalent 
monogenic hereditary anemias (see Table 1)61-65. In current medical practice, a complete blood 




states, and can also be employed alongside other signs and symptoms in determining the 
underlying cause of a wide variety of diseases66-74.  
 
3.2. Red blood cell biology 
The primary function of RBCs is to transport oxygen from the lungs to tissues throughout 
the body. In mammals, RBCs absorb oxygen at the interface of alveoli in the lungs and 
pulmonary vessels; oxygen is then delivered by RBCs to tissues throughout the body as blood is 
pumped through the vasculature. The average RBC makes over a thousand journeys per day 
through the heart to deliver oxygen to peripheral tissues. Another task delegated to RBCs is to 
clear toxic or waste materials from tissues via the bloodstream. This primarily involves  
interaction with macrophages in the liver or spleen, in which RBCs release unwanted materials 
through exocytosis for subsequent uptake by the adjacent macrophage75. Given these functions, 
which involve membrane deformation to pass through arterial and venous capillaries, a typical 
enucleated RBC is approximately 1/10 the diameter of a human hair (about 8 microns), with over 
20 trillion RBCs in circulation in an adult human at any given time. As the most numerous cell 
type in the body (similar in number to platelets, which may also be considered cell fragments) 
responsible for oxygenation of all tissues, the maintenance and development of RBCs are tightly 
regulated.  
RBCs begin their journey as multipotent hematopoietic stem cells (HSCs), which are 
located in the bone marrow. HSCs are self-renewing, meaning this population—which is the 
predecessor of every blood cell in the body—is sustained from birth through adulthood via 
mitosis. The HSC lineage is limited to blood-cell types (meaning they cannot differentiate into 




common myeloid progenitor cells. The former differentiate into white blood cells (WBCs), 
whereas the latter may differentiate into several types of white blood cells or the shared early 
progenitor cell for RBCs and megakaryocytes (which are the precursor cell that become 
platelets), appropriately designated "megakaryocyte/erythrocyte progenitors" (MEPs). Up to two 
million RBCs are degraded every second; hence, a similar number of progenitor cells need to be 
generated at the same rate to maintain a sufficient RBC population in the body. Although not the 
subject of this dissertation, 5 to 6 million megakaryocytes originating from the same HSC 
population must also be terminally differentiated each day to maintain the >100 trillion platelets 
circulating in the vasculature at a given time76. In combination, erythropoiesis and 
megakaryopoiesis are extremely demanding, further emphasizing the delicate nature of balancing 
these highly prolific processes. 
3.2.1. Three waves of hematopoiesis 
The establishment of an RBC population begins very early in fetal development and the 
required ubiquity of RBCs for oxygenation of all tissues make understanding the molecular 
underpinnings of any aspect of their development relevant to public health researchers. In utero 
RBC development is very different from the process of RBC differentiation in adults (the latter 
being the focus of this dissertation) with different genetic underpinnings, and will therefore be 
explained here only in brief. The first wave of hematopoiesis comes early in development from 
the primitive streak of mesodermal cells in the yolk sac77. These immature RBCs still contain 
nuclei and are derived from hemangioblasts, which are a shared precursor cells for blood vessel 
tissues and blood cells77. During the second wave of hematopoiesis—beginning late in fetal 
development—erythromyeloid progenitors become the primary progenitor cell from which 




derived. Erythromyeloid progenitors begin in the yolk sac and form colonies similar to those 
formed in the bone marrow in adults.  
The final wave of hematopoiesis involved emergence of HSCs from the haemogenic 
endothelium, located in the dorsal aorta of the aorta-gonad-mesonephros region of the fetus77. 
This population of HSCs migrates to the liver, expands via multiple rounds of mitosis, and 
eventually migrates further into the bone marrow78. Once this population of HSCs reaches the 
bone marrow, the cells become a self-replenishing population from which all RBCs are 
generated throughout the life of the individual77; 79. Because of the limited lifetime supply of 
these cells, their self-renewing nature, and the large number of cell types for which they act as 
the source precursor population, HSCs are susceptible to somatic mutations that can result in 
blood cancers80-82. Thus, to sustain the genomic integrity of this vital population, HSCs not 
actively involved in the cell division process preceding hematopoiesis are typically maintained in 
a quiescent state with minimal transcriptional activity83.  
3.2.2. Hemoglobin: the primary actor in RBC oxygen transportation and delivery 
Before describing stages of erythropoiesis and RBC degradation, we will briefly describe 
the hemoglobin protein, given its critical role in RBC function and tissue oxygenation. 
Hemoglobin is the protein responsible for RBC transportation of oxygen to tissues throughout 
the body and return of cellular toxins to the liver for processing. Hemoglobin was first identified 
by Engelhardt in 1825 and described in terms of chemical composition by Hünefeld in 1840, 
with several other contributors further characterizing this protein in the mid-19th century, 
including describing the structure and function in humans84; 85. In addition to having a strong 
affinity for oxygen, hemoglobin can also bind CO2, allowing for removal of the gas generated in 




which is believed to have developed from a duplication of the myoglobin gene and subsequent 
functional evolution beginning several hundred million years ago86. 
RBCs developed during the first wave of hematopoiesis express the hemoglobin genes 
most common during fetal development, and do not enucleate until entering circulation. 
Erythroblasts during the second wave of hematopoiesis express primarily the "adult" forms of 
hemoglobin protein subunits, as the fetal genes begin to be downregulated. Once fetal 
development has progressed to the final stage of hematopoiesis, the adult form of hemoglobin 
becomes established as the primary form, which this section will briefly describe87. Tight 
regulation of hemoglobin production and assembly is required for successful generation of RBC 
cells from the pool of HSCs in the bone marrow, although several compensatory mechanisms 
with overlapping functions exist that can make up for minor insufficiencies (see Section 3.2.4). 
Human adult hemoglobin is tetrahedron-shaped and comprises four subunits—two alpha 
and two beta—which are coded by the HBA and HBB genes, respectively. Insufficient 
hemoglobin transcription, translation, or assembly can lead to abnormal RBC trait values (see 
Section 3.3). Several examples of mutations in these genes causing Mendelian RBC-related 
disorders are described briefly in Section 3.4.1 and Table 1; however, these regions both exhibit 
strong association in GWAS even after adjustment for Mendelian variants, indicating that 
common variants that play a more modest role in the distribution of RBC trait values in general 
populations may exist 18.  
3.2.3. Stages of Erythropoiesis and RBC Degradation  
HSCs are located in the deep bone marrow in clusters of self-renewing cells and, as 
highlighted above, are progenitors of multiple cell types including RBCs. The first stage of 




macrophage island in the deep bone marrow, referred to as "blast-forming units" (BFUs)88; 89. 
Through the subsequent stages portrayed in Figure 1, each differentiation stage involves 
decreased cell diameter and volume; more chromatin condensation; reduced diversity of RNA 
transcription; and an increased emphasis on hemoglobin production75; 89. After HSCs become 
committed to the RBC path, all stages of erythroblast differentiation in the bone marrow involve 
direct physical contact with macrophages through a number of cell-membrane proteins, including 
erythroblast-macrophage protein (EMP), which is found in the membranes of macrophages and 
developing RBCs75. As the immature erythrocyte progresses through each stage of 
differentiation, hemoglobin transcription increases and, eventually, hemoglobin subunits become 
the dominant transcript, accompanying the dramatic downregulation of most other protein-
coding genes prior to enucleation90-92. 
In the final stage of differentiation that occurs in the bone marrow, orthochromatic erythroblasts 
in the sinusoidal bone marrow (near an entry point to the vasculature) expel their nucleus and 
most of the accompanying cellular machinery in a process referred to as "nuclear extrusion"77; 87; 
93. The nucleated portion of the RBC remaining after this division is referred to as a pyrenocyte, 
which is absorbed by the central macrophage75.  
The enucleated cell (a reticulocyte) is then released into circulation from the bone 
marrow, which circulates for one to two days while membrane composition and remaining 
hemoglobin translation are finalized, resulting in a terminally differentiated or “mature” 
erythrocyte (henceforth referred to simply as “RBCs”) with the recognizable biconcave shape. 
Of note, the enucleation process is unique to mammals, as lower vertebrates such fish and birds 
have no or very few anuclear RBCs94. While restricting the RBC to a lifespan limited by the half-




easily identifiable "donut" shape of RBCs, which allows for extensive deformation of the cell, 
facilitating travel through capillaries and intercellular spaces to deliver oxygen with extremely 
high efficiency89. After an average lifespan of 120 days, RBCs become irreparably damaged or 
enter senescence and are degraded in the red pulp of the spleen. Macrophages phagocytose RBCs 
no longer fit for circulation, recycling the iron to the bone marrow for new RBC production and 
hemoglobin loading88; 89.  
3.2.4. Iron homeostasis in erythropoiesis 
RBCs can only perform their primary function of delivering oxygen molecules to 
peripheral tissues when sufficient iron (approximately 25mg of iron per day) is available to 
produce and activate hemoglobin95-97. Free iron ions in the bloodstream are toxic, and must 
therefore be either stored in bodily tissues or, when present in the blood, bound by transferrin 
molecules97; 98. The amount of iron stored in the body at a given time is estimated based on 
measurements of molecules in the serum such as hemoglobin level and ferritin99. Iron stores are 
built up during fetal development—during which time iron molecules are crucial for a large 
number of biological processes—and infants are born with an average iron store sufficient for all 
required tissue uses until 6 months of age, with the difference required to maintain the expanding 
HSC population absorbed through the diet. The vast majority of iron molecules used in adult 
hemoglobin synthesis come not from the diet (which provides a relatively low proportion of the 
total iron used in erythropoiesis), but rather from macrophages, which accumulate iron stores in 
the spleen via the degradation of senescent RBCs95. A very small proportion (~4mg or 0.1%) of 
the body’s total iron content is transferrin-bound at any particular time, meaning nearly the entire 
supply of iron molecules for hemoglobin synthesis is recycled through the liver or macrophages 




iron storage and, therefore, RBC function, underscores the biologic relevance of genes expressed 
in those tissues (here, WBCs or liver) for RBC function and maintenance. For example, 
mutations in CFHR1 have been shown to cause a rare form of hemolytic anemia, but this gene is 
more highly transcribed in the liver than whole blood or bone marrow100; 101. Given the 
importance of iron homeostasis to maintaining a healthy RBC population, we briefly characterize 
the shared biological actors involved in iron homeostasis and erythropoiesis below. 
3.2.4.1 Genetic regulation of iron homeostasis  
A group of proteins co-regulate iron homeostasis and erythropoiesis, several of which 
have been implicated in monogenic anemias (Table 1). Briefly, Camaschella, et al, propose the 
following mechanism of inducing or repressing erythropoiesis, which is highly dependent on 
iron homeostasis (see Table 2 for a description of the relevant genes). Developing erythroblasts 
express TFR2 on the cell surface, which modulates the sensitivity of RBCs to erythropoietin 
(EPO). The presence of EPO can induce acute erythropoiesis expansion, leading to a relative iron 
deficiency. Subsequently, the presence of surface TFR2 on erythrocytes is diminished, which 
increases the effect of EPO, leading to an in-kind increase in erythroferrone (ERFE, which is 
allowed by decreased BMP/SMAD function). The presence of ERFE leads to a downregulation 
of hepcidin, followed by increased dietary iron absorption through the small intestine95. Once 
iron stores have been sufficiently restored, hepcidin is upregulated, leading to suppression of iron 
absorption through intestinal hepcidin-ferroportin interaction102. 
3.3. Red blood cell trait definitions and measurement 
A complete blood count (CBC) panel, the most common method of evaluating RBC 
traits, can be used to assess RBC development and maintenance. RBCs are described using 




that allow for population-level comparison of RBC development and maintenance. Recently 
developed hematology analyzers are capable of measuring a wide array of parameters such as 
proportion of hypochromic cells or immature reticulocytes (both of which can be used clinically 
in anemia diagnosis). However, this dissertation will focus on the seven RBC traits—described 
below—that are most commonly evaluated in clinical, epidemiological, and genomic research 
studies: hematocrit (HCT), hemoglobin concentration (HGB), red blood cell count (RBCC), red 
cell distribution width (RDW), mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), and mean corpuscular volume (MCV). Separately, each 
parameter describes a distinct aspect of RBCs that is useful in its own right; in combination, 
RBC traits are often helpful for distinguishing the cause of an anemia and potential ways to 
address that cause. Specifically, basic physiological changes that differ by underlying cause of 
anemia can lead to an increase or decrease in one or more RBC traits traditionally measured in a 
CBC, so using RBC trait values in combination can assist in diagnosis. Associations between the 
RBC traits described below and traditional epidemiologic risk factors are described in Section 
3.5.1. 
3.3.1. HCT 
HCT refers to the proportion of whole blood volume made up of red blood cells, and is 
reported as a percent. Low hematocrit is indicative of anemia, with the normal low reference 
value for adults in the United States defined as 37% for women and 42% for men103. HCT also 
directly contributes to blood viscosity—for example, individuals with polycythemia vera (excess 
RBC production and hence increased HCT and HGB) have an increased blood viscosity, which 





HGB refers to the concentration of the hemoglobin protein in whole blood, and is 
reported in grams per deciliter (g/dL). As described above, hemoglobin is the primary protein in 
RBCs and is required to effectively transport oxygen to tissues throughout the body. Anemia, 
defined by the WHO as HGB <13 g/dL in men or <12 g/dL in women, decreases with age even 
in healthy individuals with no other major risk factors (see Section 4.1.1 for description of how 
this trend varies by biological sex) 105-108.  
3.3.3. RBCC 
RBCC refers to the average number of mature (i.e., enucleated) RBCs per unit of volume, 
typically reported in millions of cells per millimeter cubed (106 cells/mm3) or billions of cells per 
milliliter (109 cells/mL). The average human produces 2 billion RBCs per day, and any 
perturbations in this tightly regulated process (in the bone marrow, vasculature, or relevant 
tissues such as liver or spleen) can lead to excessive or insufficient RBC counts75; 87; 92; 93; 109.  
3.3.4. MCH 
Mean corpuscular hemoglobin (MCH) refers to the average dry-weight mass of 
hemoglobin protein per RBC, reported in picograms and calculated as shown in Table 3. 
Hemoglobin constitutes over 90% of the dry weight of an RBC, including the cell membrane110; 
111. An increased MCH could be due to lower MCV with maintained hemoglobin transcription 
during erythropoiesis, or increased hemoglobin transcription with other parameters held constant. 
MCH varies modestly by sex and race/ethnicity, and increases with age106; 112.  
3.3.5. MCHC 
Mean corpuscular hemoglobin concentration (MCHC) refers to the average concentration 




described in Table 3. MCHC increases gradually during the life cycle of an RBC as volume 
decreases more quickly than hemoglobin content111.  
3.3.6. MCV 
Mean corpuscular volume (MCV) refers to the average cell size of mature RBCs in an 
individual, and is reported in femtoliters (fL). MCV decreases throughout the life of the mature 
RBC, with the HSC being approximately 10 times as large as a red blood cell at the end of its 
functional life (Figure 1). Incomplete or delayed enucleation can lead to an increased MCV 
(macrocytosis). Conversely, iron deficiency or insufficient hemoglobin production can cause 
decreased MCV (microcytosis)113-115. Additionally, functional deficiencies regarding 
vesiculation or hemoglobin retention can affect MCV in either direction111. 
3.3.7. RDW 
Red cell distribution width (RDW) refers to the intra-individual variation in RBC 
volume. An abnormally high or low RDW can indicate disruptions in RBC development or 
failure to remove damaged or senescent cells. There are two methods of reporting RDW—RDW-
SD (SD: standard deviation) and RDW-CV (CV: coefficient of variation). RDW-SD is measured 
as 2 times the standard deviation of the distribution of mean corpuscular volume within an 
individual. RDW-CV, the measure to be evaluated in the proposed work, is the coefficient of 
variation (reported in %) of the distribution of MCV within an individual, calculated as shown in 
Table 3. Approximately 20% of the hemoglobin protein mass and 30% of the total volume of 
mature RBCs is gradually lost post-enucleation, meaning a certain amount of variation in MCV 
is expected111. High RDW (the combined presence of abnormally small and abnormally large 
RBCs with a normal MCV) is also referred to as high anisocytosis, which is associated with 




anisocytosis may be caused by "decreased MCV; increased reticulocyte volume variance; 
[heterogeneity of volume reduction (AKA, variability in amount of membrane and hemoglobin 
lost over the lifespan) in circulating RBCs]; and delayed RBC clearance”116. 
 
3.4. Anemia definition and prevalence 
The word "anemia" generally refers to a physiologic state in which RBCs cannot perform 
their cellular functions due to an insufficiency in RBC differentiation, maintenance, or 
degradation. The World Health Organization standard definition for anemia is HGB <12g/dL in 
women or <13g/dL in men; this definition is also commonly used in research as CBCs are 
frequently available in cohort studies for which any type of biological sample is collected. 
Additional criteria can be applied by physicians to identify the cause underlying the anemia; for 
example, individuals with a normal-range MCV (80-100fL) would follow the diagnostic criteria 
for normocytic anemia, depending on other RBC traits107. While a general criterion for defining 
anemia within is useful for determining risk factors relevant to the general population, most 
specific criteria—based, for example, on MCV—can be beneficial on an individual level for 
describing the exact type of anemia, which will determine the underlying cause best course of 
treatment. 
Approximately 5.6% of U.S. adults are classified as anemic using the WHO definition, 
with nearly 2% of the population having moderate or severe anemia (HGB <11g/dL in men and 
non-pregnant women)117. In the NHANES study population, which is considered broadly 
representative of US adults, the proportion of men classified as anemic exhibits a linear 
association with age, whereas adult women not currently pregnant show a bimodal association, 




of dietary folate supplementation in cereal flours in much of the developed world beginning in 
the early 1990s—expected to contribute to the notable decrease in anemia prevalence through the 
mid-2000s—recent data indicates that anemia is once again on the rise, nearing prevalence 
estimates in all population subgroups similar to the beginning of the 21st century117-121. Given the 
topical area of this dissertation, below we briefly introduce monogenic anemias and other 
spontaneous-onset RBC diseases. 
3.4.1. Monogenic RBC anemias and related disorders 
RBC traits are, as described above, tightly regulated to maximize efficiency of oxygen 
transportation; genetic dysregulation of RBC maintenance can therefore result in heritable 
anemias (i.e., insufficient functional hemoglobin in healthy RBCs to meet tissue-oxygenation 
demands) with a wide range of severity. Dozens of heritable monogenic anemias have been 
described which are globally rare but relevantly frequent in populations with ancestry-specific 
causal variants, demonstrating the highly polygenic nature of RBC traits (Table 1). An example 
of how these proteins interactions drive molecular processes in RBCs is demonstrated by the 
interaction network shown in Figure 2. Outside of heritable disorders, somatic mutations in the 
bone marrow HSC population from which RBCs are derived can lead to blood cancers or other 
blood disorders. Below, we briefly review the anemias caused by known genetic variants, 
followed by a description of the most prevalent spontaneous-onset RBC diseases. 
3.4.1.1 Recessive anemias associated with malaria-protective variants 
A large-effect genetic variant causing a recessive anemia that is fatal prior to 
reproductive age would be expected to remain extremely rare, unless one copy of the allele (i.e., 
heterozygosity) provided some kind of evolutionary benefit, allowing it to become established. 




which confer protection against plasmodium infection have become established in human 
populations living in these areas122-129. The pathogenic variants described in this section are 
associated with modest effects on HGB and HCT in heterozygotes, but homozygous effect-allele 
carriers can be severely affected, accompanied by dramatically abnormal RBC trait values.  
3.4.1.1.1 Hemoglobinopathies: sickle-cell disease and thalassemia 
An example of a well-characterized hereditary anemia is sickle cell disease (SCD), which 
in the United States almost exclusively affects individuals with West African ancestry 
(prevalence: ~3/1,000 African Americans, 1/36,000 Hispanic/Latino Americans). Sickle-cell 
disease causes extreme pain, has severe complications, and is fatal in the first two decades of life 
without treatment130. The most common causal variant for sickle-cell trait is rs334 (which leads 
to transcription of the inefficient hemoglobin “S” beta chain), which is specific to African-
descent populations and causes SCD in homozygous individuals. Several other variants in the 
beta hemoglobin gene are also associated with RBC sickling and exhibit higher allele 
frequencies in malaria-endemic regions like the Middle East, Mediterranean countries, and South 
Asia. While carriers with one copy of the rs334 effect allele carry protection against infection 
with malaria, even sickle-cell carriers can have symptoms associated with partial sickling of 
RBCs122; 130; 131. The heterozygous state for SCD—sickle cell trait—is also associated with 
complications during exercise, from cramping to exercise-induced sudden death132. Among 
African Americans, compared to having two normal copies of the beta hemoglobin gene, sickle-
cell trait has also been associated with venous thromboembolism; ischemic stroke; and kidney-
function insufficiency (an association also identified in Hispanic/Latino Americans) 133-136.  
Another common recessive monogenic anemia is thalassemia, referring to mutations in 
either the alpha- or beta- component of the hemoglobin alpha gene that lead to an insufficient 




mutations137. When a mutation in the gene for one hemoglobin subunit leads to a reduction in 
available protein despite a normal level of transcription, excessive build-up of the other subunit 
negatively affects erythropoiesis and may also cause hemolysis of mature RBCs in the 
bloodstream126; 137; 138. Established thalassemia variants are most prevalent in Southeast Asia and 
Mediterranean countries, including Cyprus, which has a carrier frequency (i.e., heterozygosity) 
of 14.3%139. Treatments for moderate to severe thalassemia as well as SCD include frequent 
blood transfusions, which are accompanied by additional risks including iron overload; 
alloimmunization leading to extensive delayed hemolysis; and transfusion-related infection, 
particularly in low-resource areas where extensive screening is not available130; 140-142. Neither 
condition can currently be cured except with a bone marrow transplant, which is accompanied by 
a high rejection rate, particularly from unrelated donors; gene therapies have recently been 
explored as a potential alternative with more modest risks143-147. 
3.4.1.1.2 Non-hemoglobinopathy malaria-related anemia genes 
Several genes for which heterozygotes obtain protection from malaria aside from the 
hemoglobin chains have been causally associated with RBC-related conditions. Examples of 
such genes include G6PD deficiency (an X-linked condition with hemizygous inheritance in 
males), mutations in DARC, and hereditary spherocytosis due to mutations in ANK116; 129; 148; 149. 
Unlike the specific variants most commonly associated with the hemoglobinopathies, there are 
dozens of causal variants found at the DARC, G6PD, and ANK1 loci. Due to the incapacity of 
RBCs to transcribe RNA once the nucleus has been expelled, it is perhaps not surprising that 
variants in one of the many components of the highly specialized RBC membrane-cytoskeleton 
complex may cause hereditary anemias150. As described in Table 1, in addition to the 
aforementioned genes, variants within KEL, SLC4A1, SLC2A1, XK, GYPC, RhD, RHCE, 




with the rs334, most of these variants became established in a malaria-endemic region of the 
world, and are therefore either population-specific or exhibit large allele-frequency differences 
by ancestry.  
3.4.1.2 Other monogenic RBC anemias 
Aside from genetic variants specifically associated with malaria resistance, several dozen 
genes have been causally associated with dominant, recessive, or X-linked anemias. These 
anemias range in frequency from relatively common (hereditary spherocytosis affects 
approximately 0.05% of Northern Europeans, with about half of cases having causal variants in 
the ANK1 gene) to extremely rare (Nakajo-Nishimura syndrome, caused by a mutation in 
PSMB8, has only had approximately 30 cases reported despite being first described in the 1930s; 
see Table 1)152; 153. These gene products range in function from transcription factors (KLF1) to 
proteins involved in glycolysis (PKLR) to ribosomal functions (RPL and RPS family members); 
several causal genes remain incompletely characterized.  
3.4.1.3 RBC disorders attributable to somatic mutations 
In addition to heritable anemias, several other monogenic diseases can affect RBCs. 
Specifically, erythroleukemia can develop due to a somatic mutation, meaning heritability is very 
low but several genes have been identified for which causal somatic mutations occur more 
frequently than would be expected due to the normal mutation rate accompanying replication80; 
154. As another example, polycythemia vera—a myeloproliferative disorder—is not typically 
heritable but does occasionally occur in families, particularly those with a predisposition to a 





3.4.2. Summary  
Over 50 monogenic anemias—primarily with a recessive mode of inheritance—have 
been described and genetically mapped to date, providing a broad insight into RBC physiology. 
Among adults in the United States, acquired anemias (i.e., non-monogenic and have a high 
environmental component) account for the large majority of anemia prevalence117; 155. While 
environmental risk factors can affect RBC traits sufficiently to lead to an anemic state, the 
number of genes associated with monogenic anemias alone supports these traits being highly 
polygenic. While monogenic anemias are important for clinical diagnostics because of the 
relatively large effect magnitude of most known variants, many more genetic loci likely 
contribute to RBC traits via common or rare variants with small effect sizes. As described in 
Appendix A, gene expression and cellular maintenance are subject to many forms of 
environmental and genetic regulation. The combined effects of common risk factors and 
underlying genetic variation are expected to form the distribution of RBC traits within any 
particular population. Below we discuss RBC trait epidemiology, based primarily on cohort 
studies, and how traditional risk factors contribute to population-level variation for these traits.  
 
3.5. Red blood cell epidemiology  
As described in Section 3.6., RBC trait values are associated with myriad diseases of 
public health importance97; 156-159. Environmental exposures—including acidity/basicity of the 
cytoplasm; temperature; osmolarity/tonicity; molecular products released by commensal or 
pathogenic bacteria (tissue-specific); the contents of extracellular vesicles from other cell types; 
and availability of minerals or other molecules used in molecular processes—can affect gene 




Specifically, blood draws are a familiar process to most people in the United States and are 
therefore acceptable to most participants; the small amount required for a hematology analyzer to 
perform a CBC will typically have no negative health effects; and a blood draw can provide a 
large amount of information about biomarkers in addition to traditional CBC measures. 
Understanding the epidemiology of RBC traits is crucial given the increased risk for negative 
health outcomes and mortality associated with a change in one or more RBC traits across a wide 
range of circumstances2; 70; 73; 173-179. Characterizing the relationship between demographic and 
environmental factors that contribute to RBC traits helps researchers to designate relevant 
covariates for genomic or other epidemiologic analyses of RBC traits as the outcome(s). 
 
3.5.1. Traditional risk factors 
3.5.1.1 Sex 
The association between sex and RBC traits varies throughout the life course. HCT and 
HGB are both strongly associated with biological sex in adults; prior to puberty, RBC trait values 
do not differ substantially by sex180. The average HCT and HGB for adult pre-menopausal 
women are typically over a standard deviation lower than that of men at the same age112; 181. 
However, after menopause the trend is diminished: post-menopausal women typically have 
similar HCT and HGB values compared to men of the same age182. The difference in HCT and 
HGB values between men and women has diminished slightly across populations in the United 
States in parallel to the required folic-acid supplementation of cereal flours beginning in 1998120. 
Women also have a lower RBC count on average than men throughout adulthood, although the 




not been discussed at length in the literature. In GWAS of RBC traits, sex is typically adjusted 
for because it is significantly associated with all RBC traits in cohort study populations. 
3.5.1.2 Age 
All seven RBC traits being evaluated in this work are associated with age in adults. 
Anemia is also more prevalent in older adults: as of 2009, approximately 6.8% of women and 
9.4% of men in the NHANES study population over age 60 meet WHO HGB criteria for anemia, 
and 10.2% of men and 6.2% of women in the same age group exhibit macrocytosis120. In male 
NHANES participants, average HGB increases by approximately 1g/dL between early adulthood 
and age 40, then decreases at a similar rate through late life (see below for a description of 
differences by race)106. Hematocrit and hemoglobin trends are discussed more comprehensively 
above due to the sex-specific trends of these traits over the life course. MCH increases 
incrementally but steadily throughout the lifespan, whereas MCHC remains constant on average 
with age, although the two variables are associated in most study populations (including the 
PAGE cohorts participating in this work; data not shown). MCV increases with age in early 
adulthood and plateaus after middle age; RBC count exhibits a similar pattern, leveling off 
around middle age in women and peaking at the same time in men, with a slight decreasing in 
average among older men106. For example, mean MCV increases approximately 3fL over the 
course of adulthood, from 88fL in 15- to 19-year-olds to 91fL in study participants over 70 the 
overall NHANES study population (differences in mean MCV by race are described below)106; 
183. RDW increases with age independently from MCV 106; 181; 183-185. The aforementioned trends 





In the United States, African Americans are more likely to have lower values for HCT, 
HGB, and MCV across the life course compared to non-Hispanic whites, although these 
differences are well within a standard deviation for either ethnicity in population-based 
studies106; 112; 186. For example, NHANES data show HGB values approximately 1g/dL lower in 
African American or Mexican American males and females than in non-Hispanic whites in the 
same age category106. 
The aforementioned differences in RBC trait values by race/ethnicity have been observed 
in some but not all studies, and while trends are visually discernible they are not always 
statistically significant and may be modified by age112; 138; 184; 187; 188. Whether these differences 
are due to underlying genetic variation leading to expression differences by ancestry or 
environmental factors such as diet, socioeconomic status, and smoking has not been 
comprehensively evaluated155; 184; 187. As described above, known ancestry-specific genetic 
variants can have large effects on RBC trait values, particularly in the context of malaria-
infection resistance16; 122; 126; 129; 148.  However, the effect alleles for these variants are not 
expected to be found at the same frequency in admixed populations such as African Americans 
or Hispanic/Latino Americans as in African populations with no shared European ancestry, 
making predicting their effect on population-level trait variability difficult. Additionally, cultural 
and lifestyle differences between groups with shared ancestry make it difficult to elucidate the 
exact contribution of such genetic variants on population-based trait estimates189-191.  
3.5.1.4 Pregnancy 
Physiologic iron stores are depleted more easily in pregnant women due to the physical 




Additionally, the total blood volume necessarily increases during pregnancy. This often leads to 
mild or moderate anemia; dietary changes and iron supplementation may increase hemoglobin 
concentration, but evidence is inconclusive on whether such changes positively affect pregnancy 
outcomes194. The relationships between RBC traits, anemia, and pregnancy are well established. 
However, even should a pregnant woman's RBC trait measurements fall within the defined 
normal range, there is no way to tell what her normal values are while she is not pregnant.  
3.5.1.5 Smoking and alcohol use 
Both cigarette smoking and alcohol use are associated with increases in HGB 
independent of other environmental factors105; 195; 196. Furthermore, smoking has been associated 
with increased MCV, MCHC, and HCT, with multiple analyses suggesting that the effect of 
smoking on hematological parameters differs by sex105; 196-198. For example, Malenica, et al, 
report an average 0.8 g/dL higher HGB and 4.5fL higher MCV in smokers than non-smokers 
(unadjusted), whereas MCHC, MCH, RBCC, and RDW did not differ significantly between the 
groups198. RBC count has been reported to be increased in smokers; however it has been 
suggested that this finding might have been misinterpreted and is due instead to macrocytosis 
(abnormally high MCV) with a sustained RBC count198; 199. MCH and MCHC have not been 
consistently associated with smoking; however, correlation between RBC traits suggests that in 
large study populations a statistical association may be present.  
3.5.1.6 Pharmaceutical effects 
There is a well-documented history of pharmaceutical treatments for a wide range of 
conditions having temporary or permanent effects on RBC traits. In addition to being affected by 
pharmaceutical compounds introduced to bodily tissues, RBCs also play a role in metabolism of 




primarily in the liver)200. The proposed biological mechanisms underlying these conditions 
suggest that the effects often occur on a dose-response curve rather than having a binary 
threshold relationship201-207. For example, individuals with CKD receiving synthetic EPO exhibit 
a dose-response relationship with HCT: Cotter, et al, demonstrate in a population of 14,000 
hemodialysis patients that during both initiation phase (1-3 months) and maintenance phase (4-6 
months) of treatment an S-shaped curve is present for HCT increase based on EPO dose205. 
However, the effects of such medications are often described in the literature in the context of 
progressing to a clinical condition. Therefore, we will briefly discuss two specific pathologies—
iron-deficiency anemia secondary to medication use and drug-induced hemolytic anemia—that 
represent extreme (and therefore the most straightforwardly measured) instances on a spectrum 
of RBC trait-pharmaceutical associations.  
Over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs) are used frequently—
often daily—in over 10% of the adult U.S. population, with or without the recommendation of a 
physician, and this trend has increased over the last several decades208. Frequent therapeutic use 
of NSAIDs (for instance, in individuals with autoimmune inflammatory diseases) can lead to a 
substantial decrease in HGB over a relatively short time period. For example, investigators 
identified a ≥2g/dL decrease over 6 months among 2 to 6% (depending on the NSAID in 
question) of CLASS and CONDOR trial participants201. Several mechanisms have been proposed 
for NSAID-induced anemia, including blood protein loss due to gastrointestinal ulcers; protein 
deficiency caused by interactions between NSAIDs; and physiological changes caused by the 
underlying condition for which NSAIDs are used as a treatment (e.g., inflammatory diseases 




Another common effector of changes in RBC traits is chemotherapy due to a causal effect 
on iron stores or RBC production, which can lead to anemias ranging from mild to severe214-216. 
A large proportion of chemotherapy-related anemias can be attributed to iron-store depletion, 
which can sometimes be successfully treated with intravenous iron or erythropoiesis-stimulating 
agents215; 217. Patients exhibiting chemotherapy-related anemia can subsequently suffer from dose 
delay/reduction, which can alter the treatment’s maximum effectiveness if the anemia cannot be 
controlled218.  
3.5.1.7 Other environmental risk factors 
In addition to the aforementioned influences, several non-traditional risk factors have also 
been strongly associated with RBC trait values. Diet in particular is associated with iron 
absorption and iron store availability during RBC production219; 220. A diet rich in bioavailable 
iron—as well as simultaneous consumption of high-vitamin C foods to improve iron absorption 
through the small intestine—increases HGB and RBCC221; 222. Dietary iron comes in heme- and 
non-heme forms, with the former primarily coming from animal proteins and the latter from 
plants such as dark leafy greens, beans, and iron-fortified foods in developed countries. While 
heme-iron is generally considered to be more bioavailable, approximately 85% of an omnivore’s 
dietary iron comes from non-heme forms, which may lead to small differences in RBC traits due 
to the high variability of the modern diet. For example, only 10% of non-heme iron is estimated 
to be bioavailable via human digestion, and vegetarian diets exclude heme-iron-containing meat-
based proteins, meaning a much larger amount of total iron per meal is necessary to meet 
physiologic requirements223; 224. Studies performed in the late 20th century implicated specific 
chemical compounds in dietary iron absorption: vegetables or beverages (particularly black tea) 




iron absorption by as much as 75% when consumed as part of a meal, although these effects can 
be partly counteracted (up to 50%) by simultaneous consumption of ascorbic acid (Vitamin C)225; 
226. However, iron fortification has been mandated by law in a large number of developed 
countries in the world. While the purpose of this fortification was to improve access to dietary 
iron in individuals—particularly pregnant women—who could not access sufficient iron, recent 
work has shown broader benefits, although overall diet must include some form of improved 
bioavailability (such as ascorbic acid) to meaningfully increase iron absorption223; 227. 
Exercise can also have short-term and long-term effects on RBC traits. For example, iron 
stores are depleted following a session of vigorous physical activity, which leads to reduced 
hemoglobin and can result in the appearance of anemia in an otherwise-healthy individual228. 
The benefits of consistent exercise on RBC traits have also been documented—consistent 
moderate or intense physical activity leads to increased hemoglobin and red cell total mass in 
circulation228; 229. Trained athletes may even have a lower measured HCT, referred to as “sports 
anemia”, due to an increase in plasma volume compared to sedentary individuals229. 
In terms of environmental exposures, pollution has been strongly associated with multiple 
inflammatory cell types, including RBCs. Research has implicated an association between air 
pollution and hemoglobin protein function, as well as effects of pollutants on the structure and 
function of RBC membranes230-233. There are more studies evaluating associations between 
pollution and white blood cell types than RBC traits, however, meaning there is room for more 
research in this area. 
Finally, altitude has long been associated with RBC traits, most notably a decrease in 
HGB as altitude increases and oxygen becomes scarcer159. Competitive athletes may take 




blood after high-elevation training sessions for auto-transfusion prior to competition234; 235. 
Global populations that have lived at high altitudes for centuries or millennia even exhibit 
genetic adaptations to decreased oxygen availability236. 
3.5.2. RBC trait measurement and error 
The automated machines which output CBC measurements are highly accurate and 
minimally affected by human measurement error which could decrease precision for quantitative 
traits237. Particularly when a central laboratory is used for all centers within a study, as is often 
the case, machines are frequently calibrated and systematic error is unlikely. Therefore, RBC 
traits usually exhibit both high accuracy and high precision and represent excellent traits for 
epidemiologic study. 
Two specific measures are used to capture within-person or between-person variability in 
measuring quantitative traits: within-person coefficient of variation (CVw) and between-person 
coefficient of variation (CVg). For traits with a high CVg, the population-level variability is high, 
whereas for traits with a high CVw, one measurement is unlikely to accurately capture an 
individual’s mean trait value (although the population mean is not expected to be affected). CVg 
in NHANES adult participants, calculated as the ratio of the standard deviation to the mean of 
each measured trait, ranged from 2.25% (MCHC, men; 2.40 in women) to 9.33% (RBC count, 
women; 8.83 in men)184, suggesting that there is a modest level of between-person variability for 
the RBC traits discussed in this work. CVw for multiple measures of each trait (a median of 17 
days apart) ranged from 0.37% (MCV in men; equivalent in women [0.31%]) to 3.45% (RDW in 
women, equivalent in men [2.53%])184. Low CVw and CVg for RBC traits indicate that these 




lower than between-person variability, as would be expected based on the population distribution 
of RBC traits. 
A relevant statistic for capturing the level of variation and the utility of population-based 
reference intervals for a particular trait is the index of individuality, or the ratio CVw/CVg238. A 
low index of individuality means that the within-person variability is likely to be confined to a 
narrow range within the population-level reference range of a study population184; 239. In contrast, 
a high index value indicates a loss of power typically accompanied by an increase in false 
positives for the exposure-outcome analysis. The number of false positives identified in a study 
can be reduced by considering repeated measures, but such methods do little to address the 
decreased ability to detect true positives238. In the study population described above, RBC trait 
indices of individuality ranged from 0.06 for MCV in both men and women to 0.37 for RBCC in 
women (0.29 in men)184. Both the CVw and CVg are small and unlikely to dramatically affect 
precision184; 198. However, the range in CVw/CVg could be a potential contributor to the disparity 
in the number of genetic loci associated with MCV compared to HCT, for example. A relatively 
higher index of individuality could add statistical noise, reducing the ability to detect true 
associations. 
3.5.3. Summary 
RBC traits are obtained from one the most convenient biological samples (blood draw) 
and are frequently measured in cohort studies. Therefore, RBC traits and their contributing 
factors are well characterized within the general population. Due to measurement via automated 
hematology analyzers, RBC traits are measured with high accuracy; individual-level variability, 
at least in the short-term, is also small, although some variation by trait is noted. Demographic 




reported race/ethnicity, which are frequently measured in population-based studies and can be 
adjusted for in analyses of RBC traits. Additional sources of population-level RBC trait variation 
include individual-level variables such as smoking status, pregnancy, and pharmaceutical use, as 
well an environmental variables such as altitude or air pollution. Together, these results support 
the feasibility of epidemiologic studies of RBC traits.  
 
3.6. Clinical and public health significance of RBC traits  
 In addition to being the relevant phenotype(s) for diagnosing both idiopathic 
anemias (i.e., an anemia for which the underlying cause cannot be explained by another 
condition or diseases state) and blood disorders with environmental causes, RBC traits—
individually or in combination—have been associated with other diseases. To use CVD as an 
example, over the past several decades RBC trait values have been associated with stroke, 
myocardial infarction (MI), coronary heart disease, and heart failure5; 67; 173; 240-242. Given the 
relevance of anemia to a multitude of diseases, researchers have examined whether variation in 
RBC traits in populations with or without anemia are associated with a range of chronic 
diseases5; 66; 68; 177; 241; 243-246.  
Using RDW as an example, we describe below how RBC traits have been associated with 
clinical diseases in epidemiologic studies. RDW has been used as an indicator for iron-deficiency 
anemia for several decades, although there are likely multiple different biological mechanisms 
underlying this association. Research in the past decade have identified associations between 
RDW and diseases including systemic lupus erythematosus (SLE); rheumatoid arthritis; heart 
failure; and incident stroke5; 8; 70; 71; 175. To demonstrate the relevance of RBC trait physiology to 




and end-stage renal disease (ESRD, the most severe stage of chronic kidney disease [CKD]); 
heart failure (HF); and ischemic stroke. 
3.6.1. RDW and ESRD 
Kidney insufficiency prevents effective filtration of blood, which can lead to blood 
toxicity, edema, and—in the case of untreated kidney failure—death. Patients with ESRD who 
cannot receive either consistent hemodialysis or a kidney transplant have an extremely short life 
expectancy. Approximately 661,000 Americans suffer from kidney failure, with large health 
disparities by race/ethnic background247. For example, among Hispanics/Latinos, progression 
from CKD to ESRD is expected to occur more quickly than in non-Hispanic whites, given that 
the prevalence of ESRD in Hispanic US populations is nearly double that in Whites248.  
Several studies have found an association between RDW and mortality or kidney 
function, with one recent study specifically evaluating the association between RDW and 
mortality in hemodialysis patients1; 249-251. Such studies were performed because understanding 
the association between RBC traits and events secondary to hemodialysis may inform treatments 
that can limit such negative outcomes. In a retrospective study of approximately 110,000 DaVita 
hemodialysis patients for years 2007-2011, investigators identified a positive linear association 
between RDW and mortality249. Compared to the reference group with RDW values between 
15.5% and 16.5% using a fully adjusted model, patients with a baseline RDW of 16.5% to 17.5% 
had a hazard of mortality that was 16% higher (HR= 1.16; 95% confidence interval [CI]: 1.10—
1.22) and the highest category of RDW (>=17.5%) had a hazard of mortality that was 28% 
higher (HR = 1.28, 95%CI: 1.24—1.33)249. Potential mechanisms underlying this association 
involve oxidative stress and low to moderate levels of inflammation, both of which are very 




maintenance are affected by inflammation and oxidative stress (and could hence affect RBC 
heterogeneity), although neither of these mechanisms have been evaluated on a functional level 
with regard to ESRD. 
3.6.2. RDW in Heart Failure 
Nearly 6 million Americans suffer from HF, which shares risk factors with many other 
forms of CVD such as overweight, age (particularly over 65), and a history of MI252. The 
prevalence of anemia (using the WHO HGB definition described above) among patients 
hospitalized for acute HF has been reported from 20% to over 50% (compared to slightly over 
10% in the general population over age 65), and HF patients with anemia exhibit a higher 
mortality rate than non-anemic patients175; 253. The primary focus of research on the association 
between RDW and heart failure has evaluated RDW as a predictor of HF prognosis and 
outcomes. In the past decade, several studies have identified associations between RDW and HF 
or associated conditions such as raised left-ventricular end-diastolic pressure (LVEDP) 7; 10; 254-
259. For instance, in a study of over 1,000 patients undergoing elective coronary angiography and 
followed for five years, increased RDW was associated with increased LVEDP in the entire 
study population (OR: 1.14, 95% CI: 1.00 to 1.29) and in patients with no history of HF (73% of 
the study population, OR: 1.37, 95% CI: 1.13-1.67)260. One potential mechanism involved in this 
association is that high levels of chronic inflammation negatively affect erythropoiesis; another 
pathway to examine is the shared effect of iron deficiency on both LVEDP and erythropoiesis258; 
260; 261. However, neither of these mechanisms has been evaluated in a functional context.  
3.6.3. RDW and ischemic stroke  
Ischemic stroke is the fifth leading cause of death in the United States262. Although 




survival from stroke: African Americans suffer from a disproportionately high stroke mortality 
(>2-fold) compared to non-Hispanic whites263; 264. Accurately determining a prognosis for stroke 
survivors remains difficult based on current standards—in particular, the use of National 
Institutes of Health Stroke Score (NIHSS) without other risk factors or prognostic indicators265-
270. Because both stroke and RBC traits are relevant to inflammatory pathways, researchers have 
been interested in potential associations between RBC traits and stroke outcomes. 
Multiple RBC traits have been associated with both severity of the ischemic stroke and 
30-day mortality for stroke survivors4; 5; 8; 11; 103; 271. While HCT and HGB specifically show 
strong associations with stroke outcomes, evidence that RDW is informative even in ESRD 
patients with normal HGB demonstrates the relevance of studying the association between RDW 
and other cardiovascular and cerebrovascular diseases4; 6; 8; 249; 261; 272; 273. Within the last three 
years, several studies have specifically evaluated the association between RDW and ischemic 
stroke outcomes, primarily focusing on severity of disease and short-term mortality7; 9; 265; 266. For 
example, a study of 837 stroke patients in an Italian hospital found that a score derived from 
RDW at admission, age, and NIHSS had a positive predictive value (PPV) of 0.91 for the 
highest-risk group (>80% risk of unfavorable outcome), with a high specificity (0.97) but 
moderate sensitivity (0.37)266.  
Similar to ESRD and heart failure, inflammatory mechanisms are suspected to underlie 
these associations, because increased presence of proinflammatory cytokines in the bloodstream, 
for instance, can lead to inappropriate clot formation. Specifically, animal studies have shown an 
association between increased RDW and decreased nitric oxide function, which can negatively 
affect both the normal vascular constriction/dilation pathways and the ability of the brain to 




functional decline is an important part of stroke care, and current standards using NIHSS alone 
have been found wanting266; 269. While knowing the baseline RDW of a patient experiencing an 
acute stroke may not change the immediate course of treatment during the event, it may be 
beneficial for determining the patient’s prognosis as well as identifying the best follow-up 
treatment275. While this dissertation focuses on adult RBC traits, RDW has also recently been 
implicated in distinguishing stroke from similarly presenting diseases in children, for whom 
accurate and quick diagnoses are crucial to prevent permanent disability276.  
 
3.7. State of the literature: RBC trait genetics 
The relationship between genetic variation and expressed phenotypes was famously first 
described by the Augustinian friar Gregor Mendel in the late 1850s by demonstrating recessive 
trait expression patterns in pea plants277. The aptly named theory of Mendelian inheritance—i.e., 
monogenic traits or diseases that are inherited across generations following Mendel's three laws 
of inheritance—was the primary driver for discovering the genes underlying many traits, 
particularly recessive diseases, throughout the late 19th and early 20th centuries278. Genetic 
segregation of diseases using family pedigrees—particularly when the disease is highly penetrant 
and the mode of inheritance is either autosomal dominant or recessive—was the primary type of 
analysis used to identify the causes of hereditary monogenic disorders through the mid-20th 
century. Extremely detailed information on every individual pedigree member’s phenotype, risk 
factors, and relationships with other pedigree members (including consanguinity when present) 
was required in early family studies to ensure accuracy in describing the mode of inheritance so 
that candidate loci could be established in future analyses65. As described below, the challenges 




QTL linkage analysis and candidate-gene studies, so pedigree-based analyses of monogenic 
anemias dominated RBC genetic studies prior to the GWAS era.  
3.7.1. Linkage analysis studies 
Identification of causal loci throughout the second half of the 20th century was primarily 
performed using linkage analysis in family studies with large pedigrees, in which the mode of 
inheritance was discernable279. Linkage analysis examines the association between genetic 
markers (originally several thousand microsatellites distributed across all autosomal 
chromosomes) and a trait of interest by calculating the log of the odds (LOD) score, which 
utilizes the maximum likelihood of the ratio of recombination rate within observed pedigrees to 
the recombination rate for independently segregating loci (50%)280. The field-standard 
significance threshold has typically been a LOD score of 3, representing an odds of 1:1000 that 
the association exists by chance281. As linkage analysis became established as the premier 
method for studying monogenic disorders, multiple families with shared phenotypes were used 
in the same study, which had the added benefit of forcing researchers and clinicians to 
distinguish between similar phenotypes which resulted from different underlying causal loci282.  
The first genetic studies performed in RBC traits or diseases, similar to other monogenic 
and complex traits, were linkage analyses performed in family-based studies281; 283-285. 
Monogenic recessive anemias were some of the earliest diseases for which causal loci were 
identified, and this represented the vast majority of studies involving RBC traits or diseases prior 
to 2009 (Table 1). In 1997, for example, Diamond-Blackfan anemia, a very severe anemia 
typically manifesting in infancy, was mapped using linkage analysis to a 1.8Mb region on the 




year, the most common form of congenital dyserythropoietic anemia (CDA II) was mapped to 
chr20q11.2 with a maximum LOD score of 5.4287.  
Family-based linkage analysis was highly successful in identifying causal Mendelian-
disease loci, but loci associated with several complex diseases—e.g., non-Lynch syndrome 
colorectal cancer, obesity, and hypertension—have also been identified281; 288-293. With regard to 
interval-scale RBC traits, several loci were identified by linkage studies that contain genes with 
functional roles, such as the HBS1L/MYB locus on chr6q23: in a population of 1,789 people, one 
copy of the allele was associated with a decrease of 0.074x1012 RBCs/mL294; 295. In another 
example, a 2013 QTL analysis of RBC traits in an Amish pedigree with 384 individuals 
identified several blood trait associations previously unreported in linkage analysis, including a 
peak for RDW at chr10p12. The associated region contains both SEC23B, which has been 
causally associated with congenital dyserythropoietic anemia II, and BMP2, which is a known 
modifier of hemochromatosis296-298. Finally, another study in a large Amish pedigree that 
included 395 individuals with von Willebrand disease identified a significant association with 
RBCC at chr4q25299. Abbot, et al, did not implicate any candidate genes in this region; however, 
RPL34 is located within the presumed peak at chr4q25, and nine other components of the 
ribosomal protein complex have been causally associated with Diamond-Blackfan anemia, likely 
due to the highly proliferative nature of RBCs, making this a reasonable gene to explore in 
candidate-gene studies300. 
Because HSCs are the shared progenitor cells for all blood cell types, erythropoiesis 
requires a highly specialized procession of initiation and subsequent reduction in specific gene 
products to result in the final product of mature erythrocytes. Based on molecular analyses of 




proportion of population-level variability in RBC traits is likely attributable to regulatory 
variation and that all of the traits are highly polygenic31; 301. Since two copies of each gene across 
autosomal chromosomes exist for each individual and the effect size of non-coding variants is 
expected to be small on average, loci including primarily regulatory variants are expected to be 
difficult to detect using linkage analysis. See Figure S1 and Table 4 for a basic overview of how 
variation in genetic processes may affect a phenotype and which of those processes will be 
evaluated in this work.  
3.7.2. RBC trait candidate gene studies  
Genomic regions associated with complex traits in linkage analysis can be several million 
base pairs (megabases, or Mb) long, meaning a relatively large number of genes could fall within 
a suspected causal locus and require further investigation. Candidate gene studies are analyses 
that focus on a narrow genomic region or small set of genes expected to be causally associated 
with a trait of interest; historically, these studies were performed on genes within regions 
implicated by linkage analysis280. Once associations are identified, the most promising functional 
candidates being carried forward to population-based or molecular analysis.  
Several dozen genes identified using a candidate-gene approach have been well 
characterized in human or mouse molecular models of RBCs, whether for general functional 
analysis or to identify pathogenic variants (see below)78; 87; 302-307. However, the vast majority of 
genetic characterization in these studies originated from family-based studies of monogenic RBC 
diseases—rather than interval traits—as the outcome, although several interesting results have 
been reported in animal candidate-gene analyses. Hickley, et al, included a review of RBC trait 
genetic studies which included two Framingham QTL/linkage studies; two additional 




GWAS including one or more RBC traits (Table 5); and only two candidate gene studies of RBC 
traits in general population members20; 21; 25; 283; 294; 308-315.  
In one of few candidate-gene studies of RBC traits, polymorphisms in EPOR (the 
erythropoietin receptor) were associated with HCT, leading to a better understanding decades 
later of the effect of synthetic EPO treatment on anemia in hemodialysis patients316. In another 
study of participants with a long ancestry of high-altitude living, HGB was associated with 
population-specific variants in EPAS1, which encodes the known inflammatory protein HIF2α, 
or hypoxia-inducible factor 2 alpha317. The most comprehensive candidate-gene study of RBC 
interval traits was performed by Lo, et al, in 2011, evaluating genotyped SNPs in approximately 
2,100 genes318. This study was the first to report the now well-studied association between 
rs1050828 and hemolytic anemia due to G6PD deficiency (although the disorder was first 
mapped to this gene in 1998 by Puck & Willard)318; 319. 
Linkage analysis followed by candidate-gene studies is still the field standard for diseases 
or phenotypes for which only one or a few loci contribute, particularly when extensive pedigrees 
or a large number of families are available. However, while the traditional design of candidate-
gene studies is not inherently weak, this approach was not generally successful for identifying a 
large number of true associations among complex quantitative traits31; 320; 321. Recognition of this 
weakness led to the enthusiastic shift toward GWAS once genotyping assays became 
commercially available (see Section 3.7.4). Although several associations were successfully 
reported for RBC traits, linkage analysis followed by candidate-gene studies was not nearly as 
successful as GWAS have been in identifying the large number of loci expected to contribute to 




3.7.3. RBC molecular genetics 
Based in large part on the work evaluating monogenic RBC disorders, known 
contributors to RBC developmental regulation include a large number of transcription factors for 
promotion or repression of key sets of genes during the differentiation process, as well as 
microRNAs (see Appendix A). Three relevant proteins are described below for the purposes of 
explaining how molecular characterization of genetic loci successfully contributed to 
understanding the biology of RBCs based on analysis of monogenic RBC disorders prior to the 
GWAS era. Ideally, future discovery loci for RBC traits could provide candidate genes that result 
in similar elucidation of RBC physiologic mechanisms. This section addresses successful 
molecular characterization of genes associated with monogenic RBC disorders, demonstrating 
the type of information that could be gleaned from identifying RBC trait loci via population-
based studies.  
3.7.3.1  HbF (fetal hemoglobin) 
Of several genes that encode hemoglobin subunits in humans, the primary subunits 
expressed after birth are almost exclusively hemoglobin alpha (expressed from the HBA1 gene) 
and hemoglobin beta (expressed from the HBB gene). Fetal hemoglobin, encoded by the HBG1 
and HBG2 genes and resulting in similarly structured gamma subunits, are the secondary 
subunits expressed alongside the second HBA subunit (transcribed from HBA2) in utero322. 
HBG1/2 transcription is diminished to being expressed only in F blood cells after birth, with 
these cells comprising only approximately 0.6% of total RBCs on average. However, the 
proportion of total RBCs that are F cells varies up to twenty-fold in adults, and exhibits higher 
heritability than other RBC traits323-325. BCL11A, HBS1L/MYB, and Xmn1-HBG2 are major 




demonstrated to ameliorate the severity of beta thalassemia322. Several genes involved directly in 
regulating HbF have been identified in GWAS (Section 3.7.4). 
3.7.3.2  BCL11A 
BCL11A is required for HSC function and plays a large role in the repression of gamma-
globin genes during the post-natal hemoglobin switch from primarily α2γ2 (fetal hemoglobin, or 
HbF) to primarily α2β2 (the primary form of adult hemoglobin, or HbA)322; 324. BCL11A 
deficiency leads to HbF induction in mice322. Three DNAseI sites have been identified upstream 
of the transcription start site (TSS), with the one at +58kb affecting HbF expression to the 
greatest extent. The BCL11A locus has been associated with MCH, MCV, RBCC, and RDW in 
GWAS (see below)26; 301. Due to the role BCL11A plays in HbF expression, it is a target gene of 
interest for individuals with insufficient generation of HbA. In fact, some progress has been 
shown in this area of research in mice for other gene-editing therapies or induction of proteins in 
vitro, with promising results in early gene-therapy human clinical trials for patients with sickle 
cell disease or alpha- or beta thalassemia322; 326-329. One could expect that genes regulated directly 
or indirectly by BCL11A are good candidates for being involved in RBC biology, meaning this 
transcription factor should be considered in bioinformatic analysis of RBC trait GWAS. As 
described below, the BCL11A locus has been associated with multiple RBC traits17; 26; 301. 
3.7.3.3  KLF1 
Kruppel-Like Factor 1, or KLF1, was first discovered in 1992, and is a member of a 
family of zinc-finger-containing transcription factors found in the cytoplasm as well as the 
nucleus330. Exclusively expressed in erythroblasts (Figure 1), KLF1 acts as primarily as a 
transcriptional activator, including regulation of long noncoding RNAs (lncRNAs) and BCL11A 




Linkage analysis of a family exhibiting hereditary persistence of fetal hemoglobin (HPFH) led to 
candidate-gene analysis of KLF1, which identified a heterozygous mutation segregating with the 
phenotype; functional assays then implicated KLF1 haploinsufficiency with overexpression of 
hemoglobin gamma subunit in adults332. As described below, the KLF1 locus on chr19 has been 
associated with both RBCC and MCHC; other loci containing members of the KLF gene family 
have been associated with other RBC traits301. 
3.7.4. Genome-wide association studies 
The underlying theory behind GWAS is often referred to as the “common-disease-
common-variant” hypothesis, or the idea that a large number of common variants (the majority 
of which are expected to have small effects) contribute to diseases that occur frequently in most 
global populations. Linkage disequilibrium—i.e., the likelihood that two variants will be 
contained on the same haplotype across generations—at an associated locus will determine how 
physically large the association "peak" is, which is relevant to determining functional candidate 
variants285. GWAS were designed to address several insufficiencies in traditional linkage-
analysis and candidate-gene studies that prevented identification of potential causal loci. 
Specifically, complex phenotypes—particularly those expected to have a large number of 
contributing loci with small effect sizes—demanded a larger sample size with denser genomic 
coverage than is available using standard linkage-analysis markers. Furthermore, incomplete 
penetrance or lack of large pedigrees limits the utility of such studies—for instance, a phenotype 
such as SCD might be reportable across multiple generations, but HGB values were not widely 
measured before the mid 20th century.  
A decade of work by two separate groups attempting to sequence the entire genome 




arrays were designed both commercially and at select academic institutions to capture variation 
on a population level (the first arrays included 100,000 to 450,000 single nucleotide 
polymorphisms [SNPs]); this was followed by the genotyping of thousands of participants from 
established cohort studies or biorepositories. Based on the common-disease common-variant 
hypothesis, leveraging the LD structure of large study populations was expected to contribute 
findings that represented most, if not all, of the heritable portion of common complex diseases or 
traits. 
Although the methods devised to perform GWAS are more powerful than linkage 
analysis to detect narrow loci with small effect sizes, one GWAS will not be sufficient to identify 
all loci associated with the trait of interest. Of particular relevance to translational work, strong 
associations identified in a GWAS may be subject to "winner's curse", or the false-positive 
identification of an association which does not replicate in similarly structured populations335-338. 
In summary, GWAS are a useful tool for identifying genetic associations with complex 
quantitative traits, and continued efforts in this area complemented by new methods are expected 
to produce additional associated loci15; 31; 301. 
3.7.4.1  Ancestrally diverse study populations in GWAS 
An impressive catalog of genes has been associated with complex traits via GWAS, but 
missing heritability suggests more associations remain to be identified. While other genomic 
features may account for some of this heritability, it is likely that more genes affecting these 
traits remain to be discovered339-341. For the first decade of GWAS, the vast majority of study 
populations were restricted to European or European-descent populations, a practice driven by 
convenience as well as ignorance regarding the methodological benefits (never mind the ethical 




based on European LD structure and performed in European populations can face issues with 
long LD blocks which can obscure true signals346. Genes with a functional role in a given trait 
may exhibit multiple causal variants which are in LD in some populations, leading to the 
inability to detect independent multiple associations in that population or a dilution of the signal 
in instances for which the coded alleles have opposite directions of effect347. As described in 
Sections 3.8.2. and 3.8.3., study populations which are representative of global ancestral 
populations improve the ability to identify associations which may be detectable only in one 
ancestral population but applicable to the outcome of interest in all populations. 
3.7.5. RBC trait genetic association studies 
To date, 17 GWAS have been performed with various combinations of RBC traits as the 
outcome(s) of interest16-22; 24-27; 29; 301; 309; 310; 314; 348. Several exome-sequencing efforts and meta-
analyses have identified additional signals, some of which have independently replicated27; 28; 30. 
For a comprehensive description and lists of known genetic associations with the RBC traits 
discussed in this work, see Table 5 for highlights. For a highlight of associations that exhibit 
strong associations in multiple GWAS and have also demonstrated evidence of RBC trait eQTLs. 
Of note, while loci reported as discoveries in Table 5 showed the first connection to population-
level variability of with RBC traits, a large proportion were already known to play a role in RBC 
biology (such as EPO, BCL11A, and HK1).   
3.7.5.1  Major findings 
The first GWAS of RBC traits was performed by Yang, et al, in the Framingham study 
population—comprising approximately 1,000 people representing 310 families—in 2007, and 
evaluated 12 total phenotypes including HGB, RBCC, MCV, and MCH310. After adjusting for 




designed based on European ancestral variation; p<4.2x10-8), the authors did not report any 
significant associations for the RBC traits they analyzed. However, they did note suggestive 
associations for SNPs located in or near known RBC trait candidate genes, including HBB and 
EPB4IL2. While this effort was an important contribution to the beginning of the GWAS era, 
their lack of statistically significant findings foreshadowed future studies recognizing that 
sufficient sample size, dense genotyping arrays with globally representative ancestral variation, 
and high-quality imputation are important when conducting population-based genetics analyses 
with such stringent significance thresholds and power requirements310; 349; 350.  
GWAS by Soranzo, et al; Ganesh, et al; and Chambers, et al—published within one 
month of each other in fall 2009—demonstrated the benefits of improved sample size and 
methodology17; 25; 314. Of these three similarly timed GWAS, Chambers, et al, primarily focused 
on characterizing two findings: HFE variant rs199846 for HGB, MCH, MCHC, and MCV; and 
the functional TMPRSS6 variant rs855791 for HGB314. Although conditional analysis was not 
performed in this study, the authors described 13 TMPRSS6 variants and five HFE variants that 
exceeded GWS 5x10-8 in their combined study population314. Soranzo, et al, described findings 
for eight hematological traits (including five RBC traits) in the HaemGen consortium of 
approximately 14,000 European study participants25. Among their findings were the same 
TMPRSS6 and HFE functional variants described by Chambers, et al, as well as findings that 
were consistent with Ganesh, et al (TFR2, CCND3) or reported for the first time in that study 
population (FBXO7)17; 314. Ganesh, et al, identified the highest number of previously unreported 
GWS associations of the three studies published in the same month, likely due to both sample 
size and assessing the log-transformed version of each RBC trait, as prior GWAS had used 




since been replicated and generalized to multiple populations—for example, Ganesh, et al, 
identified TFRC, MARCH8, and PRKCE (Table 7)17. 
The first GWAS of hematological traits in an exclusively non-European population was 
performed by Kamatani, et al, in 2010, and included nearly 15,000 Japanese individuals in 
Japan20. This comprehensive work also evaluated platelet and white blood cell traits, and the 
authors identified 28 RBC trait discovery associations (21 loci, five of which were GWS in more 
than one RBC trait), several of which have since been classified as RBC trait eQTLs20; 109. 
Although a Japanese-only study population might suffer from similar genetic homogeneity issues 
as a European-ancestry study population, this study identified a large number of discovery loci, 
possibly due to differences in LD structure between East Asian- and European-ancestry 
populations. The same year, Kullo, et al, published a study of RBC traits performed using 
electronic medical record (EMR) data, evaluating slightly fewer than 500,000 SNPs (the Illumina 
Human660W-Quadv genotyping platform, excluding about 50,000 SNPs for QC with no 
imputation) and identifying one new signal (SLC12A2, which is over 1Mb away from the HFE 
locus but has not been considered an independent locus in other GWAS) in a study population of 
slightly over 3,000 individuals21.  
In 2012, the first RBC trait GWAS incorporating both African American and European 
American study participants was published by Li, et al, and evaluated six RBC traits, white blood 
cell count, and platelet count in over 14,000 children22. This study was performed in children and 
therefore possibly less relevant to adult phenotypes as described in the rest of this work. 
However, Li, et al, contributed the first extensive conditional analysis of the HBA1/2 region 




genetic architecture and the significance of conditional analysis and fine-mapping to identify all 
potential independent signals within a genomic region22; 351. 
Van der Harst, et al, performed the first RBC trait GWAS in a truly large study 
population of European whites and South Asians from more than a dozen cohort studies26. The 
title of the article, “Seventy-five genetic loci influencing the human red blood cell,” 
demonstrates the relative success obtained by leveraging a large study population to improve 
statistical power and identify previously unreported loci. Additionally, several loci were chosen 
by the authors for extensive molecular evaluation, resulting in high-quality functional analysis of 
traits which could be used as a guideline for future molecular follow-up to GWAS findings. 
While van der Harst, et al, contributed a large number of previously unreported loci to consider 
for further evaluation, the study population was restricted to two race/ethnic groups, and hence 
would be limited with regard to fine-mapping or identification RBC trait associations led by a 
rare variant on African or Amerindian ancestral haplotypes, for example26; 34; 352. 
Chen, et al (2013), and Hodonsky, et al (2017) performed the first RBC trait GWAS in 
solely African Americans (COGENT) and Hispanic/Latino Americans (HCHS/SOL), 
respectively18; 29. Notably, among COGENT participants an African-ancestry-specific 3.7kb 
deletion was demonstrated to associate independently of other polymorphisms at the alpha-
globin locus, which could not be evaluated in a European- or Asian-ancestry-only study 
population29. While Chen, et al, identified associations at three previously unreported loci (one of 
which was GWS for two traits), none of the associations were replicated in smaller African 
American study populations Children's Hospital of Philadelphia (CHOP) or eMERGE (an 
NHGRI-funded network of DNA repositories linked to EMR), nor achieving suggestive 




discovery findings among HCHS/SOL participants was performed in a maximum of 7,100 
Hispanic/Latino participants of MESA, WHI, and IMSSM; three of seven associations replicated 
when accounting for multiple testing18. Both of these studies demonstrate that finding an 
appropriate study population to replicate or generalize findings identified in non-European-
ancestry populations remains a challenge. More importantly, the discovery loci and independent 
associations within previously reported loci identified in each study emphasize the importance of 
including ancestrally diverse populations in genomic studies. Inclusive genomic analyses will 
better capture global variation but can also utilize differences in genetic architecture—
particularly in populations with ancestral admixture—to better allow identification of narrow 
candidate functional regions well suited for molecular characterization. 
Recently, Astle, et al, published a GWAS of over two dozen WBC, RBC, and platelet 
traits in 172,000 European-ancestry individuals, including the UK BioBank301. This study 
reported a vastly higher number of novel associations (>1,000 independent associations across 
all RBC traits) compared to previous studies, due in part to sheer sample size and improved 
imputation quality allowing for better representation of genetic variation across the genome. 
However, this effort was only recently published, meaning attempts to generalize and subsequent 
fine-mapping of these associations in non-European populations, for instance, have yet to be 
reported. Such attempts could provide a more reasonable number of candidate functional genes 
into focus for further investigation. In a similarly well-powered study, Kanai, et al, published a 
GWAS of over 50 traits in 2018—including several quantitative hematological traits—using data 
from a large Japanese BioBank (n~108,000)348. This work highlighted the relevance of known 
loci across ancestral populations, and identified an additional 44 previously unreported 





Together, published RBC trait GWAS have repeatedly identified common- or infrequent 
variants contributing to population-level RBC trait variation at genes with known Mendelian-
disease variants. For example, the AK1 locus was associated with RBCC, HCT, and HGB in the 
Astle, et al, study, even though the prevalence of the associated monogenic condition, hemolytic 
anemia due to adenylate kinase deficiency, is very rare in the general population (Table 1)301. 
Some of these findings have functions specific to RBCs, whereas some have biological 
implications for a wide range of tissues, suggesting closer examination of potential functional 
candidates is merited to determine why significant associations with RBC traits are reported. 
Furthermore, hundreds of associations have been identified through GWAS that have not been 
reported in the candidate-gene literature for monogenic anemias, some of which have been 
confirmed with in vitro or animal model experimentation26. However, based on RBC trait 
heritability estimates and the proportion of population variability explained by known loci, there 
remain additional unreported loci that are causally associated with one or more RBC traits15. As 
has recently been demonstrated, study populations exclusively representing European are more 
likely to identify genetic associations that are difficult to characterize because of large LD 
blocks. Improved representation of global ancestries will improve discovery, particularly for 
studies including populations exhibiting ancestral admixture301; 344. Additionally, even if a 
GWAS index variant is population-specific, identifying the associated gene can yield 





3.8. State of the literature: quantitative trait analysis 
The underlying philosophy driving GWAS stipulates that one or more functional variants 
within an LD-based region affect gene expression, and this transcription level change sufficiently 
affects the amount of protein end-product to affect the phenotype of interest. However, the 
assumptions underlying univariate analysis have failed to account for the proportion of 
heritability measured in many complex quantitative traits, meaning that one of the following 
situations may apply: (1) heritability estimates are failing to account for another portion of 
population-level trait variation that is neither purely genetic nor environmental in nature (see 
Appendix A for a brief introduction to epigenetics); (2) a large number of contributing loci 
remain to be identified for complex quantitative traits; or (3) some combination of both340; 341; 353-
355.  
As described above, GWAS have been extremely prolific in terms of identifying genomic 
loci that exhibit strong evidence of association with complex traits15; 356. However, 
inconsistencies between estimated and explained heritability,357-359 proportional increases in 
variance explained when considering all GWAS variants,360-363 and increases in GWAS-
identified novel loci with increasing sample size343; 362; 364-388 all suggest that multiple loci remain 
unidentified.  
3.8.1. Pleiotropy 
One avenue to address missing heritability is by exploiting the correlation between traits 
with a suspected shared genetic basis (i.e., “pleiotropy”) to increase statistical power. The 
concept of pleiotropy was first discussed in the 1950s, and animal models, particularly D. 
Melanogaster, have been used in the molecular evaluation of pleiotropy for over 50 years389-392. 




phenotypes, such as CHARGE syndrome or velocardiofacial syndrome, exhibit pleiotropy by 
definition393-396. Without identifying the actual genes at play, several family-based studies have 
successfully used pairs or groups of traits to identify pleiotropic mechanisms underlying 
phenotypes such as metabolic traits and lipid biomarkers since the early 90s397-399. Correlated 
traits have long been understood to have a shared genetic basis, and highly polygenic complex 
traits in particular have been understood to be good candidates for pleiotropy since the 
development of quantitative trait linkage analysis methods400; 401. 
Since the outset of population-based genomic analyses, multiple complex traits being 
associated with the same locus has been demonstrated for multiple seemingly distinct groups of 
phenotypes or diseases401-404. Over the past decade it has become clear that pleiotropy is 
extremely common among complex traits that share biological underpinnings, including RBC 
traits—within five years of the first GWAS, nearly 5% of GWAS loci were reported to be 
associated with more than one trait400; 401; 403; 405. As a specific example, GWAS of autoimmune 
disorders have shown that rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and 
Sjoegren’s Syndrome largely overlap in symptomatology, relevant biomarkers, and genetic-
association signatures14; 402; 406-411. These diseases typically do not present together in individuals 
but they do commonly co-occur in families, suggesting that overlapping genetic architecture of 
these diseases includes both shared and disease-specific causal variants12; 14; 402; 403; 406; 412. 
Therefore, it stands to reason that diseases like RA, SLE, and Sjoegren’s Syndrome may also 
share a genetic signature that could be identified by incorporating information from all of the 
traits into one analysis. In a gene-expression meta-analysis of RA, SLE, and Sjoegren’s 
Syndrome, Toro-Dominguez, et al, identified 371 genes that were significantly differentially 




In a separate cross-phenotype analysis of immune-disease risk SNPs in seven auto-immune 
diseases, 47% of SNPs tested were associated with more than one but not all of the phenotypes 
tested14. Continuing to leverage correlation among traits is important in the genomics era: 
identification of loci with shared effects across traits of interest as well as clarification of the 
molecular relationships between correlated traits could lead to new application of treatments that 
have been successful in diseases with shared genetic architecture413; 414. 
Despite the long-standing awareness of pleiotropy in both monogenic and complex 
phenotypes, genomic studies of pleiotropy have been mostly limited to evaluating shared signals 
in traits that have been analyzed individually. Methods to evaluate correlated traits in 
combination have only been developed within the last decade, and implementation of these 
methods requires a sufficient sample size, often deeply phenotyped data, and access to highly-
powered computing clusters. Recently introduced methods have shown the value of analyzing 
multiple related traits together that are expected to share an underlying biology. Combined-
phenotype analysis has been successful in identifying associations that were not significant in 
univariate analyses of any one trait for groups of phenotypes known to share biological pathways 
and overlap in physiologic mechanisms 415-417. Below we describe the mechanisms behind 
pleiotropy as well as the benefits of co-examining traits that likely share genetic underpinnings. 
 
3.8.1.1 Definition and description of biological pleiotropy 
In order to describe why assessing pleiotropy improves on standard GWAS methodology, 
we must consider the mechanism(s) underlying an association signal shared by multiple 
phenotypes418. As described by Solovieff, et al, in 2013, pleiotropy identified in a genetic 




on biological, or “true”, pleiotropy. Descriptions in the literature vary widely with regard to 
whether the term “pleiotropy” refers to a single causal variant, a locus, or a gene. Here, we 
define pleiotropy as the effect of one variant on multiple phenotypes (in this work, RBC traits), 
without making claims as to the relevant tissue type(s) or proposed function aside from that 
which can be implicated via bioinformatics analysis (Section 3.8.2.3.). The expectation of 
identifying "true" pleiotropic variants is that performing validation studies in a molecular setting 
would characterize one or more causal SNPs with a measurable effect on multiple associated 
traits. While we cannot assign functional pleiotropy to potential causal variants within the scope 
of this work, combined-phenotype analysis of correlated traits which are suspected to exhibit 
overlapping genetic architecture has been used as a proxy for pleiotropy with success419; 420.  
3.8.1.2 Combined-phenotype studies 
  As described above, correlated traits often show a moderate to significant amount of 
overlap in associated genomic loci, suggesting a potential point of leverage for identifying loci 
associated with multiple correlated phenotypes but not previously reported for any of them 
individually. Correlation among a set of traits that also share some biological underpinnings 
makes such traits excellent candidates for pleiotropy402; 421; 422. Many groups of correlated 
phenotypes are expected to share some underlying biology, but this potentially useful feature 
cannot be utilized in traditional GWAS. While pleiotropy is suspected to be the genomic feature 
at work behind many shared association signals across correlated traits, causality cannot be 
assigned directly in association studies. Such limitations have prompted use of the phrase 
“combined phenotype association” or “multi-phenotype association” in the absence of a 




3.8.1.2.1 Combined-phenotype analysis using summary statistics 
One area of active research is the combination of univariate GWAS summary statistics 
for combined-phenotype inference. Compared to individual-level data, analysis of summary 
statistics for multiple phenotypes benefits when population sizes differ across traits, or summary 
statistics for the traits of interest are publicly available (for instance, from dbGAP)345; 347; 419; 423. 
Ours and others' work has demonstrated that these methods are scalable to densely imputed 
GWAS data; are accurate for common (MAF>0.05) as well as uncommon (0.01<MAF<0.05) 
variants; and have shown success identifying loci undetected by very large GWAS415.  
Many combined-phenotype and multi-phenotype methods are currently available; we 
present a comprehensive evaluation of eight methods in Section 4.4.3, which indicates that the 
adaptive sum of powered score (aSPU) test is well-suited to the proposed work. In this 
supportive work, we also performed combined-phenotype analysis of published body-mass index 
(BMI),364 waist-hip ratio,365 fasting glucose, and fasting insulin424 summary statistics (HapMap 2 
imputed data) from consortia of predominantly EU participants (N range: 51,750 [fasting insulin] 
– 339,224 [BMI]) to interrogate potential pleiotropy425; 426. Six previously unreported loci were 
significantly associated (p < 5.0x10-8) with aggregated information for all four phenotypes, but 
none of the traits in univariate analysis. These results show the utility of combined-phenotype 
analyses to identify novel loci undetected by meta-GWAS. 
3.8.1.3 Leveraging RBC trait correlation for evidence of shared genetic associations 
Identifying pleiotropic loci in the context of multiple traits can benefit basic-science and 
translational research, as a shared effect on more than one trait may help elucidate undescribed 
molecular pathways contributing to that trait, or in some cases even implicate shared treatment 
options for disease phenotypes401; 402; 427. Understanding how overall gene expression affects one 




can also improve understanding of that gene’s biological role across phenotypes413; 418; 428; 429. 
RBC traits exhibit a range of correlation, with several trait pairs being moderately or highly 
correlated. While trait correlation is not necessary for pleiotropy to exist, highly correlated traits 
can be an indicator of a common underlying mechanism, either genetic or environmental, with 
pleiotropy being a reasonable expectation347.  
Of equal import, RBC trait GWAS have uncovered associations that consistently 
replicate across multiple traits and diverse study populations17; 18; 26; 29; 301. Table 6 demonstrates 
that while some signals associate strongly and repeatedly with only one or two RBC traits, 
several association signals have been found for multiple traits across study populations. In 
combination with the fact that visualization of results shows a distribution including suggestively 
significant association signals with strong tails in many published RBC trait GWAS, available 
evidence suggests that RBC traits exhibit pleiotropy and are therefore excellent candidates for a 
combined-phenotype approach28. 
3.8.1.4 Benefits of combined-phenotype analysis 
There are multiple benefits to analysis methods that leverage correlation across traits, 
beginning with statistical gains over traditional GWAS methods418; 430. The number of 
suggestively significant associations in univariate GWAS—some of which are almost certainly 
true associations that the analysis is underpowered to detect—implies that increased power 
would improve the ability to identify new associations. Recently developed methods combining 
trait summary statistics demonstrate a cost-effective gain in statistical power compared to the 
alternative of analyzing hundreds of thousands of individuals for each trait301; 425; 430; 431. 
Statistical power is increased for discovery when an association is present for multiple traits, 




for highly polygenic traits which likely have a large number of contributing causal variants with 
(primarily) small effect sizes that are influenced by lack of precision and relatively small study 
populations301; 433; 434. 
Additionally, fine-mapping of known and previously unreported loci (described more 
fully in Section 3.8.2) to detect independent associations as well as identifying potential causal 
variants can be improved when analyzing traits together435. Recent work indicates that fine-
mapping of multiple correlated traits can significantly reduce the number of SNPs required to 
identify the 90% credible set compared to fine-mapping phenotype results individually. 
Additionally, shared genetic architecture among traits with different units of measurement (i.e., 
variable effect sizes) can benefit from a combination of summary statistics which allows for 
difference in effect by trait (see Section 4.4.4.4.)347; 436. In combination, the benefits of 
combined-phenotype analysis show great promise to detect and characterize loci underlying a 
shared genetic architecture.  
3.8.1.5 Limitations of combined-phenotype analysis  
Several limitations to combined-phenotype analysis do merit examination. Foremost, all 
of the above pleiotropic mechanisms can be implied but not confirmed by association studies; 
evidence of pleiotropy requires more extensive functional evaluation than can be ascertained 
from association studies alone. Additionally, fine mapping of combined-phenotype results cannot 
detect trait-specific associations within one association signal—fine-mapping methods only test 
one variant per independent association signal but allelic heterogeneity is common, particularly 
when multiple tissues may be involved in the physiology of the outcomes. If multiple variants 
contribute to one signal via different traits, narrowing down a list of causal variants may be 




GWAS of RBC traits have consistently demonstrated replication in some traits for 
association signals that are rarely or never found in other traits—for example, the functional 
variant rs855791 in TMPRSS6 strongly associates with multiple RBC traits but has never been 
reported for RBC count (Table 6). While our definition of pleiotropy and proposed combined-
phenotype analysis methods emphasize the shared effect of a single variant within an association 
signal on correlated traits, the importance of assessing pleiotropy at the gene level cannot be 
overlooked, although it outside the scope of the proposed project. Genes expressed in multiple 
tissue types often exhibit tissue-specific isoforms, and causal variants in shared (or variably 
expressed) exons may lead to true pleiotropy even in diseases that present very differently428; 439-
442. Finally, some methods for combined analysis of summary statistics from multiple phenotypes 
require extensive computing resources for simulations, preventing analysts from differentiating 
between signals that exceed our proposed GWS threshold of ~8x10-9. However, our continued 
evaluation and refinement of available methods suggests several alternatives that are under 
investigation. Overall, none of these limitations preclude combined-phenotype analysis from 
being a useful tool to identify previously unreported genetic associations with RBC traits, and 
their benefits suggest that they will be useful for identifying associations which do not exceed 
GWS in univariate analyses. 
3.8.1.6 Summary 
The proposed work will leverage RBC trait correlation in a diverse study population and 
established combined-phenotype analysis methods to attempt to identify genomic loci that 
previous studies were underpowered to detect. We hypothesize that the improvement in power 
gained by evaluating traits with a shared genetic architecture will enable the identification of 




purposes but also for contextualizing the fine-mapping results of combined-phenotype genome-
wide-significant loci. 
3.8.2. Fine-mapping association signals identified in combined-phenotype GWAS 
Countless studies have demonstrated that—due to myriad factors including assay design, 
allelic heterogeneity and ancestral allele differences as described above, and 
genotyping/imputation quality—the index SNP within a particular association signal is rarely the 
causal variant 15; 31; 321; 443-445. Multiple functional variants may exist at one association signal 
within one or more ancestral subpopulations, and the presence of multiple associations may be 
obscured by LD with one tag SNP351. Additionally, many genetic variants exhibit some level of 
ancestry specificity (see below)—namely, their allele frequencies differ across global 
populations or may even be monomorphic in one or more continental ancestry groups. This 
becomes particularly problematic when considering that the only genotyping assays 
commercially available until very recently were biased toward European content, constraining 
studies of diverse populations.  
Once genome-wide-significant association signals for a specific trait (or group of 
correlated traits) have been determined in a GWAS, identifying and characterizing the potential 
causal variant(s) within each association signal becomes the primary task. Termed “fine-
mapping”, this approach attempts to refine loci identified through association studies include 
visualization of the LD structure within an association signal and comparison of that structure 
across ancestral populations. In addition to identifying variants most likely to affect a trait of 
interest, elucidating the LD structure underlying each association signal is merited in order to 
identify potential independent hits—i.e., the presence of more than one causal variant within one 




Once a list of potential causal variants has been generated for each GWS association 
signal, bioinformatics analysis (see below) can aid in identifying which genes may have affected 
expression based on an individual's alleles. As referenced by van der Harst, et al, a large number 
of genes can cluster within a small portion of the genome (over 3,000 protein-coding genes were 
located within 75 GWS loci identified in their study population). Furthermore, up to 95% of 
genes with more than one exon have multiple reported isoforms, and gene expression is 
frequently affected by multiple TFBS that may be bound in different combinations across tissues, 
so multiple causal non-coding variants is a logical possibility for any genetic association446-448.  
Fine-mapping can be extremely valuable for narrowing association signals to reduce the number 
of functional candidate variants. Independent signals within the same physical genomic region 
may exist, adding to the necessity of defining potential functional variants so functional variation 
within the locus can be described445. The primary benefits of fine mapping therefore include the 
ability to characterize independent signals within a locus using LD, as well as identifying a 
smaller number of potential functional variants for further characterization based on LD with the 
lead SNP at each association signal. However, in the case of combined-phenotype analysis 
results, it is possible for independent, physically proximal variants to be differentially causal for 
multiple RBC traits but contribute to the same association signal. In this situation, fine-mapping 
can only identify one candidate causal variant per association signal for all traits. This is an 
admitted limitation of the proposed work, but the broad overlap in biological pathways known to 
affect RBC traits suggests that prioritization of a single proposed functional variant per 




3.8.2.1 Allelic heterogeneity and ancestry-specific variation in fine-mapping 
Allelic heterogeneity refers to the presence of multiple causal genetic variants within one 
phenotype-associated locus, or the possibility of multiple regulatory mechanisms being affected 
for one gene. Causal variants within a locus can act separately but additively; counteract each 
other; or exhibit interaction if they are physically proximal or affected by the same regulatory 
pathway444; 449; 450. For example, variants located in two physically proximal transcription factor 
binding sites (TFBS) may both affect expression of one gene, but these may be detected as one 
signal (or go undetected) without both a diverse study population and fine-mapping efforts. 
Allelic heterogeneity is well-described for many Mendelian disorders—for example, an entire 
database has been established to describe the heterogeneity contributing to the 
hemoglobinopathies described above451; 452. This phenomenon has also been widely observed for 
complex traits, with a recently developed method implicating a substantial proportion of eQTLs 
(4-23%) and GWAS of several complex traits (35% for high-density lipoprotein concentrations 
and 50% for major depressive disorder)444. Sometimes allelic heterogeneity can be detected 
using conditional analysis, but other methods have shown promise in identifying the presence of 
multiple causal alleles within one GWAS signal, which benefit particularly from high-density 
genotyping and imputation of low-frequency or population-specific variants435; 437; 453; 454.  
As described above, the majority of published GWAS to date have been performed in 
exclusively or primarily European-ancestry populations38; 39; 455. The inclusion of ancestrally 
diverse study populations improves fine-mapping particularly in the arena of being able to detect 
variants that are very rare or monomorphic in European populations351; 437; 456. In particular, 
populations exhibiting ancestral admixture (e.g., Hispanics/Latinos and African Americans) 




contributing continental ancestries450; 457; 458. For example, a fine-mapping analysis in 
approximately 3,000 Mexican Americans of a large region containing several genes identified 
rs964184 as the only SNP in the 99% credible interval, exhibiting a strong association for 
triglyceride concentration459. This SNP has a much higher allele frequency in Native Americans 
than European-ancestry populations (MAF ~50% vs ~15%), corresponding to the admixture 
mapping association between Native American ancestry and the outcome. As this study 
demonstrates, non-coding ancestry-specific variants or variants with large allele-frequency 
differences across populations are good functional candidates; in this context, multi-ethnic fine-
mapping has been shown to greatly reduce the number of candidate functional variants.437; 460-463. 
In genomic loci exhibiting allelic heterogeneity (which is typically unknown in GWAS 
association signals), fine-mapping subsequent to conditional analysis can detect independent 
associations that may be haplotype-specific, which benefits the characterization of the biology 
underlying those loci437; 450; 464; 465. In light of the large number of loci involved in quantitative 
traits like RBC traits, fine-mapping is an important step for clarifying which variants may be 
good functional candidates when multiple may exist within one association signal in a large, 
trans-ethnic study population. 
3.8.2.2 Bioinformatic characterization of loci identified in association studies 
Within molecular genetics, a vast body of work has demonstrated that gene expression 
can be affected—even to the extreme of binary expression—by ablation or insertion of one 
nucleotide within a crucial TFBS466-469. Although molecular genetics have been employed for 
decades longer than cohort-based association studies, fine-mapping of GWAS associations has 
resulted in the successful identification of causal variants for multiple complex traits, including 




candidate genes for 75 GWS associations with one or more RBC traits using a combination of 
LD information, eQTL data, and pathway analysis; they further identified 100 candidate coding 
or regulatory sequence variants based on publicly available databases26; 470; 471. These candidate 
genes showed increased RBC-specific expression patterns compared to other genes when 
evaluated in vitro; RNA silencing experimentation in D. melanogaster also supported the role of 
several previously unreported candidate genes in RBC trait biology26. Furthermore, assessment 
of genomic segments representing regulatory function showed enrichment for RBC-related cell 
types compared to other cell types26.  
For these reasons, bioinformatic characterization of GWS association signals is important 
to prioritize potential causal variants based on available functional data, particularly via publicly 
available databases (examples representing the most common types of bioinformatic analysis are 
presented in Table 9). Computational algorithms which predict the pathogenicity of candidate 
functional variants have also been available for over a decade472-476. In the last five years, 
predictive algorithms have been designed for identifying shared pathways, protein-interaction 
networks (Figure 2), and tissue-specific gene expression based on information ranging from 
DNA sequence alone to molecular experimentation results. However, these predictive 
algorithms, while useful, are rarely tissue- or trait-specific, focusing instead on comparing final 
protein products for coding variants or the severity of transcription factor binding site changes. 
Additional resources have been developed to evaluate potential functional variants by 
incorporating multiple annotations, such as tissue-specific chromatin immunoprecipitation 
(ChIP) sequencing data or expression quantitative trait loci (eQTLs)476-481. To address the 
characterization of loci and prioritization of variants, other methods have been developed which 




FastPAINTOR and Mantra are two examples of programs designed to prioritize potential causal 
variants in fine-mapping studies435; 483. Identification of functional variants is the purpose behind 
genomic studies, because it will improve an understanding of human genetic architecture as well 
as uncovering the role of particular variants in a trait of interest484. Bioinformatic analysis is an 
excellent way to ascertain potential functional candidates within a region.  
3.8.3.     Association studies of rare variants 
Rare-variant studies are motivated by the same reason as common-variant studies: to identify 
genomic regions and, specifically, variants that may be causally associated with a phenotype of 
interest. Studies of complex traits such as metabolic disease, psychiatric disorders, and 
hypertension have identified rare- or low-frequency variants located in genomic regions not 
previously reported for these traits485-490. A rare variant is typically defined in as one which 
exhibits a minor allele frequency (MAF) < 0.01 in the total study population, and we will adhere 
to that standard in this work (Section 4.5.). Highly polygenic complex phenotypes are expected 
to be affected by a large number of both common and rare variants with variable effect sizes, 
with some combinations of allele frequency and effect magnitude being more difficult to detect 
than others using traditional GWAS43; 433.  
Inclusion of rare variants in association studies has only really been possible within the 
last five years due to improved genotyping quality; better assay coverage of non-European 
populations; increased-accuracy imputation methods; and the introduction of new forms of 
individual data (specifically, exome or whole-genome sequencing). Standard single-variant 
examination of rare variants exhibits reduced power compared to common-variant association 
studies by definition; even a reasonably large study population is unlikely to have enough copies 




typically reported in standard GWAS unless the study population is well-powered to detect the 
effects of rare variants, instead being evaluated using methods that test combined effects of 
multiple variants43; 491; 492.  
Exome-sequencing or whole-genome-sequencing studies are expected to further improve 
detection of significant associations driven by rare variants because direct measurement rather 
than genotyping allows for the capture of population-specific variants that are difficult to impute 
from genotyping arrays491. However, array-based exome-chip studies have shown success in 
identifying previously unreported associations for complex traits—for example, Nandakumar, et 
al, identified previously unreported rare variants associated with systolic- or diastolic blood 
pressure in ten genes in a study of nearly 16,000 African American participants using gene-based 
testing and single-variant analysis44; 493. While exome chips typically have better coverage of rare 
coding variants than genotyping arrays, it can be anticipated that high-quality imputation to a 
genotyping array with good coverage of variants representing multiple ancestries could be 
similarly successful to earlier efforts. For example, the Illumina Infinium Exome-24 v1.1 
Beadchip contains 227,000 exonic variants based on sequencing data from 12,000 individuals of 
European, African, Chinese, and Hispanic race/ethnic backgrounds; in contrast, the MEGA array 
contains 400,000 exonic variants based on sequencing data from over 36,000 individuals of 
diverse race/ethnic backgrounds, with 16,000 additional hand-curated variants improving 
coverage for candidate genes/regions from eight groups of traits494; 495. These findings 
demonstrate that until WGS data is widely available, high-quality imputation to genotyping 




3.8.3.1 Rare-variant studies in RBC traits 
As established above, a significant proportion of RBC trait narrow-sense heritability 
remains to be explained496; 497. Given the broad array of biological pathways in which rare 
variants are known to cause monogenic RBC disorders, it is reasonable to expect that rare 
variants with modest effect sizes contribute to similarly modest effects on RBC traits in loci that 
have yet to be reported in an association study. With regard to rare-variant studies in RBC traits, 
two exome-sequencing studies have been performed (see Table 5), but rare-variant findings 
reported outside of traditional GWAS have been limited because traditional methods with 
modest study populations are underpowered for rare-variant studies, even when sequencing data 
is available28; 30; 491. Chami, et al, performed a large exome-genotyping study incorporating both 
single-variant and gene-based analysis in a majority European-ancestry study population in 
collaboration with the Blood Cell Consortium (BCX)28. While the study authors reported 21 
previously unreported associations with RBC traits, several of those findings were located near 
genes already known to cause monogenic hereditary anemias and only four lead SNPs were low-
frequency or rare (MAF<5%) in the study population. Although the BCX study population 
comprises primarily European-ancestry study participants, approximately 20% of participants 
reported having African, East Asian, Hispanic/Latino, or South Asian ancestry, demonstrating 
that the inclusion of ancestrally-diverse study populations and dense coverage of the genome 
improve the ability to detect associations. 
3.8.3.2 Gene-based testing 
One approach to addressing the low power anticipated when testing rare variants (see 
below) is gene-based testing, or analysis of the combined effects of multiple rare variants within 




as all exons and splice site variants for all isoforms of one protein-coding open-reading-frame; 
sometimes the promoter region (100-1000bp) upstream of the first TSS is included. Several rare-
variant studies have successfully implemented gene-based analyses to identify previously 
unreported genomic loci for quantitative traits488-490; 498. The aforementioned BCX study 
highlights the relevance of gene-based testing by only reporting one significant association in 
single-variant analyses (rs201062903, a missense variant at the ALAS2 locus for MCH and MCV  
which is known to cause sideroblastic anemia), but identifying two additional genic associations 
in gene-based testing (PKLR for HCT and HGB as well as ALPK3 for MCHC)28. Gene-based 
findings reinforce the theory that a wide range of methods is required to successfully detect all 
loci contributing to population-level variability of a complex trait. Therefore, if a trait still 
exhibits evidence of missing heritability in spite of well-powered GWAS, rare-variant studies are 
a reasonable approach to identifying new associations that will contribute to characterizing the 
genetic architecture. However, the assumptions of the method being employed must be taken 
into consideration to ensure the most appropriate application for the study population(s) in 
question.  
In the most commonly used rare-variant tests, summary statistics from all variants within 
a pre-defined genomic region are collapsed or summarized to provide a single gene-based value 
(see Section 4.5.1.)499. Myriad methods have been designed and their selection depends on the 
goals of the research group performing the analysis; this work focuses on the combined 
burden/variance-component tests. Gene-based tests exhibit several benefits compared to single-
variant analyses that may be particularly meaningful in an ancestrally diverse study population 
which better represents the global distribution of rare variants than the most common study 




3.8.3.3 Benefits of gene-based testing 
A large proportion of rare variants reported in GWAS are ancestry-specific (i.e., variants 
that arose after human migration led to the establishment of modern continental ancestries)42; 470; 
500-502. It follows that rare-variant studies should not be limited to specific populations (e.g., 
European), as there is an established history—particularly with coding variants that play a role in 
hereditary anemias—of population-specific causal rare variants with causal roles in RBC traits88; 
332; 503. For example, the megaloblastic anemia-causing AMN or CUBN variants only occur in 
Nordic-descent individual for a disease prevalence of 200,000 in those populations504; 505. 
Similarly, an established 3.7kb HBA mutation is uncommon or rare in global populations (<2% 
in all non-African populations) but has been found to have a nearly 50% prevalence of 
homozygosity in a malaria-endemic region of Papua New Guinea (Table 1)506; 507. Studies 
incorporating whole-genome sequencing (WGS) would be the preferred method for discovery 
when performing gene-based testing, because variants that do not occur in reference genomes but 
are present in a particular study population would be detected in sequencing491; 508-511. However, 
WGS remains cost-prohibitive for study populations sufficiently large to have enough alleles, 
which limits the power to detect associations using gene-based or single-variant methods491; 509. 
Evaluating densely imputed genotype data in populations representing the distribution of global 
alleles provides an alternative that has shown success identifying variants for a variety of 
complex traits with different genetic architectures44; 301; 512-514. Therefore, it is advantageous to 
include large, multi-ethnic study populations, which will increase the number of rare variants 
being tested per gene when imputation quality is sufficient44; 495; 512.  
In summary, the successful causal association of both variants and genes that were not 




bolsters the argument in favor of performing rare-variant analyses. Because single variants with 
large effects are atypical (and a large number have already been reported for RBC traits), gene-
based tests have emerged for identification of rare variants, followed by bioinformatics or 
molecular characterization (see Section 3.8.3.4) to identify the most likely causal variants at 
candidate loci43; 491; 492. Since there are benefits to using gene-based testing when attempting to 
discover new associations when the limitations are appropriately addressed, we will employ this 
methodology for the second aim of this proposed work (see Section 4.5.).  
3.8.3.4 Limitations of gene-based rare-variant studies 
As with all genomic studies, rare-variant studies have disadvantages that need to be 
considered. First and foremost, accurate imputation of rare variants (MAF≤0.01) not included on 
study arrays is required in order to have sufficient information for gene-based testing to improve 
power over single-variant testing515. Attempts to improve sample size often include the 
collaboration of multiple cohort studies (as is the case with this work), which can lead to 
differences in availability of rare variants based on the genotype assay used (if varied across 
studies) and accompanying imputation quality. Several genotype assays have been recently 
developed that emphasize non-European variation into the scaffold and fine-mapped regions of 
the chip, improving the ability to impute across 1000 Genomes populations with greater accuracy 
and confidence495. A study incorporating imputed rare variants (as opposed to sequencing data) 
will need to weigh the gain in power of including study participants genotyped on a chip with 
poorer imputation data against the potential downside of including poorly imputed variants. 
Related to imputation concerns is the potential for differences in the presence of rare 
alleles by population to affect the detection of true associations using gene-based methods. The 




would prevent population microstructure from affect—even within African Americans, for 
example, exist large differences in the proportion of African ancestry and regional specificity 
depending on the geography of the study sub-population516-518. Adjusting for ancestral principal 
components—even if they were generated using common genotyped variants—does not always 
completely account for population stratification as well as in single-variant analyses of common 
or low-frequency variants. However, joint PCs in trans-ethnic study populations have recently 
been shown to properly account for the majority of population substructure492; 493. There are 
differences in frequency and race/ethnic distribution of these rare variants, requiring a balance 
between power of trans-ethnic and race/ethnic-specific pros and cons. Therefore, the decision 
between a trans-ethnic analysis and race/ethnic-stratified analysis must be made on a study-
specific basis.   
Although power is improved over single-variant analysis, low power to detect 
associations via gene-based testing remains an issue, particularly when one or more causal 
variants are ancestry-specific and therefore highly affected by sample size in multi-ethnic 
studies492. Additionally, the ability to detect signals depends on the method employed—SKAT-
O, for example, allows for the incorporation of both protective and risk alleles491; 492; 519; 
520.Furthermore, sub-analyses based on self-identified race/ethnicity will cause decreased power 
caused by meta-analyzing smaller populations rather than analyzing the entire study population 
together. For these reasons, recent efforts have typically performed trans-ethnic pooled analyses 
for gene-based tests, with ancestry-specific follow-up for variants within a significantly 
associated gene.  
Thirdly, findings from the GWAS literature and molecular studies support the 




non-coding variants regulating expression or other downstream processes463; 468; 469. However, the 
inclusion of a large number of non-functional variants may dilute the effect of a genic unit, 
potentially preventing the detection of true associations43; 492. Therefore, a genic unit including 
only coding variants is anticipated to have a greater magnitude of effect than one containing non-
coding variants, because non-coding variants vastly outnumber coding variants, and coding 
variants are likely to have a larger effect size given their potential to alter the function or 
structure of a protein491; 509; 520.  
Finally, in the event that gene-based testing does identify previously unreported genomic 
associations for a trait of interest, clarifying which rare variants may be causal is difficult using 
current methodology given the distribution of these variants by population and that the effect 
sizes of rare variants can be overstated491. Methods for identification of the variant(s) underlying 
a particular association currently include rank-based analysis, "leave-one-out" analyses, and 
Bayesian model-based analyses of expression data for individuals with both RNA-Seq and 
association data429; 521-523. The latter method shows great potential for narrowing the list of 
potential functional variant within a gene, and models have been developed that could be applied 
to studies with only genotype/imputed data. However, all currently available sequencing data in 
the GTEx Consortium was performed in European-ancestry individuals, leading to potentially 
extreme differences in the ability to predict functional consequences of variants that are very rare 
or monomorphic in Europeans but low-frequency or common in other race/ethnic populations. 
In summary, although rare-variant association testing methods have been employed for 
nearly as long as common-variant GWAS, the question of which methods are most likely to 
identify candidate variants that are truly functional remains unanswered. However, established 




power by identifying genomic regions which were not significantly associated with traits in 
common-variant or rare-variant univariate analyses43; 492. 
 
3.9. Public Health Significance 
RBCs perform the crucial function of delivering oxygen to every cell in the body and 
transporting cellular waste materials for processing in the liver. RBCs are the most numerous cell 
type in the body, with an average of 1,500 mature RBCs released into the bloodstream each 
minute in adult humans. Dysfunction or insufficient production is referred to as anemia, with 
physiologic effects ranging from mild to severe. Anemia affects a large proportion of the 
population across the life course, with a high public health burden both financially and in 
disability due to related health consequences, both in the United States and globally524-528. A non-
monogenic anemic state is expected to have a large genetic component even for individuals with 
acquired anemia, based on the complex nature of RBC trait biology. In addition to being relevant 
for diagnosing blood-related disorders, RBC traits provide clinical information related to the 
status and prognosis of other diseases. RBC traits have been variously associated with outcomes 
in patients with end-stage renal disease; autoimmune diseases such as rheumatoid arthritis and 
systemic lupus erythematosus; cerebrovascular disorders such as ischemic stroke; and 
cardiovascular diseases such as heart failure and acute myocardial infarction6; 242; 243; 255; 256; 258; 
266; 271; 529-533.  
RBC traits are complex quantitative traits regulated, we now know, by a vast number of 
genomic loci. Dozens of genes containing variants that cause monogenic anemias have been 
identified; several of the most severe anemias are recessive disorders caused by variants specific 




monogenic anemias during the latter half of the 20th century contributed greatly to understanding 
RBC development and maintenance150; 322; 330; 534; 535. GWAS within the last decade have 
identified hundreds of additional loci associated with interval-scale RBC traits; however, as of 
yet less than half of the population variation in RBC traits attributed to genetic variation can be 
explained by reported loci15; 31; 301. It is reasonable to expect that genomic loci associated with 
RBC traits remain to be discovered, and also that new methods or more diverse study-population 
composition would benefit the identification of these associations. 
The proposed work will examine two areas of RBC trait association genetics left largely 
unexplored. First, we will leverage correlation among RBC traits, which exhibit moderate to high 
heritability, to examine evidence of a shared genetic architecture for the first combined-
phenotype analysis of these traits. Significant findings from this analysis will be fine-mapped to 
narrow the association signals, identifying independent signals where they exist as well as 
potential functional variants within each association signal. Second, we will use gene-based 
testing to leverage the combined effects of coding and proximal regulatory variants. Analyses of 
single rare variants are typically extremely underpowered, but a weighted combination of 
multiple such variants has been shown to identify genes for complex diseases that may have 
multiple variants contributing to expression difference and, hence, RBC trait associations. 
The public health benefits of identifying new and characterizing known genomic loci 
associated with RBC traits are numerous, though occasionally indirect. The biology underlying 
RBC development and gene expression across relevant tissue types remains incompletely 
explained. GWAS findings of RBC traits thus far imply hundreds or even thousands of 
additional contributing variants28; 31; 403; 433; 536. The utilization of both combined-phenotype study 




improve the ability to add to the suite of genomic loci associated with RBC traits. The benefits to 
increasing the foundational knowledge underlying RBC traits are myriad. Both basic science and 
also translational research can be improved with further molecular characterization of the 
pathways involved in RBC development and maintenance. Given the expense of these 
experiments, association studies are a crucial if not necessary method of identifying candidate 
genes and variants for further exploration. For example, pharmacogenomics researchers may 
utilize findings from studies like those proposed in this work for the development and testing of 
pharmaceutical interventions for blood diseases. 
The proposed work also indirectly benefits race/ethnic populations traditionally 
underrepresented in GWAS. Since the beginning of the GWAS era, the vast majority of 
published studies comprise either exclusively European or European-ancestry populations or 
exclusively East Asian populations. Recently published studies have made obvious the benefits 
of including ancestrally diverse populations in GWAS, particularly populations exhibiting recent 
admixture; an improvement in discovery of RBC trait-associated genetic loci could be expected 
by including ancestrally diverse populations 32; 34; 38; 455; 495. In addition to the scientific benefits, 
research ethics demand equitable inclusion of diverse study populations in genomic studies40; 346. 
Lack of inclusivity in study population design can not only lead to inaccuracies in understanding 
of variant pathogenicity, but also exacerbate existing health disparities with regard to improper 
diagnosis and failure to identify causal variants or associations specific to excluded ancestral 
populations38; 537. Failure to include African Americans in studies of hypertrophic 
cardiomyopathy (HCM), for example, led to decades of misdiagnosis of HCM based on a 
presumed causal variant because of the allele’s rare frequency in European-ancestry 




discovered to have an allele frequency of nearly 25% in the Garinagu in Honduras, 
demonstrating the downside of limiting study population to one ancestry and assigning 
importance of a causal variant based on those findings (G. Wojcik, personal comm. 2018). 
Therefore, deliberate inclusion of a diverse study population stands to directly benefit the health 
of millions of Americans who are currently underrepresented in genomics research by ensuring 
that more accurate interpretation of results is possible.  
In conclusion, continued identification of RBC trait-associated loci may improve our 
understanding of the exact functions of molecular pathways preceding these RBC phenotypes. A 
better understanding of RBC physiology is clinically relevant to a broad number of disease 
pathways; knowledge leading to the identification of causal RBC trait variants could have 
positive implications for diagnosis and prognosis of diseases associated with RBC traits. 
Additionally, a clearer understanding of the genetic mechanisms affecting RBC traits could 
positively affect pharmaceutical research and genetic testing to address anemias or other RBC-
related pathologies. This work proposes improve on the body of knowledge that currently exists 
with regard to RBC trait genomics while simultaneously increasing representation of ancestrally 
diverse study populations in this research area and implementing established methods that have 




3.10. Supporting Tables & Figures 
Table 1. Discovery and genetic mapping of hereditary anemias 
Anemia Year ID’d Author Prevalence Associated genes 
Alpha thalassemia (includes 
Hb Bart's) 
1976 A Deisseroth538 Common (Hb Bart’s very 
rare) 
HBA1/2 








1 to 9/1 million HF1, CFH, MCP (AKA 
CD46), CFHR1, CFHR3, 
C4BPA 
Beta thalassemia / Cooley's 
anemia / Mediterranean 
anemia 
1925 TB Cooley ~1/100,000; more common 
in African, Middle Eastern-
descent populations 
HBB 








Rare (several hundred total 
cases reported) 
CDAN1 (Type I), 
SEC23B (Type II), 





1974; 2015 Glader544; 
Glogowska545 and 
Rapetti-Mauss546 
<1/1 million KCNN4 
Diamond-Blackfan 1936 HW Josephs 5 to 7 per million RPL5, RPL11, RPL35A, 
RPS7, RPS10, RPS17, 
RPS19, RPS24, RPS26 




AR Thompson547; C 
Yu548 
<1/1 million GATA1 (X-linked) 
Elliptocytosis (accompanied 





1 per 2,000 – 4,000 














~1/50,000 PRF1 & UNC13D 
account for 40-60% of 
cases; STX11, STXBP2, 
unknown 
Fanconi anemia / congenital 
hypoplastic anemia 
1927 G Fanconi 1/160,000 (Ashkenazi, 
Roma, black South African 
increased) 
BRCA2, BRIP1, FANCA, 
FANCB, FANCC, 
FANCD2, FANCE, 
FANCF, FANCG, FANCI, 
FANCL, FANCM, 
PALB2, RAD51C, SLX4  
Hemolytic anemia 1956; 
mapped 1998 
PE Carson554; Puck 
& Willard319 







Hemolytic anemia due to 
adenylate kinase deficiency 
1969; 
mapped 1989 
A Szeinberg555; S 
Matsuura556 
<1/1 million AK1 




Uncommon (now classified 
as a type of elliptocytosis) 
SPTA1; SPTB  
Hereditary spherocytosis 1962; 
mapped 1975 





ANK1 (~50%), EPB42, 
SLC4A1, SPTA1, SPTB 
Hypochromic microcytic: 
sideroblastic 
2011 C Kannengiesser561 Rare SLC25A38 
Hypochromic microcytic: X-
linked sideroblastic 
1992 TC Cox562 Unknown (uncommon) ALAS2 (exacerbated by 
additional mutation in 
HFE) 
Hypochromic microcytic: X-
linked sideroblastic w/ ataxia 
1998 Y Shimada563 <1/1 million ABCB7 
Hypochromic microcytic: X-

















<1/1 million TMPRSS6 
Majeed syndrome 1993 El-Shanti, H568 3 known families LPIN2 
Megaloblastic anemia 1960; 
mapped 1995 
Imerslund-
Grasbeck504; 569; M 
Aminoff505 





LE Rogers570; EJ 
Neufeld571 
<1/1 million SLC19A2 





~30 cases described PSMB8 
Nonspherocytic hemolytic 




WN Valentine575;  H 
Kanno534, A 
Larochelle576 
1/20,000 Europeans PKLR 
Phosphoglycerate kinase 1 
deficiency 
1969; 1980 Kraus577; Fujii & 
Yoshida578 
<1/1 million PGK1 
Porphyria (all types) 1937 Waldenstrom63 
(PCT) 
1/500 to 1/50,000 ALAD, ALAS2, CPOX, 
CYP1A2, FECH, HMBS, 




mapped 2001  
JD Upshaw579; GG 
Levy580 
Common ADAMTS13 
Hereditary anemias and conditions for which anemia is always present are listed. Several extremely rare diagnoses excluded. First 
publication date listed refers to phenotype description (often presented as a case report), followed by first published report of 









Table 2. Description of proteins involved in iron homeostasis and erythropoiesis. 
Protein(s) Transcribed in: Role: Regulates: 
BMP/SMAD 
pathway 
Broadly BMP, a ligand of the TGFβ family, activates SMAD family 
members by binding TGFβ receptors. SMADs are 




kidney Generated in response to hypoxia. Binds EPO receptors on 
RBCs to stimulate erythropoiesis. Recombinant (i.e., 
exogenous) EPO has been successful in hemodialysis 
patients with end-stage renal disease, in whom it has been 
shown to improve hematological parameters as well as 
increased left-ventricular mass and accompanying decrease 
in cardiac output177; 581; 582. Recent work in animal models 
suggests consistent use of EPO can have negative long-
term cardiovascular effects67; 583. 
 
Transferrin (TF) liver Glycoprotein which reversibly binds free iron (Fe[3+]) ions 
in the bloodstream 
 
Iron regulatory 
proteins   
(IRP1 and IRP2) 
broad (highest in liver) Binds iron-responsive elements (IREs) in transferrin 
receptor 3' UTRs to regulate cellular uptake of iron. In 
iron-deficiency, IRP1 increases iron uptake into cells by 
stabilizing transferrin receptor and limits iron sequestration 
by limiting ferritin mRNA translation. Iron contributes to 




ferritin L & H 
subunits, 
ferroportin,  
Transferrin receptors    
(TfR1 and TfR2) 
immature RBCs* 
(TfR1 and TfR2) or 
liver (TfR2) 
Cellular uptake of transferrin-bound iron (HFE binds 
competitively). 
Hepcidin 
Hepcidin liver Activated by TfR2; prevents iron absorption from the small 
intestines and the release of iron by macrophages into the 




muscle Rapidly inhibits hepcidin transcription in the liver, leading 
to increased iron acquisition. Only co-occurs with low 
activity of the BMP/SMAD pathway. 
Hepcidin, 
mTOR (liver) 
See Table 1 for monogenic anemias caused by mutations in sequences for any of these proteins. 







Table 3. Descriptions of red blood cell primary traits and derived indices. 
 RBC trait Calculation Units Indices measured 
HCT N/A % Proportion of whole blood comprising RBCs 
HGB N/A g/dL Blood level of hemoglobin 
RBCC N/A 106 cells / mm3 Number of RBCs per unit of volume 
RDW-CV SDMCV          
MCV 
% Representation of distribution of RBC size 
MCH HGB*10       
RBC 
picogram Average hemoglobin protein quantity per RBC (by mass) 
MCHC HGB*100     
HCT 
g/dL Average hemoglobin protein quantity per RBC (by 
concentration) 
MCV HCT*10        
RBC 
femtoliter Average size of RBC 
HCT: hematocrit; HGB: hemoglobin; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin 
concentration; MCV: mean corpuscular volume; RBCC: red blood cell count; RDW-CV: red cell distribution width 






Table 4. Brief overview of genetic and epigenetic processes and effects of variation. 
Mechanism Cellular Location Effect of genetic variation 
Exonic or splice-site 
variant 
Nuclear DNA Change in mRNA sequence or secondary structure (can 
reduce or increase mRNA stability prior to translation) or 
change protein function (amino acid substitutions/changes) 
Intronic/intergenic 
variants 
Nuclear DNA Change in enhancer/promoter region can alter binding 
efficiency of regulatory factors, leading to changes in 
transcription 
DNA methylation Nuclear DNA Addition or removal of a CpG can add or eliminate 
methylation with a downstream effect on transcription; may 
be cell-type specific 
3D chromatin structure Nuclear DNA Change in chromatin structure (euchromatin vs 
heterochromatin) can affect nearby gene expression; may be 
cell-type specific 
Histone Modification Nuclear chromosome 
structure 
Change in epigenetic histone marks can increase or decrease 
accessibility of genes for transcription 
MicroRNA (miR) Nucleus, cytoplasm, 
extracellular vesicle 
Altered miR sequence can affect the binding specificity for 
mRNAs, leading to broad increase or decrease in protein 
translation; altered miR consensus sequence in one gene can 
have the same effect 
Post-translational 
modification 
Nucleus, cytoplasm Protein folding and stability can be affected by intracellular 
conditions or availability of complementary molecules (ex: 






Table 5. Published English-Language GWAS and Exome Association Studies of RBC Traits 
First Author Year Ancestry N Relevant traits included 
Discovery 
Associations* 
Yang310 2007 European 1,000 HGB, MCHC, MCV, RBCC 0 
Soranzo25 2009 European 13,943 HGB, MCH, MCHC, MCV, 
RBCC 
6 
Chambers314 2009 European; South Asian 16,001 HGB, MCH, MCHC, MCV, 
RBCC 
5 
Ganesh17 2009 European 24,167 HCT, HGB, MCH, MCHC, 
MCV, RBCC 
23 
Ferreira309 2009 European 6,015 HCT, HGB, MCH, MCHC, 
MCV, RBCC 
2 
Kamatani20 2010 Japanese 14,700 HCT, HGB, MCH, MCHC, 
MCV, RBCC 
28 
Kullo21 2010 European 3,012 HCT, HGB, MCH, MCHC, 
MCV, RBCC 
1 
Van der Harst26 2012 European; South Asian Up to 
85,000 
HCT, HGB, MCH, MCHC, 
MCV, RBCC 
67 




HCT, HGB, MCH, MCHC, 
MCV, RBCC 
4 
Chen29 2013 African American 16,500 HCT, HGB, MCH, MCHC, 
MCV, RBCC, RDW 
4 
Pistis24 2013 European 1,653 HCT, HGB, MCH, MCHC, 
MCV, RBCC 
1 
Iotchkova19 2016 European 3,210 HGB, MCH, MCHC, MCV, 
RBCC 
2 
Chami28 2016 European; African 
American; 
Hispanic/Latino; East 
Asian; South Asian 
Up to 
130,273 
HCT, HGB, MCH, MCHC, 
MCV, RBCC, RDW 
21 




HCT, HGB, MCH, MCHC, 
MCV, RBCC, RDW 
0 
Astle301 2016 European 172,433 HCT, HGB, MCH, MCHC, 
MCV, RBCC, RDW 
1,362 
van Rooij27 2017 European, African 
American, and Asian 
Up to 
65,000 
HCT, HGB, MCH, MCHC, 
MCV, RBCC, RDW 
9 
Hodonsky18 2017 Hispanic/Latino 12,500 HCT, HGB, MCH, MCHC, 
MCV, RBCC, RDW 
7 
      
Kanai348 2018 Japanese 108,794 HCT, HGB, MCH, MCHC, 
MCV, RBCC 
44 
Yasukochi584 2018 Japanese 4,884 HCT, HGB, MCH, MCHC, 
MCV, RBCC, RDW 
0 
GWS = genome-wide-significant (p<5x10-8); EMR = electronic medical records.* Associations reported as “discovery” if the 
locus has not been previously associated with the reported RBC trait in a GWAS—multiple associations had been previously 
reported in linkage analysis or candidate-gene studies. Several associations were reported as novel in multiple papers that 





































































































































HCT (11) 3  1 2  3 2  2 2 2 2 0.04 
HGB (15) 2  1 3  2 3  2 3 4 7 0.12 – 0.84 
RBCC (15) 3 1 3 1 4 7 1 1 4 1 2  0.23 – 0.61 
RDW (4)  1  1 1 1  1 1 1  1 0.35 
MCH (14)  2 2 4 3 5  3 1 1 1 6 0.22 
MCHC 
(15) 
 1  1  3   2   4 0.48 
MCV (15)  2 4 4 7 8  5 1 1 1 6 0.20 – 0.96 
Number below each trait represents the number of GWAS evaluating that trait. Shading intensity represents proportion of 
studies evaluating that trait that reported a GWS association for at least one SNP with the named gene as the designated 
locus (given the allelic heterogeneity reported as common among most complex quantitative traits, we are reporting only by 
gene and do not imply that only one causal variant is located within each locus). To increase visibility, a baseline of 10% 







Table 7. Examples of genome-wide significant RBC trait associations with cis-eQTL 
evidence and a plausible biological mechanism for a proximal gene. 
Gene Chr GWAS Associations Role/function in RBCs* 
CCND3 6 MCH, MCV, RBCC, 
RDW 
Important for erythropoiesis; signal identified in GWAS 
contains TFBS for TAL1, KLF1, and GATA1. Reduced levels 
= fewer cell divisions during terminal erythropoiesis, leads to 
fewer but larger terminally differentiated RBCs. 
HBS1L-MYB 6 HCT, HGB, MCH, 
MCHC, MCV, RBCC, 
RDW 
SNPs in 2 QTLs upstream of MYB disrupt enhancer binding 
which affects MYB expression. MYB regulates hematopoiesis 
and erythropoiesis: indirectly through alteration of kinetics of 
erythroid differentiation; directly via activation of KLF1 and 
other repressors of gamma-globin genes. Low MYB levels 
accelerate erythroid differentiation leading to release of early 
erythroid progenitor cells that are larger and still synthesizing 
mostly HbF. 
CITED2 6 MCH, MCV, RBCC Master regulator of stem cell fate, key role in adult HSC 
maintenance. Regulates iron homeostasis and erythropoiesis 
via HIF1 and GATA1. 
CD164 6 MCH Codes for MUC24, a transmembrane molecule that affects 
HSC proliferation, adhesion and migration. Interacts with 
CXCR4, which has a role in HIV cellular transport. 
TFR2 7 HCT, HGB, MCH, 
MCHC, MCV, RBCC, 
RDW 
Transferrin receptor 2 is a membrane-bound protein that takes 
up transferrin-bound iron; may be involved in erythropoiesis. 
Mutations reported in hemochromatosis III (rare). 
SH2B3 12 HCT, HGB, MCH, 
MCV, RBCC 
Negatively regulates hematopoietic cytokine signaling. 
Suppression increases erythroid expansion and maturation by 
augmenting EPO and KIT pathways. 
HMOX2 16 MCH, MCV The constitutive form of heme oxygenase, a membrane-bound 
enzyme that cleaves the heme ring to form biliverdin 




16 HGB, MCH, MCHC, 
MCV, RBCC 
Function unknown—variants in this gene have been causally 
associated with malaria resistance in the heterozygous state16. 





Figure 1. A basic overview of RBC development stages and accompanying molecular processes (prepared by Hodonsky, 2018) 
 
From left to right, developmental stages progressing from HSC to senescent RBC. The red-shaded cell represents an RBC at each stage of differentiation (including 
nucleus with chromosomes when appropriate). The gray cell represents a macrophage, a crucial component of successful RBC differentiation. Top blue bars: location of 
the developing cell at each stage of differentiation. Bottom green bars: standard amount of time required for the stage(s) of cell differentiation or maintenance occurring in 
the respective tissue. Text boxes include particularly relevant information about events occurring at each stage. Bottom box outlined in blue indicates percent of activity for 
DNA transcription, mRNA translation, and chromatin density within the developing RBC. DNA transcription and chromatin density become irrelevant after enucleation. 
DNA: deoxyribonucleic acid; EMP: erythroblast-megakaryocyte protein; Fe2+: iron ions recycled by macrophages from phagocytosed RBCs to developing RBCs; mRNA: 












Figure 2. Example network of key protein-protein interactions involving molecules 






 RESEARCH PLAN 
4.1. Overview 
In this section, I will outline the resources and order of analyses required to investigate 
specific aims 1 and 2 as introduced above. In sum, the first aim will evaluate both known and 
previously unreported associations between seven RBC traits and common and infrequent 
genetic variants in the PAGE and collaborating study populations (see below), and identify 
candidate functional variants using bioinformatics and fine-mapping tools. The second aim will 
evaluate both known and previously unreported associations between seven RBC traits and genes 
in the same study populations. Below, I will first briefly describe participating study populations, 
genotyping arrays, and all covariates and exclusion criteria relevant to the study population. I 
will then discuss the statistical methods and relevant tools (including software and public 
databases) that will be used for each aim. Finally, I will review the strengths and limitations of 
the proposal at hand, and provide a timeline for expected completion of each aim and the 
accompanying manuscript. 
 
4.2. Study populations 
4.2.1. Population Architecture using Genomics and Epidemiology: The PAGE study 
 The PAGE consortium was first funded in 2008 as a demonstration of NHGRI support 
for expanding the genetic diversity of large-scale genomics studies342; 455. For the proposed work, 




genotype or sequencing data were included. Specifically, the Atherosclerosis Risk in 
Communities (ARIC); Coronary Artery Risk Development In young Adults (CARDIA); 
Hispanic Community Health Study/Study of Latinos (HCHS/SOL); Mt. Sinai School of 
Medicine BioMe Biobank (ISSMS); and Women's Health Initiative (WHI).  
The proposed work will include all PAGE participants with phenotype and genotype 
information self-identifying as Hispanic/Latino, African American, Asian American, Native 
American or American Indian, or European American—while Native Hawaiian individuals from 
multiple cohort studies participated in PAGE cohorts, these studies did not report RBC traits and 
hence will not be included. Studies participating in the PAGE-II program that may be included in 
these analyses are the CALiCo Consortium (ARIC, CARDIA, HCHS/SOL), Icahn Mt. Sinai 
School of Medicine (IMSSM), and the Women’s Health Initiative (WHI). Over 70,000 total 
PAGE participants and participants of collaborating studies with genotype and phenotype 
information. Not all studies or study visits measured all RBC phenotypes (see below); when 
required, we will use data from multiple visits from the same cohort study to obtain the earliest 
phenotype measurements possible (and minimize the effects of loss to follow-up or mortality).  
4.2.1.1 Atherosclerosis Risk in Communities (ARIC) Study 
The ARIC study recruited 15,792 participants aged 45-64 for the first visit (of seven 
currently completed or planned) beginning in 1986585. Participants were located in four centers: 
Jackson, Mississippi, Forsyth County, North Carolina, Minneapolis, Minnesota, and Washington 
County, Maryland. The study was designed to include rural, suburban, and urban households of 
either African American or European American descent. Approximately 55% of participants 
were female, with about 4,000 African Americans (25%, primarily from Jackson, Mississippi) 




RBC trait measurements, which will also affect the number of participants reported for each trait: 
Visit 1, at which HCT, HGB, and MCHC were first reported; Visit 2, at which MCV, MCH, and 
RBCC were first reported; and Visit 5, at which RDW was first reported.  
4.2.1.2 BioME Biobank: Icahn Mt. Sinai School of Medicine (IMSSM) 
The Medican Institute for Personalized Medicine BioME Biobank is affiliated with 
IMSSM and participates in eMERGE (electronic medical records and genomics)586. IMSSM 
clinics are located in areas serving ethnically diverse populations, including Central Harlem, East 
Harlem, and the upper east side of Manhattan. 30 IMSSM clinical care sites are involved in 
recruitment for participants, who donate blood samples for genotyping; these samples are linked 
to EMR which is de-identified but kept current through IMSSM. Since recruitment began in 
2011, over 32,000 patients have been recruited to participate. Approximately 60% of participants 
are female and three fourths report the US as their country of origin; with regards to ethnicity, 
over one third of participants identify as Hispanic/Latino (primarily with Caribbean country of 
origin), over one quarter as African American, and approximately one quarter white.  
4.2.1.3 Coronary Artery Risk Development in Young Adults (CARDIA) Study 
The CARDIA study was designed in 1983 to evaluate risk factors for cardiovascular 
disease, including subclinical phenotypes, throughout the life course starting in early adulthood. 
Baseline examinations were performed on 5,115 African American or White men and women 
(with approximately equal distribution across ethnicity and gender groups) aged 18 to 30 in 
1985-1986 at four centers: Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; 
and Oakland, California587. Blood trait phenotypes being collected on the maximum number of 





4.2.1.4 Hispanic Community Health Study/Study of Latinos (HCHS/SOL) 
The Hispanic Community Health Study completed its first visit of 16,415 
Hispanics/Latinos aged 18-74 in 2011, with the aim of representing the diversity of 
Hispanics/Latinos living in the United States. A stratified two-stage area probability sample of 
household addresses was used to in order to recruit a nationally representative sample. 
Participants were recruited from Miami, Florida (school), Chicago, Illinois (Northwestern), the 
Bronx, New York City, New York (Albert Einstein), and San Diego, California (school), with 
the coordinating center at UNC Chapel Hill in North Carolina588. Participants self-identified with 
one of five national backgrounds or countries of origin, including Cuban, Dominican, Mexican, 
Puerto Rican, and South/Central American. Participants at the baseline exam underwent 
extensive phenotyping and interviewing (conducted in either English or Spanish depending on 
participants’ preferences). Consent and genotype are available for approximately 12,500 
participants.  
4.2.1.5 Women’s Health Initiative (WHI) 
The Women’s Health Initiative began recruitment in 1991 a clinical trial and an 
observational cohort study, originally designed to evaluate the health effects of hormone therapy 
in over 150,000 women aged 50-79589. The study population was broadly representative of post-
menopausal women in the US, recruiting from over 40 field centers with race/ethnic sampling 
based on proportions from the 1990 US census. Distribution of race/ethnicity was primarily 
white (83%) participants followed by proportionally underrepresented participants self-
identifying as African American (9%), Hispanic/Latino American (4%), Asian American (3%), 
and Native American (0.4%). Genotyping information was obtained from consenting participants 




Americans, 550 Asian Americans, 500 participants identifying as "Other" race/ethnicity, and 
18,000 European Americans590.  
 
4.3. Phenotypes: outcome and covariate assessment 
4.3.1. RBC trait descriptive statistics and transformation 
As described above, the following RBC traits will be used as the outcome variables in 
univariate analyses and gene-based tests for both specific aims: HCT, HGB, RBCC, RDW, 
MCH, MCHC, and MCV. As is consistent with population-based genetic association studies of 
complex quantitative traits, all RBC traits will be evaluated for a skewed distribution of the 
residuals, which could violate assumptions of the models incorporated in the methods described 
below. For any trait exhibiting excessive skewing in the overall study population, that trait will 
be regressed on using all non-genetic terms in the model, and then inverse-normal transformation 
will be performed on the residuals. Interpretability of results from this type of transformation is 
limited; however, effect estimates in GWAS discovery findings are not expected to represent the 
global effect size15; 403. Furthermore, because the lead variant at a given discovery association 
signal is not necessarily expected to be a functional variant for the trait of interest, the effect 
estimate may not be an accurate proxy for the functional variant or variants31.  
4.3.2. Exclusion Criteria 
We will be excluding participants meeting criteria that may have a strong effect on RBC 
traits, and which may therefore give those observations undue influence on the genotype-
phenotype association. As described above, we are concerned that we will not accurately capture 
these influential individuals by simply evaluating statistical outliers, but not that these variables 




RBC trait GWAS literature, and will exclude based on the following when information is 
available:  
(1) Pregnancy 
(2) HIV (+) status 
(3) Ever-diagnosis of blood cancer 
(4) Current treatment with chemotherapeutic medications (any cancer) 
(5) Hereditary anemias (primarily SCD but not sickle-cell trait) 
(6) Extreme outliers (+/- 4 standard deviations from the mean for the outcome of interest) 
Aside from pregnancy in study populations that recruited pre-menopausal women, all exclusion 
criteria are rare in PAGE-participating study populations (<0.5% of participants). Of note, 
individuals with one excluded RBC trait value due to outlier status will not be excluded from 
analyses for other non-outlying traits. 
4.3.3. Adjustment covariates 
Genetic association studies typically do not suffer from the same confounding issues as 
traditional epidemiology studies, because any confounder would need to causally affect both the 
SNP of interest and the outcome. Anticipating which covariates may be confounders in this 
context and, additionally, overadjusting in all analyses for covariates that are only confounders 
for one or a small number of SNPs is inappropriate. Therefore, genetic epidemiology typically 
adjust for covariates associated with the outcome but not the exposure to add precision to the 
effect estimate. This added precision is particularly helpful in the case of GWAS because the 
effect magnitude for true associations with individual genetic variants is anticipated to be 




4.3.3.1 Age and sex 
Age and sex are significantly associated with RBC traits in the PAGE study population. 
In keeping with field standards for GWAS analyses, age and sex terms will be included in all 
models.  
4.3.3.2 Self-reported race/ethnicity 
Reports in the hematology literature vary on whether and how much race and ethnicity 
affect RBC traits112; 180; 181; 592. However, adjusting for self-reported race/ethnicity in GWAS adds 
precision to the results as well as reducing issues involving population stratification, which can 
lead to false-positive association signals that actually identify ancestry593-596. We will include 
self-reported race/ethnicity in four categories: African ancestry or Black (African-descent 
individuals living in the United States or Europe); Hispanic/Latino (non-overlapping with 
African Americans: HCHS/SOL participants will all be considered Hispanic/Latino); Native 
American; and White/European American. No PAGE II-participating study populations with 
individuals of Native Hawaiian or Asian descent reported RBC trait phenotypes, therefore no 
participants identifying with either of those groups will be included in this work.  
4.3.3.3 Study and study center 
While genotyping and complete blood count sample collection and processing have been 
relatively standardized for decades, each cohort study follows its own protocol and uses 
machinery specific to that protocol. Therefore, slight differences caused by sample processing by 
individual lab technicians or minor differences in how/when machines are calibrated can affect 
the outcome measurements due solely to the cohort study and not the true value of the RBC traits 
measured. Adjustment for participating study is the standard established in the field in genetic 




Similar to the concerns related to cohort study, samples collected for CBC assays are 
often processed separately by study center. This can lead to batch effects, therefore adjustment 
for study center in the model can reduce statistical noise. For studies with multiple centers 
reported (including WHI, which uses region rather than center), we will adjust for study center, 
as is the field standard for studies incorporating multiple centers. 
4.3.3.4 Ancestral admixture and principal components  
Haplotype recombination events in admixed populations can lead to narrower LD blocks 
than might be observed in either founder population. Differences in recombination peaks across 
populations with different recent continental ancestry mean that inclusion of ancestrally diverse 
study populations—particularly those exhibiting a high degree of admixture—may lead to 
overlapping haplotyplp0u7de blocks, which can be utilized to narrow association signals in fine-
mapping (see below)595; 597; 598. For example, among PAGE Hispanics/Latinos, individuals 
identifying as of Mexican ancestry have primarily Native American and European haplotypes, 
ranging from nearly 100% European to 100% Native American ancestry (Figure 3). In contrast, 
individuals self-reporting Dominican descent have ancestral haplotypes primarily from Africa 
and Europe, with most individuals having only a small proportion of Native American ancestry.  
Ancestry-specific variants can lead to spurious associations in GWAS if ancestry is 
inappropriately adjusted for, which is a primary reason why principal components must be 
calculated within study populations and adjusted for in GWAS599 600; 601. To avoid identifying 
genetic associations due to population stratification rather than associations with the outcome, 
ancestral principal components (PCs) are used as covariates. Based on PAGE analyses of the 




PCs as that is sufficient to remove population stratification concerns with the exception of 
several known loci that are already known in the field455.  
Traditionally, GWAS were performed by stratifying study populations based on self-
reported race/ethnicity and then meta-analyzing all groups to report trans-ethnic results. 
However, rather than properly adjusting for potential confounding by ancestry, this form of 
adjustment fails to account for the fact that ancestry represents a spectrum rather than definitive 
categories. See Figure 4 for population stratification of ancestry groups by principal 
components, demonstrating the continuum of ancestral relationships in PAGE participants which 
justifies analysis of participants grouped only by genotyping assay rather than race-ethnic 
specific analysis for Aim 1 (see below) (Wojcik 2017, personal communications).  
 
4.4. Specific Aim 1: Combined-phenotype GWAS of red blood cell traits 
This aim will leverage trait correlation to identify previously unreported RBC trait 
genetic associations in a large, ancestrally diverse study population. These associations will then 
be evaluated using conditional analysis and fine-mapping techniques that will allow for 
designation of candidate functional variants. 
4.4.1. Quality control for genotypes and imputed data and statistical threshold 
Genotype QC has already been performed by the PAGE coordinating center. Imputation 
to 1000 Genomes Phase 3 was also performed by the coordinating center. Rather than using a 
simple allele frequency threshold to exclude rare variants, we will implement an effective 
heterozygosity requirement for variants included in single-variant analyses. This allows for the 
inclusion of a larger number of variants in small study populations, while excluding low-




to the number of expected heterozygotes with a particular variant, based on the following 
equation: effN = 2 * n * MAF * (1-MAF) * oevar. SNPs with an effective heterozygosity (effN) 
> 30 will be evaluated in univariate analysis. Rare-variant gene-based analyses will be performed 
to identify previously unreported RBC trait associations in Specific Aim 2. 
For the purposes of discovery, we will be using a GWS threshold of  = 5x10-9 to 
account for the fact that we are evaluating approximately 30 million variants. While a strict 
Bonferroni-corrected p-value would be 1.6x10-9, it is expected that some variants will be in very 
strong LD and hence not independent, therefore we are adjusting for a test of 10 million variants. 
In the context of GWAS, effect heterogeneity refers to a difference in magnitude of effect by 
study population, typically in reference to the potential for difference by ancestry450; 602; 603. We 
will consider effect heterogeneity by race/ethnic group by evaluating Cochran's Q statistic. 
Once known associations have been assessed, all variants outside of previously described 
regions (using a +/-1Mb window) and uncorrelated with a known variant (using European LD 
r2<0.2 as a conservative metric) that exceed the genome-wide-significance will be examined as 
potential discovery association signals.  
4.4.2. Univariate analyses 
Univariate analyses will be performed with generalized estimating equations (GEE), 
which estimate model parameters averaged over the study population, assuming additive 
inheritance. GEE models are beneficial in that they do not assume normality or independence of 
the outcome measurements across individuals, improve computational efficiency, and allow for 
correction for family structure. The GEE method will use the relationship matrix K to divide the 
sample up into discrete groups of closely related participants, each group assumed to be 




matrix with an empirically estimated “sandwich” estimate that accounts for within-group 
relationships. Clusters of relatedness for studies sampling related individuals (in this case only 
HCHS/SOL is expected to have large numbers of related individuals, but will be relevant for all 
MEGA-genotyped individuals since we are doing a trans-ethnic analysis) will be defined using a 
relationship matrix to account or family structure. Robust standard errors are calculated for those 
instances in which a relationship matrix is required.  
We will only be performing trait associations on the autosomal chromosomes, i.e., 
chromosomes 1 through 22. Study participants will be analyzed by genotyping chip—MEGA-
typed participants will be analyzed trans-ethnically, and remaining participants will be analyzed 
by study and genotyping platform using previously calculated study-specific PCs. Heterogeneity 
of variance by self-identified race/ethnicity will be included for all models stratified by genotype. 
Allowing for the presence of such heterogeneity within GEE models using SUGEN can improve 
detection of genetic associations in populations in which ancestry-specific variants may 
contribute differentially to the total effect estimate of that locus represented by a tag SNP.   
4.4.2.1 Inverse-variance-weighted meta-analysis of study-specific results 
Meta-analysis within each RBC trait will be performed using METAL604. Briefly, 
inverse-variance weighting will be used for meta-analysis of the summary results for genotype 
assay-specific results. A z-statistic is calculated for each study-specific association, which 
incorporates effect magnitude and direction of effect. In order to account for the difference in 
study population size, as well as the difference in effect size across populations (which could be 
due to lack of precision for not adjusting for covariates that affect the outcome), results will be 




reported race/ethnicity will be meta-analyzed first; subsequently, all race/ethnic groups will be 
meta-analyzed together 
4.4.3. Comparison of available combined-phenotype methods 
We evaluated eight methods that are generally representative of the wide array of 
available statistical methods to estimate combined-phenotype effects with regard to 
computational expense, type of statistical test, and use of summary vs. individual-level data. 
Specifically, we compared aSPU with S=Z; aSPU_R with S=R-1Z, which is most powerful in the 
presence of homogeneity of marginal association effects (as opposed to homogeneity of joint 
association effects, for which aSPU with S=Z is more powerful); our score-based chi-squared 
test; minimum P-value across phenotypes (minP); a test for heterogeneous (SHet) and 
homogeneous (SHom) effects; an adaptive association test based on mixed models (MPAT-
mixAda); and a unified score-based association test (metaUSAT)422; 425; 605-607. We simulated 
2,500 participants, 16 correlated phenotypes, and one variant with MAF=1%. Under the null 
hypothesis of no effect, uniformity of p-values was assessed by plotting the ratio of observed to 
expected p-values versus expected p-values, with both quantities on a -log10 scale; the 
proportion of p-values<1x10-5 was also assessed, with values of this proportion>1x10-5 
representing excess type I error.  
When the sample size varied across the phenotypes, all methods except aSPU and minP 
showed evidence of inflated type I error (Figure 5); similar evidence of inflation was 
demonstrated in empirical tests. While performance of alternate methods improved with 
increaing MAF, aSPU’s preservation of type I error at low MAF ensures validity for uncommon 
variants, as previously suggested425. The newer adaptive tests (MPAT-mixAda and metaUSAT) 




These results support the use of aSPU to identify possibly pleiotropic loci. However, neither 
multi-phenotype methods nor multivariate methods utilizing individual-level data can determine 
the nature of the association(s) between a given locus and phenotypes of interest (i.e., biologic 
vs. mediated pleiotropy). Association signals also most likely remain broad in size, necessitating 
fine-mapping. Thus, additional statistical dissection is needed to characterize causal 
relationships. 
Our aSPU implementation offers a large increase in speed and simultaneous decrease in 
memory requirement compared to the standard implementation. Multi-phenotype tests are 
computationally demanding, particularly when assessing levels of significance used in GWAS 
settings evaluating millions of variants (in our case, p<5x10-9). After observing the low 
efficiency of existing software when applied to TopMED-imputed data, which contain >30M 
variants, we developed an efficient implementation of aSPU in Julia—an open source, high-
performance scientific computing language. Our aSPU implementation reduced computational 
time when using 50 CPUs from 25 days to 13 hours using a significance threshold of 5x10-8; 
decreasing the threshold to 5x10-9 will be more computationally expensive using our methods 
but would not even be feasible without our implementation. Given these preliminary findings, 
we will proceed with aSPU for combined-phenotype analysis. 
4.4.4. Combined-phenotype analysis using aSPU 
aSPU refers to an adaptive sum of powered scores statistical test which combines 
summary data from univariate analyses of multiple traits. aSPU combines the sum of Z-scores 
from univariate GWAS raised to a power, γ, which can take multiple values which allows the 
program to detect a multi-phenotype effect with maximum efficiency (see below). A higher γ 




the distribution of null z-scores for each trait's univariate statistics (Nk[0,Σ]) and samples from 
that distribution utilizing Monte Carlo simulations (with the number of simulations indicating the 
minimum p-value that can be detected by the procedure, in our case 109). Each SNP has k z-
scores, where k is the number of traits for which summary statistics are available. The 
association of each trait with a given SNP from the trans-ethnic univariate meta-analysis will be 
adaptively selected based on the maximally powerful score SPU(γ) using the following model, 
where γ = 0, 1, …, 8, ∞: 
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,    
An overall Monte-Carlo p-value, paSPU, is then calculated for the selected score, and this 
is reported for each SNP. Squaring the gamma removes concerns about SNPs exhibiting opposite 
directions of effect by trait inappropriately minimizing the summary effect. A second Monte-
Carlo procedure is then used to simulate the null behavior of the aggregate test-statistic, yielding 
a p-value for G, taken to quantify evidence for aggregate effects of G across the k traits. 
4.4.4.1 Power 
Statistical power for RBC traits is high because they are consistently and accurately 
measured. We assumed a cross-sectional design, a two-sided α=5x10-9, an additive genetic 
model, MAF 1-50%, and n=30,000-70,000 participants (the number of phenotypes available 
varies by study). The correlation matrix used for power calculation was generated in the MEGA-
genotyped PAGE-participating study population, using inverse-normal transformed residuals of 
each trait as the outcome to match the proposed univariate analyses. While correlation structure 
is expected to differ across populations, the differences are slight and should not affect the 
accuracy of the predicted power. Seven RBC traits and their multivariate distribution were 




1 due to the nature of the inverse normalization and subsequent residual calculation as described 
above). For HGB, MCV, and RDW, we simulated one pleiotropic variant using LMM with per-
allele effects of 0.1 SD, 0.04 SD, and 0.05 SD, respectively, based on the median effect size for 
significant findings in the largest available RBC trait GWAS301. We also examined per-allele 
effects 50% smaller in magnitude. 
Statistical power to detect multi-phenotype effects was excellent for effects of the 
magnitude observed in our preliminary RBC trait findings were simulated for MAF>1% (Figure 
6, panel A). For univariate associations, 80% statistical power was achieved for HGB at 
MAF=4%, and the maximum power achieved for MCV and RDW at MAF=50% was 27% and 
54%, respectively. When effect sizes 50% smaller in magnitude were examined (Figure 6, panel 
B), only the multi-phenotype approach was well powered to detect effects >5% MAF. 
4.4.4.2 Independent association-signal identification 
Every genome-wide-significant association signal in both univariate and multivariate 
analyses—both discovery and previously reported—will be evaluated for independent signals 
using conditional analysis. These analyses will be performed iteratively in SUGEN, adjusting for 
all lead SNPs from primary GWS association signals (see below)435. A lead SNP will be defined 
as the variant with the most significant p-value among all SNPs within a 1Mb window in which 
at least one SNP exceeds GWS; all lead SNPs within a 1Mb window exceeding GWS after 
conditional analysis will be defined as representing independent association signals.  
4.4.4.3 Bioinformatic analysis  
Discovery association signals will be analyzed using publicly available databases and 
prediction algorithms. Examples of various resources for bioinformatics analysis are described 




that new resources become available within the timeline of this dissertation): GTex and the 
ENSEMBL Variant Effect Predictor429; 435; 608-611. 
4.4.4.3.1 Resources for bioinformatic characterization of GWS association signals 
In order to characterize the effect a particular gene has on an associated trait, in the 
presence of likely allelic heterogeneity all potentially functional variants—particularly 
noncoding variants in regulatory regions—must be considered. We will evaluate candidate 
functional variants, and all findings will be reported in the supplement with results that are 
biologically plausible highlighted in a main table. The Variant Effect Predictor (VEP) is a vast, 
publicly available database of both sequence and structural genomic variants in all species with 
reported genome assemblies, with extensive data available for humans608. VEP data include 
known or suspected effects on transcripts, proteins, and regulatory regions, as well as allele 
frequencies by 1000 Genomes populations. GTEx is a database of gene expression (determined 
by RNA sequencing) across a large number of human tissue types as well as several dozen 
immortalized cell lines, and expression data is accompanied by genotyping information 
(https://www.gtexportal.org)429.  
 
4.5. Specific Aim 2: Gene-based rare variant analysis of red blood cell traits 
Identification of functional variants within a genomic region associated with a phenotype 
of interest is difficult. Even more challenging can be identifying genetic associations with 
variants that are ancestry-specific (monomorphic in most populations) or present but rare (MAF 
< 0.01) in all populations. The trade-off for a low false-positive rate often reduces the power to 
detect a true association when the effect size is small or the variant is rare491; 612. For these 
reasons, methods have been developed over the past decade to address the wealth of information 




499; 613; 614. This proposal will perform gene-based testing using a combined analysis (jointly 
employing burden and variance-component tests), as these methods are currently the best suited 
for our traits of interest and study population, although no currently available combination of 
study population and methodology can provide a power exceeding the 80% preferred for GWAS 
(see below). 
4.5.1. Gene-based testing: combined VC and burden test implemented in MASS 
As briefly introduced above, combining the methods of burden and variance components 
tests improves power to detect loci with different distributions of causal variants. In genetic 
transcripts containing few variants with large effects which all act in the same direction, a burden 
test is better powered to detect an effect. However, in genomic loci for which a large number of 
non-causal variants are present alongside functional variants, or for which causal variants exhibit 
opposite directions of effect—both completely reasonable scenarios given current knowledge of 
human evolution—SKAT (Sequence Kernel Association Test) is more powerful than burden 
tests. A combined test which allows for both of these scenarios uses the effect magnitude and 
standard error values for all rare variants within a defined region to identify genes that exhibit 
association with the trait of interest615.  
First, we will generate variant annotation set files in R for deleterious and CADD-filtered 
transcripts (see below). Defining each annotation set as the respective group files, we will 
generate score statistics by transcript group for each annotation set using SUGEN, which is well-
suited to produce input files for the combined test because it automatically outputs a mass-
compatible results file (https://github.com/dragontaoran/SUGEN)616. We will then use the “VC-
O” test flag in MASS to perform the combined test with a minor allele count (MAC) minimum 




can only simulate a minimum p-value of 1E-6, which is higher than our genome-wide-
significance threshold, we will increase the number of simulations to 25 million (minimum 
p~4E-08) for variants with a p-value lower than 1E-5 in the first run. Due to computational 
limitations, we currently do not expect to simulate p-values lower than 1E-9. 
MASS automatically outputs both fixed-effect and random-effect p-values, as it functions 
primarily as a meta-analysis program, as well as the Het-SKAT-O p-value using the method 
described by Lee, et al615. However, our study does not meet the criteria for the Lee method, 
which was designed for binary outcomes with small study populations, and we are only 
evaluating one study population, therefore we will be using the fixed-effects p-value. SKAT-O 
generates a weighted average of the burden test and SKAT statistics into one framework, 
resulting in the following test statistic:  
𝑄𝑘(𝜌) = (1 − 𝜌)𝑄𝑘,𝑆𝐾𝐴𝑇 +  𝜌𝑄𝑘,𝑏𝑢𝑟𝑑𝑒𝑛 
This statistic follows a chi-square distribution, which allows for the combination of 
effects with opposite directions of effect. Because we are under-powered to evaluate ancestry-
specific effects genome-wide, we will perform sensitivity analyses for transcripts significant for 
each trait within each mask in African American- and Hispanic/Latino-only subpopulations. 
4.5.1.1 Variant inclusion, genic unit definition, and adjustment for known variants 
In order to perform gene-based testing, we will generate an inclusive list of all variants 
with a MAF >1% in the MEGA-genotyped study population. Parameters will be defined based 
on previously described standard field practices. A maximum threshold of 1% minor allele 
frequency will be used for incorporating variants, a strategy which is supported by both field 
standards and the fact that common and low-frequency variants will be analyzed individually in 




Two groups of variants will be used to define the respective annotation sets: deleterious 
coding variants only (frameshift, stop-gain, stop-loss, and nonsynonymous coding variants), and 
a set additionally allowing for filtered regulatory variants (employed the recommended PHRED-
scaled CADD score filter>10 to restrict to variants expected to have modest or higher effects)617 
Using whole-genome-sequence annotation files for all MEGA-imputed variants generated by the 
PAGE coordinating center, we will compile both annotation sets defining all transcripts meeting 
the aforementioned criteria and comprising >2 variants. All genes with ENSEMBL-defined 
transcripts will be included in the analysis, resulting in a GWS alpha threshold of 2.87x10-7, or a 
significance threshold Bonferroni-corrected for 25,000 genes and seven traits. Variants with an 
imputation quality below 0.4 were excluded during imputation for VCF genotype files by the 
PAGE coordinating center. Genic unit size (i.e., the number of variants included per gene) is 
expected to range from very small (~3 variants, particularly for the deleterious mask) to very 
large (several hundred for protein-coding genes with a large number of CADD-significant 
regulatory variants).  
4.5.1.2 Power 
As an approximation, PAGE investigators recently performed power simulations for 
SKAT testing in 10,000 individuals under the assumption of 1% variance explained per region. 
In SKAT and related tests, power in a region depends on the proportion of phenotype variance 
that is explained by the linear effects of the full set of variants being included in the test (the 
narrow-sense heritability, h2), the number of variants being tested (varying from a handful to 
many thousands), and the sample size (scaled by the imputation info). Finally, there is a 
Bonferroni correction for the total number of regions tested. Figure 7 shows approximate power 




at alpha= 0.05/number of regions. With a sample size of 10,000 and 1,000 variants tested per 
region, there is 80% power to detect heritability greater than 3 percent in any one region; with a 
sample size of 100,000 individuals, the detectable heritability would be approximately 10 times 
lower, or 0.3%. These simulations provide a reasonable framework for the power that can be 
expected from the proposed work.  
4.5.2. Interpretation of results 
While the association of specific genes with phenotypes is difficult in traditional GWAS, the 
nature of gene-based testing for rare-variant analysis increases the likelihood that a particular 
gene will causally affect the trait of interest. Individual variants within GWS associations will be 
evaluated to identify likely causal candidate variants (see below). Confirmation of individual-
variant causal associations using molecular methods is outside the scope of this work.  
4.5.2.1 GO term overrepresentation  
As described in Aim 2b, pathway analysis will be performed for genes that are GWS 
(p≤2x10-6) for each trait, and pathways which are represented in multiple traits will be 
highlighted in a results table. Terms will be obtained from the String Consortium’s online 
resource, which is part of the ELIXIR core infrastructure and is updated frequency618. This 
resource provides assembled information about known gene functions that can be used to 
identify the cellular pathways that are most strongly represented in a particular study’s findings, 
specifically by identifying enriched gene ontology terms (e.g., cell-cell signaling or ion 
transport)619; 620.  
4.5.2.2 Protein-protein interaction network generation 
Protein-protein interactions can be beneficial to evaluating the context of genomic 




genes (discovery and known) for each phenotype using String-DB to determine whether there are 
overlapping interactions between genes that may indicate a core gene function for RBC traits433; 
621.  
4.5.2.3 Ancestry specificity of lead variants 
Unlike univariate analyses, gene-based testing does not produce an obvious index SNP 
within each identified gene based on p-values from the results. Therefore, for each GWS 
transcript identified significantly associated with one or more traits, we will evaluate the most 
significant variant by trait for evidence of ancestry specificity by allele frequency. We will also 




4.6. Supporting Tables & Figures 
Table 8. The PAGE Study: descriptive statistics for PAGE participants and collaborators by 
study and self-reported race/ethnicity. 
PAGE II Study Population N Race/ethnicity 
Age, years 
(mean, SD) % Female 
Atherosclerosis Risk in Communities 2,825 African American 53 (6) 63 
Atherosclerosis Risk in Communities 9,266 European American 54 (6) 53 
Coronary Artery Risk Development in 
Young Adulthood 
2,636 African American 24 (4) 56 
Coronary Artery Risk Development in 
Young Adulthood 
2,479 European American 25 (3) 53 
Hispanic Community Health 
Study/Study of Latinos 
11,936 Hispanic/Latino 46 (14) 59 
BioME Biobank program 7,138 African American 50 (15) 63 
BioME Biobank program 10,152 Hispanic/Latino 52 (16) 63 
BioME Biobank program 2,729 European American 63 (12) 45 
BioME Biobank program 800 Asian American 44 (15) 64 
BioME Biobank program 1,094 Other 48 (16) 50 
Women’s Health Initiative 10,035 African American 62 (7) 100 
Women’s Health Initiative 4,705 Hispanic/Latino 60 (7) 100 
Women’s Health Initiative 594 American Indian 61 (7) 100 
Women’s Health Initiative 516 Asian American 67 (6) 100 
Women’s Health Initiative 18,180 European American 67 (7) 100 
TOTAL 85,085    
CBC = complete blood count; N = number of study participants with genetic and RBC trait data; SD = standard deviation. 
This table represents the total number of participant from each study; individuals without phenotype and/or genotype data 






Table 9. Representative sample of bioinformatics analyses for identifying candidate 
functional variants.  
Program Type Year Description 
Transfac473 Regulatory effects 2008 Database of information on transcription factor consensus sequences 





2012 Database including 100 reference epigenomes for multiple healthy 
hematopoietic cell types and diseased cells from the same individuals. 
Begun in 2011, eQTLs available in 2012.  
PolyPhen-2472 Pathogenicity 
prediction 
2013 Program predicting possible effects of amino-acid substitution; 
compares structural differences of amino acids. Specific to 
nonsynonymous coding mutations in humans. 
CADD476 Database 2014 Predicts pathogenicity based on metrics including prediction 
algorithms (PolyPhen) and functional data. Uses a release-specific 
version of the VEP. 
VEP609 Function 
prediction 




2015 Uses RNA-seq data from tissues of interest to generate predicted 
genome-wide transcription levels based on genotype data. 
FastPAINTOR435 Fine-mapping 2016 High-resolution causal-variant prediction using functional annotation 
data and results from multiple correlated traits. 
ClinVar622 Database 2016 Database combining variants with known or suspected functional effect 
in humans. 
bloodmIRs623 Blood miR 
expression 
database 
2017 High-throughput sequencing of miRs in 7 blood cell lines from a 
library of 450 samples. Cataloged online by the Institut für Klinische 
Molekularbiologie in Germany (all European ancestry):  
http://134.245.63.235/ikmb-tools/bloodmiRs.  
CADD: combined annotation dependent depletion; eQTL: expression quantitative trait locus; miR: microRNA; PIPS: 





Figure 3. PAGE II participants self-identifying as Hispanic/Latino stratified by ethnicity 
 




Figure 4. Ancestral principal components demonstrate the continental-ancestry continuum 
among participants of the PAGE study. 
 
Scatter plot of PCs for PAGE racial/ethnic groups. Each point represents an individual, color-
coded by self-identified race/ethnicity. (Left panel) Global variation (PC1 vs PC2) (Right panel) 





Figure 5. Comparison of multi-phenotype methods under the assumption of no genetic effect to 
examine systematic evidence of type I error inflation.  








Figure 6. Statistical power for univariate and multi-phenotype associations by effect size.  
Gray shading indicates 80% statistical power. 
 





Figure 7. Selected approximate power curves for 20,000 genes by number of variants per 
region 








 MANUSCRIPT A: ANCESTRY-SPECIFIC ASSOCIATIONS 
IDENTIFIED IN GENOME-WIDE COMBINED-PHENOTYPE STUDY OF RED 
BLOOD CELL TRAITS EMPHASIZE BENEFITS OF DIVERSITY IN GENOMICS 
 
5.1. Overview 
Quantitative red blood cell (RBC) traits are highly polygenic clinically relevant traits, 
with approximately 500 reported GWAS loci. The majority of RBC trait GWAS have been 
performed in European- or East Asian-ancestry populations, despite evidence that rare or 
ancestry-specific variation contributes substantially to RBC trait heritability. Recently developed 
combined-phenotype methods which leverage genetic trait correlation to improve statistical 
power have not yet been applied to these traits. Here we leveraged correlation of seven 
quantitative RBC traits in performing a combined-phenotype analysis in a multi-ethnic study 
population. 
We used the adaptive sum of powered scores (aSPU) test to assess combined-phenotype 
associations between ~21 million SNPs and seven RBC traits in 68,634 participants (24% 
African American, 30% Hispanic/Latino, 43% European American, 76% female).  
Thirty-nine loci contained at least one significant association signal (p<5E-9), with lead 
SNPs at five loci significantly associated with three or more RBC traits. A majority of the lead 
SNPs were common (MAF>5%) across all ancestral populations. 19 additional independent 
association signals were identified at seven known loci (HFE, KIT, HBS1L/MYB, 




conditionally independent association signals, 11 of which were novel and specific to African 
and Amerindian ancestries. One variant in this region was common in all ancestries, but 
exhibited a narrower LD block in African Americans than European Americans or 
Hispanics/Latinos. GTEx eQTL analysis of all independent lead SNPs yielded 31 significant 
associations in relevant tissues, over half of which were not at the gene immediately proximal to 
the lead SNP.  
The complex genetic architecture notable at the HBA1/2 locus—which was only revealed 
by the inclusion of ancestrally diverse populations—underscores the continued importance of 
expanding existing GWAS of European and East Asian populations to include other race/ethnic 
groups when attempting to identify and characterize complex trait loci.  
 
5.2. Introduction 
In the average adult, 200 billion red blood cells (RBCs) are generated daily from 
hematopoietic stem cells in the bone marrow. The most commonly assessed traits for mature 
RBCs are hematocrit (HCT), hemoglobin concentration (HGB), mean corpuscular hemoglobin 
(MCH), MCH concentration (MCHC), mean corpuscular volume (MCV), RBC count (RBCC), 
and red cell distribution width (RDW); together, these traits are used to characterize RBC 
development and function, diagnose anemic disorders, and identify risk factors for complex 
chronic diseases5; 107; 175; 273; 624; 625. RBC traits also are moderately to highly heritable, making 
these complex quantitative traits excellent candidates for genomic interrogation157; 497; 626. 
Improved characterization of RBC molecular pathways has benefitted both disease diagnosis and 
pharmaceutical development, as has been demonstrated by recent successes in a BCL11A-




Genetic association studies have reported over 500 independent loci for RBC traits16-27; 29; 301; 309; 
310; 314; 318; 348; 584. However, several research gaps remain which may be addressed via recently 
developed methods and broadly representative study populations. First, previously published 
RBC trait genome-wide association study (GWAS) populations have mostly been ancestrally 
homogeneous32; 343; 348; 435; 456; 459; 470; 594; 627. Utilization of diverse study populations can improve 
identification of rare or ancestry-specific variants located in biological pathways that affect 
phenotypes in global populations. Relatedly, gaps between estimated heritability and the 
proportion of variance explained by GWAS findings suggest that additional associations remain 
to be identified, including rare variants and independent secondary associations at known loci 
that are both more likely to be ancestrally specific301; 340; 496. Finally, RBC traits exhibit modest to 
high correlation, and several dozen loci have been reported for two or more RBC traits, although 
few studies have leveraged this shared genetic architecture to increase statistical power to map 
novel RBC trait loci 20; 26; 28; 301; 405; 419.  
In this work, we examined the individual and shared genetic architecture of seven RBC 
traits in participants of the ancestrally diverse Population Architecture using Genomics and 
Epidemiology (PAGE) study342. Our findings reinforce the necessity of incorporating multi-
ethnic study populations in genomics in order to accurately characterize RBC trait loci and 
encourage equitable application of the results to translational work627. The complexity of 
association signals at loci previously characterized in European- and East Asian-ancestry 







5.3.1. Study population 
The PAGE study comprises ancestrally-diverse study populations from United States 
cohorts and biobanks evaluating common complex diseases and accompanying risk factors (see 
online supplement for more information). This study used data from self-reported African 
American, Asian American, European American, Hispanic/Latino, and Native American 
participants from the Atherosclerosis Risk in Communities Study (ARIC); the Coronary Artery 
Risk Development in Young Adults Study (CARDIA); the Hispanic Community Health 
Study/Study of Latinos (HCHC/SOL); the Icahn Mt. Sinai School of Medicine BioME Biobank 
(BioME); and the Women’s Health Initiative (WHI, described above). Participants were 
excluded if they met any of the criteria described in Section 4.3.2.  
5.3.2. RBC Trait Measurement 
RBC traits were measured with hemanalyzers following standardized laboratory 
protocols from blood draws at the earliest available visit (see online supplement) for the three 
primary (HCT, HGB, and RBCC) and four derived (MCH, MCHC, MCV, and RDW) RBC traits 
(Table 3). RBC trait values that exceeded four standard deviations from the mean of the trait in 
the overall study population were excluded, mirroring protocols established by prior GWAS17; 18. 
5.3.3. Genotyping and Imputation 
Study-specific genotyping information is described in the supplemental methods. All 
studies were imputed to the 1000 Genomes phase 3 reference panel after study-specific quality 
control criteria were applied (Table 11). We further excluded SNPs on a sub-study-specific basis 




CAF x (1-CAF) x N x imputation quality, where CAF is coded allele frequency and N is sample 
size). 
5.3.4. Statistical Methods 
5.3.4.1 Overview 
Briefly, we used an adaptive sum of powered scores (aSPU) simulation-based method to 
perform a combined-phenotype analysis incorporating univariate results from seven RBC traits 
in sixteen analytic subgroups that were combined using inverse-variance-weighted meta-
analysis. Fifteen of the sixteen analytic subgroups were identified by study and self-reported 
race/ethnicity (Tables 12-14). The sixteenth subgroup was a pooled sample of self-reported 
African American, Asian American, Hispanic/Latino, Native American, and “Other” MEGA-
genotyped individuals from BioMe, HCHS/SOL, and WHI. Sensitivity analyses by trait and 
race/ethnicity were also performed. Complete summary level results are available through dbGaP 
(phs000356). 
5.3.4.2 Reporting 
Previously-reported SNPs for the seven RBC traits evaluated in this study were identified 
through review of the NHGRI-EB GWAS Catalog21 as of January 1, 2019, supplemented by a 
PubMed search. Multi-ethnic combined-phenotype results were presented as the primary 
findings, employing Bonferroni correction assuming 10M independent tests (i.e., paSPU<5E-9). 
We defined a locus using physical proximity (+/-500kb from the lead SNP), and we defined an 
association signal as the lead (most significant) SNP and proxy SNPs in local LD based on 
conditional independence within ten megabases. Discovery loci were defined as ≥500kb from 




8 for any of the seven RBC traits. Ancestry-specific and trait-specific analyses were performed 
as sensitivity analyses to improve interpretation of results. 
5.3.4.3 Univariate analysis 
Univariate associations for the seven RBC traits were estimated assuming an additive 
genetic model of inheritance and adjusting for linear effects of age at blood draw, sex, study site 
or region, and ancestral principal components23. The total MEGA-genotyped subgroup was 
analyzed using generalized estimating equations allowing correlated errors for first or second-degree 
relatives, and independent error distributions by self-reported ancestry group24. Linear regression was 
implemented in SUGEN for the other 15 analytic subgroups24. For each RBC trait, METAL 
software was used to perform inverse-variance-weighted meta-analysis across all sub-studies604. 
SNP effect heterogeneity was measured with the Cochran’s Q test. SNP meta-analysis p-values 
were assessed by RBC trait by calculating genomic inflation factors (λ) and plotting the expected 
distribution against observed results.  
5.3.4.4 Combined-phenotype analyses 
To evaluate evidence for shared genetic effects across all seven RBC traits, we combined 
meta-analyzed univariate results with aSPU to generate a combined-phenotype p-value for each 
SNP17. In comparison with other available methods, we chose aSPU because it exhibited low 
type 1 error rate in simulations (data not shown); accommodated direction of effect; and was 
computationally scalable to the millions of SNPs measured using 1000 Genomes Phase 3 
imputed data628. We implemented aSPU using Julia 1.0 to optimize efficiency 
(https://github.com/kaskarn/aspu_julia).  
aSPU incorporated univariate summary z-scores, calculated for each SNP across all 7 




a given SNP. Briefly, the procedure estimates Σ, the 7 × 7 correlation of null z-scores across 
univariate results and draws 1011 Monte-Carlo samples from the multivariate 𝑁7(0, Σ̂) 
distribution. For each SNP j, the results for all 7 traits 𝑧𝑗1, … , 𝑧𝑗7 are used to form a sequence of 
sums of powered scores: 𝑆𝑃𝑈(𝛾) = 𝑧1
𝛾
+ … + 𝑧7
𝛾
, where γ = 0, 1, …, 8, plus 𝑆𝑃𝑈(∞) =
max |𝑆7|. Each powered score is compared  to the distribution of the 10
11 powered scores 
calculated using simulated null values with the same γ to calculate a Monte-Carlo p-value. An 
overall SNP- p-value (paSPU), ranging between 1/(1+1011) and 1, is calculated by comparing the 
minimum p-value across the sequence of powered scores to the reference distribution of 
minimum p-values across the sequence of powered scores computed using the simulated null 
data. The adaptive aspect of the test lies in the potential for different γ values to yield the 
maximal SPU across SNPs, maintaining power compared to a test with only a single possible 
alternative hypothesis. 
5.3.4.5 Sensitivity Analyses 
Sensitivity analyses were performed for combined-trait results by self-reported 
race/ethnicity among populations with greater than 1,000 participants (African Americans, 
Hispanics/Latinos, and European Americans). We also examined whether there was evidence of 
significant loci that were not identified in combined phenotype analyses. Finally, in an attempt to 
examine the influence of the previously identified 3.7 kb structural variant esv3637548 in the 
HBA1/2 region of chromosome 16, we also adjusted for esv3637548 dosage (r2=0.86) in the 
MEGA-genotyped subgroup18. Combined phenotype p-values were then compared before and 





All SNPs located within 500kb of a variant previously reported for any RBC trait were 
evaluated for evidence of association in the combined phenotype analysis as well as each 
individual trait analysis. A generalization significance threshold of 1.07E-4 was calculated using 
Bonferroni correction for the previous number of one-megabase genomic regions for which one 
or more genome-wide-significant variants were reported for one or more RBC traits (n=466, 
representing 1,308 index SNPs previously reported for one or more of the seven RBC traits we 
evaluated). We first report trait-specific associations—i.e., index variants that have been reported 
by trait. We did not report SNPs that exceed genome-wide-significance for the first time in one 
RBC trait but have been reported for another trait as discovery associations; therefore, we also 
used the aforementioned significance threshold to evaluate generalization of association signals 
in each trait across all known loci.  
5.3.4.7 Identification of conditionally independent association signals  
Iterative conditional analysis was performed to identify all independent, genome-wide-
significant combined-phenotype lead SNPs as described above. To avoid identifying SNPs as 
independent that were in long-range LD, we began by conditioning on the top SNP within ten 
megabase windows on each chromosome. To identify conditionally independent SNPs, linear 
models were extended to include all PAGE combined-phenotype lead SNPs on shared 
chromosomes using the same methods described above for univariate analysis, with an added 
covariate to include the dosage information for each participant at each lead SNP. Following 
each round of conditioning, aSPU was re-run on conditioned results. Additional rounds of 
conditional analyses were performed as an iterative process until no genome-wide-significant 




5.3.5. Publicly available expression quantitative trait locus (eQTL) analysis 
To help prioritize causal genes at identified loci, we attempted to evaluate all lead SNPs 
within significant loci in relevant available tissues (whole blood, liver, spleen, and thyroid) for 
evidence of association with gene expression using the Genotype Tissue Expression (GTEx) 
portal429. 
5.4. Results 
In total, 68,634 participants met study inclusion criteria, with the number of participants 
by trait ranging from 33,526 (RDW) to 67,856 (MCHC) (Tables 13,14). Seventy-eight percent 
of participants were female and the average participant was 57 years old at time of blood 
collection. Self-reported race/ethnicity in the total study population was approximately 20% 
African American, 30% Hispanic/Latino, and 40% European American (Table 12). Partial 
correlation by RBC trait pair ranged from HCT-MCHC (partial correlation ρ = -0.02) to HCT-
HGB (ρ = 0.94, Figure 8A). Approximately 21M SNPs met our inclusion criteria (Table 11).  
5.4.1. Combined-phenotype analyses 
SNP associations with the combined RBC phenotype exceeded genome-wide 
significance at 39 loci (Figure 10), all of which were identified previously. Lead SNPs at five 
loci (SLC17A2/TRIM38, HFE, HBS1L/MYB, HBA1/2, and TMPRSS6) were associated with three 
or more RBC traits at genome-wide significance (Tables 15-22). HCT, HGB, and MCHC 
exhibited the fewest genome-wide-significant associations with lead SNPs (eleven, ten, and two, 
respectively), whereas MCH and MCV had the largest number of associations (nineteen and 
twenty respectively, Tables 15-22). Consistent with other GWAS of quantitative complex traits, 




Trait-specific directions of effect were largely consistent with pairwise correlations, as expected 
given the methodological design of aSPU. Of 106 associations which were genome-wide 
significant for two traits, in 98 instances (93%) direction of effect matched the direction of the 
pairwise correlation (Figure 8C, Tables 15-22). All eight trait-pair associations with directions 
of effect opposite of expectation were instances in which MCH or MCV drove the lead SNP 
association, and HCT or HGB had a different lead SNP in high LD with the combined-phenotype 
lead SNP (r2>0.8 in the combined MEGA-genotyped study population). Notably, of the eight 
associations with unexpected directions of effect by trait pair, none of the pairs were more than 
modestly correlated (0.2<ρ <0.4). 
5.4.1.1 Evidence of independent associations at established loci 
We identified 20 independent association signals at seven loci (HFE, CCND3, 
HBS1L/MYB, CITED2, ABO, HBA1/2, and PLIN4/5, Table 10, Figure 8C). The majority of lead 
SNPs were common to all ancestries (MAF>0.01); evidence of association was most significant 
in European Americans at HFE and HBS1L/MYB loci, whereas Hispanics/Latinos had the most 
significant association at both CITED2 lead SNPs. In two instances, known causal variants 
accounted for the entire association signal after conditioning. At the HFE locus, both rs1800562 
(C282Y) and rs1799945 (H63D, r2~0.99 with lead SNP rs2032451) are known coding 
hemochromatosis variants and accounted for all significant associations within +/-3Mb of the 
lead SNP. Similarly, rs2519093 and rs10901252 are in moderate to high LD with variants that 
affect RBC traits but also determine an individual’s ABO blood type, and adjusting for these two 
variants accounted for the entire association at this locus.  
Of note, the HBA1/2 locus demonstrated ancestry specificity (i.e., the lead SNP was 




9A). With the exception of rs60125383 (frequency of the A allele: 0.43 in African Americans, 
0.55 in European Americans, 0.62 in Hispanics/Latinos), located in a nonsense-mediated-decay 
transcript for NPRL3, no lead SNP at this locus was common to all ancestries. The LD block for 
rs60125383 contained fewer variants in African Americans (Figure 9B, no SNPs r2>0.4) 
compared to Hispanics/Latinos (Figure 9C, 10 SNPs r2>0.6) and European Americans (Figure 
9D, 13 SNPs r2>0.6).  
5.4.1.2 Sensitivity Analyses 
Trait-specific sensitivity analyses identified two previously-unreported variants exceeded 
genome-wide significance for a single RBC trait in the univariate analyses, yet did not meet 
genome-wide significance in the combined phenotype. Rs6573766 was specific to RBCC 
(p=1.1E-9) and is common to all ancestries but was poorly captured by earlier genotyping arrays 
and is not represented in 1000 genomes phase 3 data (Figure 11, Table 44). Rs145548796 was 
significant for MCV (p=4.6E-9) and is rare (< 1%) in all populations, only meeting the inclusion 
criteria in the MEGA pooled sample and one study sub-population (Figure 12, Table 45). When 
adjusting for esv3637548 deletion dosage in the MEGA-genotyped subgroup, we observed 
evidence of both attenuation and strengthening of effect at otherwise conditionally independent 
lead SNPs at the HBA1/2 locus (Table 46). Specifically, eight lead SNPs lost more than two 
orders of magnitude p-value after conditioning on esv3637548, one increased in significance, 
and five remained unchanged.  
5.4.1.3 Generalization of previously reported associations 
Generalization of previously identified association signals varied for trait-specific loci 
(p<1.07E-4, Tables 47-51), ranging from 50 of 143 (35%) for MCHC to 93 of 121 (77%) for 




generalization occurring in the European-ancestry sub-population and the lowest occurring in 
African Americans, which may be due to power differences to detect associations by ancestry. 
5.4.2. eQTL function of index SNPs 
To assess the potential regulatory roles of lead SNPs, we evaluated cis-eQTL (<500kb) 
associations for all lead SNPs in GTEx as available429. Thirty-three of 51 SNPs were low-
frequency or common (MAF>1%) in the European-ancestry GTEx population and had available 
information in whole blood, liver, spleen, and/or thyroid tissues. Fourteen SNPs exhibited 
significant associations in RBC-relevant tissues; seven SNPs were eQTLs for multiple genes 
(Table 52). Although approximately 40 genes were within 500kb of each of the chromosome 16 
lead SNPs, none of the lead SNPs in this region exceeded a MAF>1% in the GTEx study 
population and hence could not be evaluated for cis-eQTLs. 
 
5.5. Discussion 
RBC traits are complex quantitative phenotypes that have been broadly examined in 
GWAS of European- and East Asian-ancestry study populations. Here, we examine the benefits 
of identifying and characterizing RBC trait associations in the ancestrally diverse PAGE study 
population using a combined-phenotype approach. We demonstrate that ancestral diversity 
improves characterization of loci containing both ancestry-specific and common variants. 
Overall, the complex genetic architecture at several RBC loci, which was revealed by inclusion 
of ancestrally diverse populations, underscores the continued importance of expanding existing 
RBC trait GWAS of European and East Asian populations when attempting to identify and 




With regard to regions exhibiting multiple independent significant associations, our 
results demonstrate allelic heterogeneity at known RBC trait loci, the characterization of which 
was enabled by an inclusive study design. Of particular note was our identification of eleven 
variants specific to African and/or Amerindian ancestries within the first megabase of 
chromosome16. The chromosome 16 region includes hemoglobin protein-coding genes HBA1, 
HBA2, HBM, and HBZ as well as fifty other protein-coding genes with plausible roles in RBC 
trait biology, for example genes harboring monogenic causal variants for blood disorders (e.g., 
rs33987053, an HBA2 variant causing alpha-thalassemia). Decades of research have 
demonstrated selective pressure in this region occurring over millennia in malaria-endemic 
regions of the world, but as with many other complex quantitative traits, HBA1/2 has been 
primarily analyzed in Eurocentric study populations. Given the high polygenicity and complexity 
of quantitative RBC traits, our identification of over a dozen independent association signals 
suggests a highly-transcribed region with either complementary or redundant regulatory 
mechanisms that may affect multiple genes. Future work should extend our efforts by examining 
other populations in malaria-endemic regions, as well as previously identified and highly 
influential structural variants, including a previously identified 3.7kb copy number variant, 
which was not included in our analysis because we did not evaluate insertion/deletion variants18.  
A combined-phenotype method was selected due to its purported ability to increase 
statistical power to identify novel loci with modest effects across multiple correlated traits. 
However, sample sizes of previous RBC trait GWAS suggest that many loci with modest effects 
and lead SNPs in the low to common allele frequency range in European or East Asian 
populations already have been identified. Power was also lacking to detect loci that might be 




proportionally well-represented in this study, sample sizes similar to European populations will 
not be proportionately representative of genetic diversity, particularly for variants that are low-
frequency or difficult to impute. This should encourage an increase in representation of African 
Americans and Hispanics/Latinos, as the narrower (on average) LD blocks in populations 
exhibiting ancestral admixture also improve fine-mapping for prioritizing candidate variants for 
functional characterization.  
The possibility that combined-phenotype methods could benefit the study of other 
correlated polygenic traits still merits further investigation, particularly with groups of traits that 
may overlap in genetic architecture, but have not been previously examined in concert. Over the 
past three decades, RBC traits have been associated with cardiovascular disease outcomes like 
heart failure and stroke, highlighting the potential for identifying novel pleiotropic loci2; 5; 261; 275; 
402; 405; 629. Indeed, combined-phenotype approaches that examine the shared genetic architecture 
underlying intermediate phenotypes and clinical events may be particularly powerful for 
outcomes like stroke and heart failure, given that phenotypic heterogeneity of these phenotypes 
has complicated locus identification and characterization.  
Our evaluation of lead SNPs’ effects on expression in RBC-relevant tissues faced known 
constraints that limited interpretation and contextualization of identified variants. Crucially, the 
vast majority of publicly available functional data were collected from European-ancestry 
individuals, precluding the use of these databases for interpreting potential effects of ancestry-
specific or low-frequency SNPs on gene expression. For example, rs8051004 is one of two less 
frequent variants that were detected in European-ancestry populations at the HBA1/2 locus 
(CAF=0.02). However, rs8051004 was reported as “monoallelic” in spleen tissue in GTEx, 




1000G African and East Asian superpopulations, respectively. The exclusion of populations with 
African, Amerindian, and Asian ancestry continues to hamper the potential benefits of these 
resources. Additionally, while the GTex consortium has made extensive efforts to characterize a 
wide array of tissue types, bone marrow was not included429. RBCs enucleate in the bone 
marrow prior to entering circulation, with no nuclear transcription and extremely limited 
translation occurring in mature RBCs. Therefore, bone marrow is the only tissue for which eQTL 
data characterizing the effects of genetic variation on gene expression for RBCs directly—
eQTLs in any other tissue only represent biological processes in other cell types that affect RBC 
traits post-enucleation.  
As with other genetic association studies, we faced several limitations. First, sample sizes 
for RBC trait GWAS have ballooned to nearly 200,000 participants and we were restricted to a 
smaller study population. However, the PAGE study has recently demonstrated that modest-
sized studies that are more ancestrally diverse improve detection of novel and independent 
signals compared to simply increasing the number of European-ancestry individuals455. Second, 
while this study did improve on previous studies in terms of representation from African and 
Amerindian continental ancestries, we were unable to evaluate associations in several 
populations, particularly South Asians, Pacific Islanders, Native Americans, and Native 
Hawaiians. Native Americans and Native Hawaiians are represented in PAGE, but RBC 
phenotypes were not measured in contributing studies. South Asian study populations have been 
included in several previous RBC trait GWAS; and Native Americans and Pacific Islanders 
remain underrepresented in GWAS of all complex traits26; 314; 627; 630. Nonetheless, efforts like 
these underscore the need for ancestral diversity, especially as clinical applications of RBC trait 




variations, which have traditionally been difficult to impute, and re-calling all structural variants 
within significant loci was outside the scope of this work. A sensitivity analysis accounting for 
the effect of esv3637548 in MEGA-genotyped study participants suggests that further evaluation 
is required to determine whether true causal variants overlap the position of this 3.7kb structural 
variant on other ancestral haplotypes. However, it is expected that some structural variants will 
be adequately represented by proxy SNPs, and future sequencing-based studies will be able to 
characterize these rare variants. Finally, expression quantitative trait locus data could not be 
comprehensively interpreted given the limitations of publicly available databases as described 
above. It is imperative that these resources focus their efforts on becoming more inclusive over 




In conclusion, we identified over 50 association signals within 39 loci in a combined-
phenotype analysis of seven RBC traits. We did not observe large improvement in discover 
signal detection by using the combined-phenotype methods, although further work is required to 
fully test the utility of these approaches. However, our work demonstrates the benefits of diverse 
study populations for highly polygenic traits, in spite of the fact that as global populations are 
increasing in genetic diversity, genetic research has become less diverse. As genomics tools 
become more broadly available, our results underscore the critical importance of including 




5.7. Main Figures & Tables 
 
Figure 8. Identification and characterization of 39 loci in a multi-ethnic study population.  
A. RBC trait pair partial correlations among MEGA-genotyped participants adjusted for linear regression model covariates (N=29,090 for HCT, HGB, and 
MCHC measurements; N=22,330 for MCH, MCV, and RBCC; and N=19,573 for RDW had all required phenotype and covariate information). B. Low-
frequency and rare alleles exhibit larger magnitude of effect across RBC traits in the total multi-ethnic study population. x-axis represents minor allele 
frequency; y-axis represents trait-specific effect size (z-score). Green dots are present in all ancestry sub-populations; purple dots are monomorphic in one or 
more ancestries; only variants exceeding nominal significance (p<0.05) are included. C. Lead SNPs from combined-phenotype analysis show shared genetic 
















Figure 9. Multiple independent associations with MCH demonstrate complex genetic architecture at HBA1/HBA2 locus.  
All plots: x-axis represents position on chromosome 16, y-axis represents -log10(pvalue) of the association with MCH. A. Regional association plot of 14 
independent associations in unadjusted analysis of multi-ethnic study population. Large circles represent conditionally independent lead SNPs; colored 
SNPs represent variants in high LD (r2>0.8 in LD in pooled MEGA subpopulation) with the corresponding lead SNP. B-D. Locus-Zoom plots of MCH 
association with rs60125383 (11th round of conditioning, purple diamond) in African Americans on an African American LD background (B), 
Hispanics/Latinos on a Hispanic/Latino LD background (C), and European Americans on a European LD background (D). 
B. African Americans C. Hispanics/Latinos D. European Americans 





















































































































































































































































































































































































Figure 10. Evidence of genetic associations shared across correlated RBC traits. 
X-axis: chromosome and position (top) and rsid (bottom) for each combined-phenotype lead SNP. Y-
axis: trait-specific –log10(p-values), with increased intensity representing higher significance, for each 






















































































































































































































































































































































































































































































Figure 11. Locus-Zoom plots of the association between rs6573766 and RBCC in PAGE African 
Americans (A), Hispanics/Latinos (B), and European Americans (C) 
 
C. RBCC-rs6573766 association in PAGE 
European American study participants 
A. RBCC-rs6573766 association in PAGE 
African American study participants 
B. RBCC-rs6573766 association in PAGE 






Figure 12. Locus-Zoom plot of the association between MCH (A) and MCV (B) and 
rs145548796 in the total MEGA study population 
 
A. MCH-rs145548796 association in 
MEGA-genotyped study participants 
B. MCV-rs145548796 association in 
MEGA-genotyped study participants 
135 
 
Table 10. RBC trait loci with evidence of multiple independent signals among PAGE study participants. 
       p values 
    CAF* Multi-ethnic RBC trait-specific  Combined phenotype  by 
race/ethnicity* 
 Signal Chr:pos Ref/Alt AA HL EU HCT HGB MCH MCHC MCV RBCC RDW  AA HL EU 
HFE locus   
rs2032451 1 6:26092170 T/G 0.96 0.88 0.85 4.0E-16 1.4E-30 8.2E-38 1.8E-22 2.3E-27 0.01 3.4E-25  2.0E-4 2.3E-3 1.0E-11 
rs1800562 2 6:26093141 A/G 0.98 0.98 0.93 1.4E-4 2.4E-5 7.7E-30 3.1E-3 1.2E-3 0.78 0.05  1.0E-5 1.0E-10 1.0E-11 
                  
CCND3 locus   
rs1410492 1 6:41907855 C/G 0.94 0.86 0.75 0.24 0.21 1.0E-14 0.59 3.5E-19 1.5E-14 1.9E-6  0.04 1.4E-7 1.0E-11 
rs11964516 2 6:41860252 T/C 0.15 0.16 0.17 0.04 0.01 5.6E-13 0.12 3.0E-12 8.8E-4 0.03  0.02 1.6E-6 1.0E-11 
                  
HBS1L/MYB locus   
rs35786788 1 6:135419042 A/G 0.92 0.85 0.74 8.8E-20 7.0E-11 3.0E-66 6.2E-07 1.1E-59 3.3E-60 1.6E-16  8.0E-7 1.0E-11 1.0E-11 
rs12664956 2 6:135384188 T/C 0.22 0.26 0.37 2.6E-4 2.3E-3 1.1E-14 7.9E-3 2.4E-12 2.0E-9 0.52  0.03 8.1E-5 1.0E-6 
                  
CITED2 locus   
rs590856 1 6:139844429 A/G 0.63 0.41 0.45 1.2E-4 2.1E-4 7.7E-16 0.44 1.4E-23 2.2E-8 0.79  1.3E-4 1E-11 5.1E-7 
rs607203 2 6:139841653 T/C 0.79 0.93 0.96 0.02 0.04 7.9E-11 0.12 2.1E-13 8.8E-5 0.13  5.3E-3 6.2E-6 2.9E-7 
                  
ABO locus   
rs2519093 1 9:136141870 T/C 0.89 0.85 0.80 5.7E-16 8.7E-18 0.32 0.05 0.85 1.1E-7 0.09  2.1E-4 1.1E-8 1.0E-8 
rs10901252 2 9:136128000 C/G 0.84 0.93 0.92 0.02 3.4E-4 4.2E-5 5.5E-4 7.9E-8 8.0E-8 0.82  5.3E-5 2.4E-4 5.0E-6 
                  
HBA locus   
rs9924561 1 16:314780 G/T 0.91 0.99 -- 1.4E-4 3.6E-26 5.8E-158 9.7E-87 2.4E-135 8.6E-49 4.9E-6  1.0E-11 -- -- 
rs76613236 2 16:230724 C/G 0.98 0.995 -- 0.79 0.03 6.2E-20 2.0E-5 3.0E-18 5.3E-14 2.7E-5  1.0E-11 -- -- 
rs142154093 3 16:366048 C/G 0.98 0.99 -- 0.02 4.0E-7 1.3E-32 2.2E-12 4.9E-33 6.5E-13 2.1E-5  1.0E-11  -- 
rs186066503 4 16:405483 T/C -- 0.994 -- 0.34 8.5E-3 3.6E-30 4.4E-18 2.8E-19 2.7E-15 3.5E-6  -- 1.0E-11 -- 
rs530159671 5 16:250184 A/G -- 0.991 0.997 4.5E-3 7.5E-8 1.7E-24 7.2E-12 2.0E-16 2.3E-7 2.2E-4  -- 1.0E-11 -- 
rs8058016 6 16:228786 A/C 0.99 0.992 -- 2.2E-3 2.8E-5 1.8E-22 1.7E-5 3.5E-21 1.0E-4 8.0E-3  1E-11 2.6E-8 -- 
rs60616598 7 16:297264 A/G 0.83 0.96 -- 0.04 1.0E-5  8.1E-23 2.2E-11 1.8E-16 9.7E-9 2.3E-9  1.0E-11 2.8E-9 -- 
rs145752042 8 16:267208 A/G 0.993 -- -- 1.0E-4 2.4E-7 1.2E-18 1.2E-4 3.1E-19 3.0E-4 0.04  3.2E-10 -- -- 
rs145546625 9 16:220583 T/C 0.98 0.93 -- 0.19 0.08 2.5E-14 0.17 8.8E-15 1.4E-5 5.9E-3  0.22 1.0E-11 -- 
rs115415087 10 16:205132 T/C 0.018 0.004 -- 0.80 0.24 1.2E-12 1.2E-4 3.5E-14 3.2E-10 0.17  1.4E-10 1.3E-3 -- 
rs61743947 11 16:240000 T/C 0.995 -- -- 0.04 7.0E-5 2.4E-13 1.4E-11 8.7E-12 0.13 2.3E-6  3.1E-8 -- -- 
rs60125383 12 16:176446 A/T 0.43 0.62 0.55 0.11 0.001 3.1E-13 2.1E-6 4.5E-8 1.3E-4 0.91  6.1E-7 0.01 2.0E-5 
rs55932218 13 16:221151 T/C 0.05 0.01 -- 0.52 0.03 6.3E-10 1.2E-4 2.0E-8 2.1E-3 3.2E-5  5.0E-8 0.01 -- 
rs8051004 14 16:198835 T/C 0.10 0.05 0.02 0.81 0.04 7.2E-11 3.2E-8 8.1E-8 0.06 0.04  0.01 5.1E-7 0.04 
                  












PLIN4/PLIN5 locus   
rs919797 1 19:4498157 A/G 0.68 0.49 0.46 5.1E-2 5.5E-4 1.9E-11 1.8E-5 6.5E-9 4.4E-1 8.8E-1  0.35 9.5E-3 1.1E-8 
rs12459922 2 19:4455862 A/G 0.12 0.25 0.26 0.003 0.003 4.3E-8 0.34 1.4E-9 0.09 0.11  0.17 4.9E-5 1.0E-4 
Bold font for combined-phenotype analysis indicates that the index SNP also had the lowest reported p-value for that particular trait. Variants not meeting effective heterozygosity criterion of 35 











Table 11. Genotyping platforms and QC measures used by participating study populations.    















































































90% 98% 90% 98% 98% 98% 98% 90% 90% 98% 98% 
ARIC: Atherosclerosis Risk in Communities Study, MESA: Multi-Ethnic Study of Atherosclerosis, PAGE: Population Architecture using Genetic Epidemiology study, WHI: 
Women’s Health Initiative. *PAGE includes all participants of the BioME Biobank, Hispanic Community Study/Study of Latinos, and WHI that were genotyped on the MEGA 
array. All genotypes imputed to the 1000 Genomes phase 3 v 5 reference panel; Build 37 of the Genome Reference Consortium was used to assign chromosomal positions and rsid 














Table 12. Ancestry representation by self-reported race/ethnicity by RBC trait. 
        
Number of study participants by self-reported race/ethnicity 
 HCT HGB MCH MCHC MCV RBCC RDW 
African American 16,256 16,258 8,707 16,301 8,690 8,692 6,153 
Hispanic/Latino 20,796 20,784 17,426 20,811 17,409 17,439 17,305 
European American 29,514 29,509 14,715 29,494 14,710 14,712 9,630 
Asian 634 633 127 633 127 127 123 
Native American 604 604 20 20 603 20 20 
Other 383 383 383 383 383 383 383 
Total 68,187 68,171 41,378 67,642 41,922 41,373 33,614 
        
Proportion of study participants by self-reported race/ethnicity 
 HCT HGB MCH MCHC MCV RBCC RDW 
African American 23.8% 23.8% 21.0% 24.1% 20.7% 21.0% 18.3% 
Hispanic/Latino 30.5% 30.5% 42.1% 30.8% 41.5% 42.2% 51.5% 
European American 43.3% 43.3% 35.6% 43.6% 35.1% 35.6% 28.6% 
Asian 0.9% 0.9% 0.3% 0.9% 0.3% 0.3% 0.4% 
Native American 0.9% 0.9% 0.0% 0.0% 1.4% 0.0% 0.1% 
















Table 13. Descriptive statistics for PAGE participants by study and race/ethnicity for ARIC, BioME, and CARDIA participants.   














































































































































































































ARIC: Atherosclerosis Risk in Communities Study. *Note: N represents the maximum number of individuals with any phenotype at 

































100% 100% 100% 100% 100% 6,929 (59%) 
Age (yrs), 
SD 
61.7 (7.05) 66.7 (6.43) 66.96 (6.56) 60.5 (6.75) 61.7 (7.31) 46.0 (13.83) 








MCH 28.71 (2.27) N/A 30.26 (1.82) 29.98 (1.88) N/A 29.22 (2.11) 




MCV 88.21 (6.51) N/A 91.80 (4.97) 90.31 (4.99) N/A 89.31 (5.72) 
RBCC 4.43 (0.47) N/A 4.41 (0.42) 4.42 (0.40) N/A 4.73 (0.44) 
RDW 14.48 (1.33) N/A 13.95 (1.14) 13.89 (1.07) N/A 13.67 (1.14) 
HCHS/SOL: Hispanic Community Health Study/Study of Latinos, PAGE: Population Architecture 
using Genetic Epidemiology study, WHI: Women’s Health Initiative. *Note: N represents the 










Table 15. Univariate allele information and frequencies for combined-phenotype lead SNPs in 












rs61523591 2:46372781 t c 0.160 0.207 0.146 0.146 
rs2361016 3:24341268 a t 0.719 0.803 0.680 0.751 
rs73210009 3:195830276 a g 0.623 0.786 0.554 0.659 
rs218265 4:55408999 t c 0.231 0.242 0.158 0.319 
rs4535497 5:1107428 a c 0.526 0.642 0.432 0.607 
rs3749748 5:127350549 t c 0.795 0.944 0.757 0.838 
rs2032451 6:26092170 t g 0.870 0.964 0.848 0.882 
rs607203 6:139841653 t c 0.886 0.789 9.957 0.933 
rs1800562 6:26093141 a g 0.947 0.985 0.938 0.981 
rs11964516 6:41860252 t c 0.169 0.147 0.178 0.165 
rs13203155 6:109614844 t c 0.598 0.609 0.553 0.686 
rs35786788 6:135419042 a g 0.784 0.924 0.739 0.848 
rs12664956 6:135384188 t c 0.320 0.216 0.375 0.259 
rs590856 6:139844429 a g 0.480 0.635 0.449 0.413 
rs12718598 7:50428445 t c 0.520 0.530 0.493 0.573 
rs28832309 7:80319938 c g 0.947 0.915 0.371 0.986 
rs7385804 7:100235970 a c 0.346 0.341 0.710 0.296 
rs10253736 7:151415256 t c 0.757 0.859 0.202 0.803 
rs7853365 9:4855858 a c 0.188 0.140 0.803 0.185 
rs2519093 9:136141870 t c 0.829 0.891 0.064 0.850 
rs10901252 9:136128000 c g 0.898 0.839 0.920 0.927 
rs34793991 10:46080590 a c 0.055 0.024 0.095 0.040 
rs17476364 10:71094504 t c 0.080 0.020 0.095 0.065 
rs33930165 11:5248233 t c 0.993 0.988 -- 0.998 
rs28456 11:61589481 a g 0.322 0.170 0.300 0.480 
rs12320749 12:4331647 c g 0.225 0.248 0.210 0.228 
rs597808 12:111973358 a g 0.604 0.905 0.507 0.710 
rs8013143 14:23494277 a g 0.380 0.750 0.290 0.304 
rs11621325 14:65472241 t c 0.428 0.405 0.442 0.421 
rs4887023 15:78535437 c g 0.374 0.394 0.380 0.337 
rs9924561 16:314780 t g 0.941 0.903 -- 0.987 
rs186066503 16:405483 t c 0.996 -- -- 0.989 
rs530159671 16:250184 a g 0.995 -- -- 0.991 
rs8058016 16:228786 a c 0.994 0.990 -- 0.996 
rs60616598 16:297264 a g 0.898 0.834 -- 0.963 




rs145546625 16:220583 t c 0.958 0.975 -- 0.931 
rs115415087 16:205132 t c 0.011 0.018 -- 0.004 
rs61743947 16:240000 t c 0.998 0.995 -- -- 
rs60125383 16:176446 a t 0.544 0.434 0.552 0.619 
rs55932218 16:221151 t c 0.030 0.052 -- 0.010 
rs8051004 16:198835 t c 0.064 0.103 0.016 0.048 
rs2608604 16:88849421 a g 0.619 0.660 0.629 0.566 
rs4890634 18:43854259 t c 0.306 0.402 0.253 0.312 
rs71176524 19:2177925 a at 0.548 0.556 0.535 0.568 
rs919797 19:4498157 a g 0.515 0.676 0.462 0.491 
rs1799918 19:13002400 c g 0.662 0.783 0.636 0.619 
rs958483 19:33759240 t c 0.939 0.983 0.933 0.927 
rs6014993 20:55991637 a g 0.576 0.709 0.495 0.652 
rs4820079 22:32879617 t g 0.502 0.542 0.504 0.467 
rs855791 22:37462936 a g 0.610 0.831 0.567 0.562 






Table 16. HCT univariate results for combined-phenotype lead SNPs in combined multi-
ethnic study population. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.2117 0.0295 6.93E-13 0.402 10,384 
rs2361016 3:24341268 0.0164 0.0201 4.14E-01 0.02638 25,423 
rs73210009 3:195830276 -0.0465 0.0186 1.23E-02 0.289 29,952 
rs218265 4:55408999 -0.0852 0.0219 9.88E-05 0.7663 21,985 
rs4535497 5:1107428 0.0062 0.0184 7.37E-01 0.6698 29,771 
rs3749748 5:127350549 0.011 0.0227 6.28E-01 0.01551 21,907 
rs2032451 6:26092170 -0.2195 0.027 3.97E-16 0.9999 15,327 
rs1800562 6:26093141 -0.3803 0.0444 1.04E-17 0.1412 6,576 
rs11964516 6:41860252 0.0416 0.0231 7.11E-02 0.08621 18,581 
rs13203155 6:109614844 0.0594 0.0178 8.23E-04 0.1056 32,578 
rs35786788 6:135419042 0.2029 0.0223 8.81E-20 0.486 22,457 
rs590856 6:139844429 0.0672 0.0175 1.24E-04 0.7537 33,426 
rs12718598 7:50428445 -0.0153 0.0175 3.82E-01 0.8567 32,359 
rs28832309 7:80319938 0.046 0.065 4.79E-01 0.3201 3,483 
rs7385804 7:100235970 0.117 0.0185 2.35E-10 0.4761 28,584 
rs10253736 7:151415256 0.1546 0.0213 3.91E-13 0.5274 22,262 
rs7853365 9:4855858 8.00E-04 0.0221 9.71E-01 0.6919 20,608 
rs2519093 9:136141870 0.1893 0.0234 5.71E-16 0.8805 18,507 
rs34793991 10:46080590 0.0068 0.0399 8.65E-01 0.6702 6,791 
rs17476364 10:71094504 0.3706 0.0351 4.37E-26 0.2504 8,662 
rs33930165 11:5248233 0.7231 0.1891 1.31E-04 0.2443 411 
rs28456 11:61589481 0.1099 0.0197 2.40E-08 0.6768 27,718 
rs12320749 12:4331647 -0.0814 0.021 1.00E-04 0.5262 22,243 
rs597808 12:111973358 -0.1402 0.0196 9.34E-13 0.3607 31,312 
rs8013143 14:23494277 -0.0203 0.0197 3.20E-01 0.8497 30,270 
rs11621325 14:65472241 6.00E-04 0.0177 9.71E-01 0.9126 31,612 
rs4887023 15:78535437 -0.0483 0.0178 6.73E-03 0.7273 31,532 
rs2608604 16:88849421 -0.0513 0.0185 5.58E-03 0.4054 28,550 
rs4890634 18:43854259 0.0581 0.0189 2.10E-03 0.1049 28,463 
rs71176524 19:2177925 -0.1052 0.018 4.93E-09 0.2478 30,693 
rs919797 19:4498157 -0.0356 0.0183 5.12E-02 0.6535 30,484 
rs1799918 19:13002400 0.0479 0.0187 1.05E-02 0.774 28,946 
rs958483 19:33759240 -0.1161 0.0409 4.57E-03 0.5942 5,603 
rs6014993 20:55991637 0.0206 0.0182 2.57E-01 0.9732 30,025 




rs855791 22:37462936 0.2256 0.0185 4.02E-34 0.4115 30,495 
rs140523 22:50962782 0.0252 0.021 2.30E-01 0.7152 16,684 
rs9924561 16:314780 0.1812 0.0599 2.49E-03 0.1862 3,926 
rs186066503 16:405483 -0.2596 0.275 3.45E-01 0.0245 246 
rs530159671 16:250184 0.5115 0.1805 4.59E-03 0.4598 355 
rs8058016 16:228786 0.5625 0.1834 2.16E-03 0.6508 369 
rs60616598 16:297264 0.0985 0.0488 4.36E-02 0.332 6,715 
rs145752042 16:267208 -1.136 0.2927 1.04E-04 0.08684 215 
rs145546625 16:220583 0.0916 0.0692 1.86E-01 0.2643 3,474 
rs115415087 16:205132 0.0353 0.1406 8.02E-01 0.8619 732 
rs61743947 16:240000 0.6984 0.3376 3.86E-02 1 108 
rs60125383 16:176446 0.0294 0.0186 1.14E-01 0.7982 31,927 
rs55932218 16:221151 -0.0533 0.0835 5.24E-01 0.2245 2,204 
rs8051004 16:198835 0.0117 0.0486 8.10E-01 0.5986 7,246 
rs1800562 6:26093141 -0.3803 0.0444 1.04E-17 0.1412 66022 
rs11964516 6:41860252 0.0416 0.0231 7.11E-02 0.08621 18580 
rs12664956 6:135384188 -0.0341 0.0189 7.19E-02 0.3611 29049 
rs607203 6:139841653 -0.1132 0.0323 4.61E-04 0.2249 13333 







Table 17. HGB univariate results for combined-phenotype lead SNPs in combined multi-
ethnic study population. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0696 0.008 4.26E-18 0.1845 18,218 
rs2361016 3:24341268 0.0094 0.0068 1.71E-01 0.03582 25,467 
rs73210009 3:195830276 -0.0277 0.0063 1.19E-05 0.4922 29,980 
rs218265 4:55408999 -0.0208 0.0074 5.14E-03 0.884 21,927 
rs4535497 5:1107428 0.0098 0.0063 1.16E-01 0.2285 29,771 
rs3749748 5:127350549 0.0022 0.0077 7.80E-01 0.1099 21,990 
rs2032451 6:26092170 -0.1056 0.0092 1.41E-30 0.9758 15,394 
rs1800562 6:26093141 -0.1679 0.015 4.26E-29 0.1487 6,586 
rs11964516 6:41860252 0.0187 0.0079 1.74E-02 0.1666 18,586 
rs13203155 6:109614844 0.0067 0.006 2.69E-01 0.1852 32,602 
rs35786788 6:135419042 0.0494 0.0076 7.01E-11 0.5427 22,519 
rs590856 6:139844429 0.0221 0.006 2.10E-04 0.6879 33,419 
rs12718598 7:50428445 -0.0025 0.0059 6.79E-01 0.6516 32,353 
rs28832309 7:80319938 0.0479 0.0221 3.02E-02 0.4646 3,482 
rs7385804 7:100235970 0.0296 0.0063 2.51E-06 0.4949 28,612 
rs10253736 7:151415256 0.0547 0.0073 4.72E-14 0.6186 22,313 
rs7853365 9:4855858 -0.0034 0.0075 6.54E-01 0.6038 20,612 
rs2519093 9:136141870 0.0684 0.008 8.67E-18 0.8338 18,528 
rs34793991 10:46080590 0.0148 0.0136 2.74E-01 0.3951 6,801 
rs17476364 10:71094504 0.1301 0.012 1.46E-27 0.2726 8,719 
rs33930165 11:5248233 -0.0544 0.0645 3.99E-01 0.9468 411 
rs28456 11:61589481 0.0419 0.0067 4.50E-10 0.4198 27,658 
rs12320749 12:4331647 -0.0271 0.0071 1.51E-04 0.3309 22,224 
rs597808 12:111973358 -0.0531 0.0067 2.11E-15 0.2253 31,383 
rs8013143 14:23494277 -0.0145 0.0067 3.09E-02 0.9065 30,245 
rs11621325 14:65472241 0.0059 0.006 3.28E-01 0.8688 31,611 
rs4887023 15:78535437 -0.0114 0.0061 6.13E-02 0.7968 31,535 
rs2608604 16:88849421 -0.0368 0.0063 5.70E-09 0.6424 28,535 
rs4890634 18:43854259 0.023 0.0065 3.74E-04 0.03955 28,415 
rs71176524 19:2177925 -0.0315 0.0061 2.76E-07 0.1145 30,688 
rs919797 19:4498157 -0.0216 0.0062 5.47E-04 0.5471 30,479 
rs1799918 19:13002400 0.012 0.0064 5.94E-02 0.8099 28,931 
rs958483 19:33759240 -0.0382 0.014 6.37E-03 0.5518 5,618 
rs6014993 20:55991637 0.013 0.0062 3.63E-02 0.9039 30,056 
rs4820079 22:32879617 0.0214 0.0058 2.45E-04 0.5727 33,778 




rs140523 22:50962782 0.011 0.0072 1.25E-01 0.8818 16,680 
rs9924561 16:314780 0.1968 0.0203 2.60E-22 
0.00013
09 3,925 
rs186066503 16:405483 0.2585 0.0982 8.51E-03 0.08275 246 
rs530159671 16:250184 0.3409 0.0634 7.46E-08 0.4964 349 
rs8058016 16:228786 0.2687 0.0642 2.80E-05 0.3386 369 
rs60616598 16:297264 0.0774 0.0175 1.00E-05 0.05922 6,393 
rs145752042 16:267208 -0.5187 0.1005 2.45E-07 0.3859 215 
rs145546625 16:220583 0.0412 0.0238 8.38E-02 0.1134 3,465 
rs115415087 16:205132 -0.0569 0.0487 2.43E-01 0.801 752 
rs61743947 16:240000 0.4709 0.1184 6.97E-05 1 108 
rs60125383 16:176446 0.0202 0.0063 1.37E-03 0.5925 31,924 
rs55932218 16:221151 -0.0607 0.0286 3.35E-02 0.2664 2,225 
rs8051004 16:198835 -0.0341 0.0166 3.96E-02 0.6503 7,245 
rs1800562 6:26093141 -0.1679 0.015 4.26E-29 0.1487 6,586 
rs11964516 6:41860252 0.0187 0.0079 1.74E-02 0.1666 18,585 
rs12664956 6:135384188 -0.0061 0.0065 3.46E-01 0.3891 29,095 
rs607203 6:139841653 -0.0347 0.011 1.58E-03 0.6092 13,361 









Table 18. MCH univariate results for combined-phenotype lead SNPs in combined multi-
ethnic study population. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.0059 0.0199 7.67E-01 0.1719 11,007 
rs2361016 3:24341268 0.106 0.0168 2.87E-10 0.9028 15,469 
rs73210009 3:195830276 -0.1044 0.0155 1.58E-11 0.4444 18,035 
rs218265 4:55408999 0.1932 0.0181 1.22E-26 0.5851 13,721 
rs4535497 5:1107428 -0.0569 0.0154 2.10E-04 0.07997 18,356 
rs3749748 5:127350549 -0.0156 0.0187 4.06E-01 0.1507 13,310 
rs2032451 6:26092170 -0.2825 0.022 8.22E-38 0.05654 9,352 
rs1800562 6:26093141 -0.4537 0.0369 1.16E-34 0.4352 3,876 
rs11964516 6:41860252 0.1687 0.0192 1.71E-18 0.1094 11,321 
rs13203155 6:109614844 -0.1128 0.0148 2.83E-14 0.389 19,753 
rs35786788 6:135419042 -0.3173 0.0185 3.00E-66 0.1533 13,609 
rs590856 6:139844429 0.1173 0.0146 7.71E-16 0.4587 20,365 
rs12718598 7:50428445 0.1119 0.0146 2.00E-14 0.06985 19,532 
rs28832309 7:80319938 0.0487 0.0598 4.16E-01 0.4092 2,483 
rs7385804 7:100235970 -0.1191 0.0155 1.44E-14 0.09905 17,036 
rs10253736 7:151415256 0.0295 0.0176 9.34E-02 0.916 13,593 
rs7853365 9:4855858 -0.1399 0.0184 2.81E-14 0.6896 12,569 
rs2519093 9:136141870 0.0192 0.0196 3.29E-01 0.4778 11,212 
rs34793991 10:46080590 0.2094 0.0334 3.70E-10 0.6701 4,018 
rs17476364 10:71094504 0.1254 0.029 1.55E-05 0.7716 5,170 
rs33930165 11:5248233 1.3127 0.165 1.80E-15 0.1668 324 
rs28456 11:61589481 -0.016 0.0163 3.26E-01 0.4805 17,123 
rs12320749 12:4331647 0.0655 0.0174 1.64E-04 0.6853 13,550 
rs597808 12:111973358 -0.0302 0.0163 6.36E-02 0.0146 18,903 
rs8013143 14:23494277 -0.0391 0.0165 1.82E-02 0.3599 17,894 
rs11621325 14:65472241 0.0967 0.0147 5.40E-11 0.5608 19,185 
rs4887023 15:78535437 0.0333 0.0149 2.57E-02 0.74 19,088 
rs2608604 16:88849421 -0.016 0.0155 3.03E-01 0.8609 17,690 
rs4890634 18:43854259 0.0872 0.0158 3.79E-08 0.07243 17,224 
rs71176524 19:2177925 0.0172 0.0151 2.52E-01 0.05867 18,993 
rs919797 19:4498157 -0.1034 0.0154 1.90E-11 0.6489 18,147 
rs1799918 19:13002400 -0.1187 0.0155 2.10E-14 0.6512 17,652 
rs958483 19:33759240 0.1408 0.0331 2.11E-05 0.4684 3,631 
rs6014993 20:55991637 0.1083 0.0151 8.40E-13 0.9958 18,398 
rs4820079 22:32879617 0.0822 0.0143 9.03E-09 0.5197 20,563 




rs140523 22:50962782 0.0975 0.0162 1.76E-09 0.199 10,875 
rs9924561 16:314780 1.5441 0.0559 1.02E-167 
3.90E-
11 2,842 
rs186066503 16:405483 2.201 0.1929 3.61E-30 0.1758 205 
rs530159671 16:250184 1.4072 0.1378 1.71E-24 
1.94E-
05 275 
rs8058016 16:228786 1.7363 0.178 1.80E-22 0.02998 233 
rs60616598 16:297264 0.4482 0.0456 8.12E-23 0.2428 4,802 
rs145752042 16:267208 -2.2842 0.2591 1.20E-18 0.9663 171 
rs145546625 16:220583 0.4016 0.0527 2.48E-14 0.1236 2,964 
rs115415087 16:205132 -0.9756 0.1373 1.19E-12 0.03722 523 
rs61743947 16:240000 2.2678 0.3096 2.40E-13 1 59 
rs60125383 16:176446 0.1122 0.0154 3.14E-13 0.01865 19,377 
rs55932218 16:221151 -0.4601 0.0744 6.32E-10 0.07002 1,494 
rs8051004 16:198835 -0.2613 0.0401 7.20E-11 0.8688 4,271 
rs1800562 6:26093141 -0.4537 0.0369 1.16E-34 0.4352 3,876 
rs11964516 6:41860252 0.1687 0.0192 1.71E-18 0.1094 11,321 
rs12664956 6:135384188 0.049 0.0157 1.85E-03 0.06695 17,620 
rs607203 6:139841653 -0.241 0.0284 1.94E-17 0.2514 7,608 







Table 19. MCHC univariate results for combined-phenotype lead SNPs in combined multi-
ethnic study population. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.003 0.0076 6.96E-01 0.3383 18,288 
rs2361016 3:24341268 0.0091 0.0065 1.63E-01 0.7151 25,533 
rs73210009 3:195830276 -0.0277 0.0061 5.18E-06 0.8902 30,027 
rs218265 4:55408999 0.0187 0.0072 9.34E-03 0.9052 21,744 
rs4535497 5:1107428 0.0219 0.006 2.87E-04 0.1073 29,807 
rs3749748 5:127350549 -0.0105 0.0074 1.53E-01 0.08491 22,080 
rs2032451 6:26092170 -0.0863 0.0088 1.76E-22 0.009454 15,507 
rs1800562 6:26093141 -0.1196 0.0144 1.23E-16 0.5233 6,615 
rs11964516 6:41860252 0.011 0.0075 1.44E-01 0.7896 18,601 
rs13203155 6:109614844 -0.0326 0.0058 1.55E-08 0.4052 32,625 
rs35786788 6:135419042 -0.045 0.0073 5.52E-10 0.9977 22,584 
rs590856 6:139844429 -0.0044 0.0057 4.45E-01 0.02882 33,441 
rs12718598 7:50428445 0.0075 0.0057 1.90E-01 0.3087 32,384 
rs28832309 7:80319938 0.0588 0.0206 4.31E-03 0.06603 3,532 
rs7385804 7:100235970 -0.0224 0.006 2.02E-04 0.6981 28,574 
rs10253736 7:151415256 0.0074 0.0069 2.86E-01 0.9849 22,431 
rs7853365 9:4855858 -0.0085 0.0072 2.39E-01 0.5081 20,596 
rs2519093 9:136141870 0.0151 0.0076 4.82E-02 0.508 18,587 
rs34793991 10:46080590 0.0303 0.013 1.94E-02 0.7964 6,841 
rs17476364 10:71094504 0.0159 0.0115 1.69E-01 0.7174 8,736 
rs33930165 11:5248233 -0.9275 0.063 5.53E-49 2.24E-07 428 
rs28456 11:61589481 0.0066 0.0065 3.04E-01 0.7948 27,613 
rs12320749 12:4331647 
-2.00E-
04 0.0068 9.75E-01 0.7072 22,208 
rs597808 12:111973358 -0.01 0.0064 1.22E-01 0.1628 31,550 
rs8013143 14:23494277 -0.0132 0.0064 3.97E-02 0.6124 30,222 
rs11621325 14:65472241 0.0146 0.0058 1.13E-02 0.5484 31,613 
rs4887023 15:78535437 0.0079 0.0058 1.72E-01 0.2675 31,545 
rs2608604 16:88849421 -0.0529 0.0061 2.99E-18 0.4051 28,516 
rs4890634 18:43854259 0.0138 0.0062 2.59E-02 0.2619 28,356 
rs71176524 19:2177925 0.0095 0.0059 1.06E-01 0.9195 30,717 
rs919797 19:4498157 -0.0275 0.006 4.36E-06 0.3908 30,513 
rs1799918 19:13002400 -0.0147 0.0061 1.68E-02 0.7336 28,964 
rs958483 19:33759240 0.0177 0.0136 1.93E-01 0.4297 5,666 
rs6014993 20:55991637 0.0018 0.0059 7.67E-01 0.8094 30,090 
rs4820079 22:32879617 0.01 0.0056 7.39E-02 0.8647 33,807 




rs140523 22:50962782 0.0062 0.0069 3.69E-01 0.582 16,735 
rs9924561 16:314780 0.3738 0.0189 7.57E-87 3.43E-08 3,983 
rs186066503 16:405483 0.7504 0.0866 4.41E-18 0.4525 360 
rs530159671 16:250184 0.4093 0.0597 7.19E-12 0.1162 349 
rs8058016 16:228786 0.2783 0.0646 1.67E-05 0.2908 364 
rs60616598 16:297264 0.1076 0.0161 2.22E-11 0.001721 6,814 
rs145752042 16:267208 -0.3695 0.0961 1.21E-04 0.1249 209 
rs145546625 16:220583 0.0319 0.0233 1.70E-01 0.4442 3,431 
rs115415087 16:205132 -0.1834 0.0477 1.22E-04 0.04448 720 
rs61743947 16:240000 0.7279 0.1078 1.44E-11 1 113 
rs60125383 16:176446 0.0306 0.0064 2.09E-06 0.08923 28,977 
rs55932218 16:221151 -0.104 0.027 1.15E-04 0.5502 2,251 
rs8051004 16:198835 -0.0872 0.0158 3.17E-08 0.8564 7,286 
rs1800562 6:26093141 -0.1196 0.0144 1.23E-16 0.5233 6,614 
rs11964516 6:41860252 0.011 0.0075 1.44E-01 0.7896 18,601 
rs12664956 6:135384188 0.0063 0.0062 3.04E-01 0.9766 29,153 
rs607203 6:139841653 0.0195 0.0104 6.24E-02 0.01405 13,280 








Table 20. MCV univariate results for combined-phenotype lead SNPs in combined multi-
ethnic study population. 
rsid Chr:Pos Beta SE p-value Het p-value effN 
rs61523591 2:46372781 0.0474 0.052 3.63E-01 0.2967 11,012 
rs2361016 3:24341268 0.2602 0.0438 2.74E-09 0.8001 15,504 
rs73210009 3:195830276 -0.2453 0.0403 1.13E-09 0.3526 18,079 
rs218265 4:55408999 0.5089 0.0474 7.47E-27 0.7617 13,557 
rs4535497 5:1107428 -0.2471 0.04 6.82E-10 0.03222 18,357 
rs3749748 5:127350549 -0.0253 0.0485 6.02E-01 0.2001 13,403 
rs2032451 6:26092170 -0.6189 0.0571 2.28E-27 0.1273 9,410 
rs1800562 6:26093141 -0.9309 0.0955 1.95E-22 0.5983 3,928 
rs11964516 6:41860252 0.4471 0.0502 5.20E-19 0.4012 11,336 
rs13203155 6:109614844 -0.2713 0.0386 2.18E-12 0.5726 19,783 
rs35786788 6:135419042 -0.7814 0.048 1.13E-59 0.06354 13,745 
rs590856 6:139844429 0.3791 0.0379 1.43E-23 0.2855 20,347 
rs12718598 7:50428445 0.3065 0.0382 9.72E-16 0.07093 19,520 
rs28832309 7:80319938 0.0319 0.1565 8.39E-01 0.6698 2,569 
rs7385804 7:100235970 -0.2714 0.0403 1.69E-11 0.04316 17,050 
rs10253736 7:151415256 0.0402 0.0457 3.79E-01 0.6778 13,689 
rs7853365 9:4855858 -0.3747 0.0479 5.32E-15 0.758 12,588 
rs2519093 9:136141870 -0.01 0.0512 8.46E-01 0.7421 11,320 
rs34793991 10:46080590 0.5708 0.0866 4.26E-11 0.7771 4,063 
rs17476364 10:71094504 0.3633 0.0752 1.35E-06 0.6988 5,220 
rs33930165 11:5248233 6.0733 0.4307 3.75E-45 5.54E-07 339 
rs28456 11:61589481 -0.1092 0.0426 1.04E-02 0.6303 17,018 
rs12320749 12:4331647 0.2248 0.0454 7.21E-07 0.4018 13,520 
rs597808 12:111973358 -0.0874 0.0422 3.86E-02 0.1134 18,985 
rs8013143 14:23494277 -0.0742 0.043 8.46E-02 0.1555 17,839 
rs11621325 14:65472241 0.207 0.0384 6.98E-08 0.4844 19,173 
rs4887023 15:78535437 0.0541 0.0388 1.64E-01 0.872 19,089 
rs2608604 16:88849421 0.1512 0.0405 1.88E-04 0.5188 17,645 
rs4890634 18:43854259 0.2101 0.0414 3.99E-07 0.08241 17,151 
rs71176524 19:2177925 0.0039 0.0393 9.21E-01 0.06443 18,980 
rs919797 19:4498157 -0.2325 0.0401 6.45E-09 0.5538 18,130 
rs1799918 19:13002400 -0.2862 0.0408 2.28E-12 0.3417 17,649 
rs958483 19:33759240 0.3301 0.0868 1.42E-04 0.6988 3,628 
rs6014993 20:55991637 0.311 0.0394 2.82E-15 0.9769 18,419 




rs855791 22:37462936 0.5954 0.0395 3.06E-51 0.7942 18,793 
rs140523 22:50962782 0.2524 0.0423 2.34E-09 0.05907 10,889 
rs9924561 16:314780 3.7073 0.146 2.87E-142 3.65E-07 2,925 
rs186066503 16:405483 4.5701 0.5091 2.79E-19 0.06771 209 
rs530159671 16:250184 3.0586 0.372 1.99E-16 0.0004187 265 
rs8058016 16:228786 4.3502 0.4605 3.50E-21 0.07391 240 
rs60616598 16:297264 0.9611 0.1167 1.82E-16 0.3492 4,884 
rs145752042 16:267208 -5.9748 0.6665 3.13E-19 0.4115 183 
rs145546625 16:220583 1.0984 0.1416 8.84E-15 0.2418 2,955 
rs115415087 16:205132 -2.641 0.3485 3.49E-14 0.2764 518 
rs61743947 16:240000 5.6057 0.8212 8.72E-12 1 59 
rs60125383 16:176446 0.2222 0.0406 4.55E-08 0.005679 19,370 
rs55932218 16:221151 -1.0939 0.1948 1.97E-08 0.07124 1,552 
rs8051004 16:198835 -0.569 0.1061 8.10E-08 0.7759 4,316 
rs1800562 6:26093141 -0.9309 0.0955 1.95E-22 0.5983 38,729 
rs11964516 6:41860252 0.4471 0.0502 5.20E-19 0.4012 41,253 
rs12664956 6:135384188 0.1304 0.041 1.45E-03 0.002992413 17,689 
rs607203 6:139841653 -0.7377 0.0743 3.09E-23 0.3559 7,613 









Table 21. RBCC univariate results for combined-phenotype lead SNPs in combined multi-
ethnic study population. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0225 0.0039 1.20E-08 0.6916 11,117 
rs2361016 3:24341268 -0.0134 0.0034 7.18E-05 0.01339 15,292 
rs73210009 3:195830276 0.0042 0.0031 1.74E-01 0.2226 17,849 
rs218265 4:55408999 -0.0382 0.0035 5.06E-27 0.4253 13,997 
rs4535497 5:1107428 0.0127 0.0031 3.36E-05 0.7516 18,299 
rs3749748 5:127350549 -0.0037 0.0038 3.28E-01 0.03913 13,041 
rs2032451 6:26092170 0.0111 0.0045 1.27E-02 0.3875 9,161 
rs1800562 6:26093141 0.0032 0.0077 6.73E-01 0.7533 3,759 
rs11964516 6:41860252 -0.0188 0.0038 9.86E-07 0.4553 11,272 
rs13203155 6:109614844 0.0223 0.003 6.56E-14 0.5968 19,652 
rs35786788 6:135419042 0.0611 0.0037 3.34E-60 0.9665 13,223 
rs590856 6:139844429 -0.0163 0.0029 2.16E-08 0.7455 20,378 
rs12718598 7:50428445 -0.02 0.0029 7.89E-12 0.3873 19,516 
rs28832309 7:80319938 -0.0021 0.0113 8.51E-01 0.01732 2,615 
rs7385804 7:100235970 0.025 0.0031 7.09E-16 0.05119 16,941 
rs10253736 7:151415256 0.0177 0.0036 6.34E-07 0.1959 13,344 
rs7853365 9:4855858 0.0175 0.0037 2.12E-06 0.8254 12,470 
rs2519093 9:136141870 0.0209 0.0039 1.12E-07 0.3303 11,028 
rs34793991 10:46080590 -0.0384 0.0068 1.51E-08 0.5006 3,907 
rs17476364 10:71094504 0.0232 0.0059 8.56E-05 0.6616 5,024 
rs33930165 11:5248233 -0.2182 0.0314 3.94E-12 0.08639 340 
rs28456 11:61589481 0.0192 0.0033 3.92E-09 0.1064 17,197 
rs12320749 12:4331647 -0.0219 0.0035 2.36E-10 0.7261 13,591 
rs597808 12:111973358 -0.0123 0.0033 1.98E-04 0.5381 18,639 
rs8013143 14:23494277 0.0016 0.0033 6.32E-01 0.785 18,108 
rs11621325 14:65472241 -0.0101 0.003 6.52E-04 0.7282 19,160 
rs4887023 15:78535437 -0.009 0.003 2.57E-03 0.4397 19,068 
rs2608604 16:88849421 -0.0142 0.0031 4.49E-06 0.5997 17,701 
rs4890634 18:43854259 -0.006 0.0032 5.62E-02 0.4185 17,405 
rs71176524 19:2177925 -0.0158 0.003 1.48E-07 0.8274 18,978 
rs919797 19:4498157 0.0024 0.0031 4.44E-01 0.99 18,138 
rs1799918 19:13002400 0.022 0.0031 1.59E-12 0.8491 17,583 
rs958483 19:33759240 -0.044 0.0066 2.45E-11 0.7654 3,600 
rs6014993 20:55991637 -0.0108 0.003 3.69E-04 0.5721 18,273 




rs855791 22:37462936 -0.0067 0.0031 2.87E-02 0.8674 18,718 
rs140523 22:50962782 -0.0085 0.0032 8.22E-03 0.1238 10,847 
rs9924561 16:314780 -0.1645 0.0107 3.46E-53 0.04545 2,967 
rs186066503 16:405483 -0.2684 0.034 2.77E-15 0.4032 201 
rs530159671 16:250184 -0.1424 0.0275 2.26E-07 0.003154 280 
rs8058016 16:228786 -0.1294 0.0334 1.05E-04 0.07766 233 
rs60616598 16:297264 -0.0503 0.0088 9.70E-09 0.3888 4,029 
rs145752042 16:267208 0.1861 0.0515 2.99E-04 0.8732 175 
rs145546625 16:220583 -0.0446 0.0103 1.39E-05 0.932 2,981 
rs115415087 16:205132 0.1524 0.0242 3.21E-10 0.1171 482 
rs61743947 16:240000 -0.0911 0.0597 1.27E-01 1 59 
rs60125383 16:176446 -0.0122 0.0032 1.31E-04 0.3929 19,381 
rs55932218 16:221151 0.044 0.0143 2.09E-03 0.2602 1,498 
rs8051004 16:198835 0.0153 0.008 5.71E-02 0.8478 4,395 
rs1800562 6:26093141 0.0032 0.0077 6.73E-01 0.7533 3,759 
rs11964516 6:41860252 -0.0188 0.0038 9.86E-07 0.4553 11,271 
rs12664956 6:135384188 -0.0121 0.0032 1.32E-04 0.2538 17,397 
rs607203 6:139841653 0.0276 0.0055 5.54E-07 0.5485 7,993 









Table 22. RDW univariate results for combined-phenotype lead SNPs in combined multi-
ethnic study population. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.0022 0.0105 8.34E-01 0.3971 8,967 
rs2361016 3:24341268 -0.0241 0.009 7.60E-03 0.9458 12,248 
rs73210009 3:195830276 0.0417 0.0081 2.96E-07 0.08424 15,032 
rs218265 4:55408999 -0.0152 0.0092 9.99E-02 0.6041 11,851 
rs4535497 5:1107428 0.0631 0.0079 1.53E-15 0.2214 15,915 
rs3749748 5:127350549 0.1218 0.0101 1.80E-33 0.03663 10,187 
rs2032451 6:26092170 0.1245 0.012 3.40E-25 0.4457 6,998 
rs1800562 6:26093141 0.1666 0.0215 1.04E-14 0.5427 2,824 
rs11964516 6:41860252 -0.0402 0.0102 7.72E-05 0.5712 9,260 
rs13203155 6:109614844 0.0358 0.008 7.52E-06 0.933 15,760 
rs35786788 6:135419042 0.0827 0.01 1.57E-16 0.04951 10,450 
rs590856 6:139844429 -0.0021 0.0077 7.90E-01 0.07623 16,523 
rs12718598 7:50428445 -0.0077 0.0077 3.17E-01 0.4873 16,203 
rs28832309 7:80319938 -0.2072 0.0305 1.12E-11 0.1689 1,825 
rs7385804 7:100235970 0.0305 0.0082 1.86E-04 0.8961 14,135 
rs10253736 7:151415256 0.0035 0.0094 7.12E-01 0.1159 11,222 
rs7853365 9:4855858 0.0291 0.0098 3.14E-03 0.1242 9,994 
rs2519093 9:136141870 -0.0178 0.0104 8.55E-02 0.459 9,234 
rs34793991 10:46080590 0.0094 0.0183 6.06E-01 0.9347 3,107 
rs17476364 10:71094504 0.0061 0.0155 6.95E-01 0.4403 4,074 
rs33930165 11:5248233 -0.5348 0.095 1.79E-08 1 140 
rs28456 11:61589481 -0.0288 0.0085 6.98E-04 0.9971 14,730 
rs12320749 12:4331647 -0.006 0.0091 5.09E-01 0.1015 11,390 
rs597808 12:111973358 0.0013 0.0087 8.78E-01 0.9252 15,008 
rs8013143 14:23494277 0.0923 0.0086 1.17E-26 0.9374 15,251 
rs11621325 14:65472241 -0.0157 0.0079 4.61E-02 0.9749 15,630 
rs4887023 15:78535437 -0.0573 0.0079 5.45E-13 0.4464 15,406 
rs2608604 16:88849421 0.0265 0.0079 8.08E-04 0.1786 15,227 
rs4890634 18:43854259 -0.0625 0.0084 7.90E-14 0.1874 14,176 
rs71176524 19:2177925 -0.0144 0.0077 6.28E-02 0.2381 16,062 
rs919797 19:4498157 -0.0012 0.0079 8.78E-01 0.971 15,605 
rs1799918 19:13002400 0.0158 0.0081 5.06E-02 0.141 15,011 
rs958483 19:33759240 -0.0116 0.0167 4.87E-01 0.5987 3,164 
rs6014993 20:55991637 -0.0101 0.008 2.07E-01 0.7561 15,074 
rs4820079 22:32879617 -0.0213 0.0076 5.10E-03 0.9492 16,680 




rs140523 22:50962782 -0.0417 0.0084 6.21E-07 0.3139 9,648 
rs9924561 16:314780 -0.2675 0.0293 7.79E-20 0.0001387 1,875 
rs186066503 16:405483 -0.427 0.092 3.50E-06 0.5336 203 
rs530159671 16:250184 -0.2442 0.0662 2.23E-04 0.01148 261 
rs8058016 16:228786 -0.2406 0.0907 8.03E-03 1 161 
rs60616598 16:297264 -0.1366 0.0229 2.30E-09 0.4977 3,466 
rs145752042 16:267208 0.3255 0.1609 4.31E-02 1 50 
rs145546625 16:220583 -0.0696 0.0253 5.95E-03 0.1456 2,158 
rs115415087 16:205132 0.0922 0.0672 1.70E-01 0.9596 345 
rs61743947 16:240000 -0.7066 0.1497 2.34E-06 1 55 
rs60125383 16:176446 0.001 0.0086 9.06E-01 0.8255 15,682 
rs55932218 16:221151 0.1604 0.0386 3.23E-05 0.3911 1,162 
rs8051004 16:198835 0.0452 0.0214 3.50E-02 0.6202 3,255 
rs1800562 6:26093141 0.1666 0.0215 1.04E-14 0.5427 2,824 
rs11964516 6:41860252 -0.0402 0.0102 7.72E-05 0.5712 9,260 
rs12664956 6:135384188 -0.0297 0.0085 4.80E-04 0.2719 13,874 
rs607203 6:139841653 0.0259 0.0148 7.97E-02 0.002358 6,048 









Table 23. HCT univariate results for combined-phenotype lead SNPs in African Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.1999 0.0445 6.89E-06 7.69E-01 5264 
rs73210009 3:195830276 -0.0621 0.0453 1.70E-01 9.27E-01 5194 
rs2361016 3:24341268 0.0033 0.0467 9.44E-01 5.24E-02 4796 
rs218265 4:55408999 -0.0742 0.043 8.48E-02 2.74E-01 5558 
rs4535497 5:1107428 -0.013 0.0387 7.37E-01 7.90E-01 6689 
rs3749748 5:127350549 -0.087 0.0811 2.84E-01 1.80E-02 1705 
rs2032451 6:26092170 -0.3344 0.099 7.28E-04 7.27E-01 1112 
rs1800562 6:26093141 -0.6347 0.165 1.20E-04 2.88E-02 419 
rs11964516 6:41860252 -0.0688 0.0512 1.79E-01 1.94E-01 4023 
rs13203155 6:109614844 -0.0482 0.037 1.93E-01 8.70E-01 7646 
rs35786788 6:135419042 0.1909 0.0695 6.03E-03 8.58E-01 2194 
rs590856 6:139844429 0.0878 0.038 2.10E-02 5.78E-01 7376 
rs7385804 7:100235970 0.1122 0.0402 5.29E-03 1.85E-02 6546 
rs10253736 7:151415256 0.0612 0.054 2.57E-01 7.73E-01 3542 
rs12718598 7:50428445 -0.0544 0.0372 1.44E-01 3.97E-01 7672 
rs28832309 7:80319938 0.0352 0.0686 6.08E-01 3.85E-01 2274 
rs2519093 9:136141870 0.2275 0.0578 8.32E-05 7.61E-01 3085 
rs7853365 9:4855858 3.00E-04 0.052 9.96E-01 4.19E-01 3856 
rs34793991 10:46080590 0.1782 0.1223 1.45E-01 7.45E-01 695 
rs17476364 10:71094504 0.3177 0.1431 2.64E-02 3.69E-01 522 
rs33930165 11:5248233 0.5522 0.2055 7.21E-03 4.98E-01 262 
rs28456 11:61589481 0.0632 0.051 2.15E-01 9.77E-01 4189 
rs12320749 12:4331647 -0.0397 0.0437 3.64E-01 1.44E-01 5657 
rs597808 12:111973358 -0.0554 0.0653 3.96E-01 8.65E-01 2722 
rs8013143 14:23494277 -0.025 0.0442 5.71E-01 9.55E-01 5710 
rs11621325 14:65472241 0.011 0.0381 7.73E-01 7.81E-01 7211 
rs4887023 15:78535437 -0.0148 0.0369 6.88E-01 4.81E-01 7651 
rs60125383 16:176446 0.0403 0.0394 3.06E-01 4.37E-01 7525 
rs8051004 16:198835 0.0338 0.0686 6.23E-01 4.15E-01 2717 
rs115415087 16:205132 -0.0087 0.1485 9.54E-01 9.49E-01 514 
rs145546625 16:220583 -0.353 0.2699 1.91E-01 1.00E+00 145 
rs55932218 16:221151 -0.0088 0.0896 9.22E-01 5.25E-02 1578 
rs8058016 16:228786 0.5558 0.2031 6.20E-03 1.81E-01 272 
rs61743947 16:240000 0.2996 0.381 4.32E-01 1.00E+00 65 
rs145752042 16:267208 -1.0134 0.3114 1.14E-03 4.63E-02 115 




rs9924561 16:314780 0.1548 0.0623 1.30E-02 2.47E-01 2674 
rs2608604 16:88849421 -0.05 0.0391 2.02E-01 8.73E-01 6783 
rs4890634 18:43854259 0.1136 0.0371 2.19E-03 3.14E-01 7614 
rs71176524 19:2177925 -0.0619 0.037 9.48E-02 9.06E-02 7615 
rs919797 19:4498157 0.05 0.0414 2.26E-01 9.30E-01 6162 
rs1799918 19:13002400 0.0735 0.0445 9.85E-02 8.21E-01 5409 
rs958483 19:33759240 0.1051 0.1657 5.26E-01 2.46E-01 380 
rs6014993 20:55991637 -0.0698 0.0414 9.16E-02 9.16E-01 6082 
rs4820079 22:32879617 0.0482 0.0364 1.85E-01 9.36E-01 7933 
rs855791 22:37462936 0.1654 0.05 9.28E-04 2.90E-01 4297 









Table 24. HGB univariate results for combined-phenotype lead SNPs in African 
Americans. 
rsid Chr:Pos Beta SE p-value Het p-value effN 
rs61523591 2:46372781 -0.0626 0.0149 2.53E-05 4.88E-01 5265 
rs73210009 3:195830276 -0.0376 0.0151 1.29E-02 8.13E-01 5193 
rs2361016 3:24341268 0.0014 0.0156 9.26E-01 9.90E-02 4799 
rs218265 4:55408999 -0.0145 0.0144 3.14E-01 5.84E-01 5557 
rs4535497 5:1107428 -0.0051 0.0129 6.93E-01 2.79E-01 6689 
rs3749748 5:127350549 -0.0202 0.0271 4.55E-01 6.94E-02 1708 
rs2032451 6:26092170 -0.139 0.033 2.52E-05 7.40E-01 1118 
rs1800562 6:26093141 -0.2436 0.055 9.49E-06 1.31E-02 424 
rs11964516 6:41860252 0.0014 0.0171 9.34E-01 2.90E-01 4021 
rs13203155 6:109614844 -0.0225 0.0124 6.92E-02 9.30E-01 7648 
rs35786788 6:135419042 0.0371 0.0232 1.10E-01 8.13E-01 2199 
rs590856 6:139844429 0.0257 0.0127 4.35E-02 8.48E-01 7380 
rs7385804 7:100235970 0.0312 0.0135 2.03E-02 6.93E-03 6554 
rs10253736 7:151415256 0.0172 0.018 3.39E-01 7.18E-01 3545 
rs12718598 7:50428445 -0.0167 0.0125 1.81E-01 3.00E-01 7671 
rs28832309 7:80319938 0.0388 0.023 9.11E-02 5.44E-01 2270 
rs2519093 9:136141870 0.0724 0.0193 1.78E-04 3.85E-01 3087 
rs7853365 9:4855858 -0.0088 0.0174 6.11E-01 4.08E-01 3857 
rs34793991 10:46080590 0.0874 0.0408 3.21E-02 3.15E-01 695 
rs17476364 10:71094504 0.0918 0.0478 5.48E-02 4.75E-01 522 
rs33930165 11:5248233 -0.0594 0.0689 3.88E-01 3.34E-01 260 
rs28456 11:61589481 0.0247 0.017 1.47E-01 9.78E-01 4197 
rs12320749 12:4331647 -0.0022 0.0146 8.80E-01 1.83E-01 5662 
rs597808 12:111973358 -0.0379 0.0217 8.12E-02 9.18E-01 2732 
rs8013143 14:23494277 -0.0205 0.0148 1.64E-01 9.57E-01 5718 
rs11621325 14:65472241 -0.0027 0.0127 8.30E-01 9.03E-01 7212 
rs4887023 15:78535437 0.0027 0.0123 8.29E-01 7.80E-01 7650 
rs60125383 16:176446 0.0274 0.0131 3.70E-02 8.46E-02 7528 
rs8051004 16:198835 -0.018 0.0229 4.32E-01 4.42E-01 2715 
rs115415087 16:205132 -0.0613 0.0494 2.14E-01 8.83E-01 514 
rs145546625 16:220583 -0.1382 0.0885 1.18E-01 1.00E+00 146 
rs55932218 16:221151 -0.0431 0.0298 1.48E-01 9.78E-02 1578 
rs8058016 16:228786 0.2657 0.0683 1.00E-04 4.06E-01 267 
rs61743947 16:240000 0.4404 0.1236 3.69E-04 1.00E+00 65 
rs145752042 16:267208 -0.4828 0.1032 2.91E-06 2.78E-01 115 




rs9924561 16:314780 0.1814 0.0208 2.60E-18 5.80E-04 2667 
rs2608604 16:88849421 -0.0224 0.0131 8.73E-02 6.75E-01 6788 
rs4890634 18:43854259 0.0322 0.0124 9.42E-03 3.21E-01 7615 
rs71176524 19:2177925 -0.0203 0.0124 1.02E-01 4.82E-02 7615 
rs919797 19:4498157 0.0095 0.0138 4.91E-01 7.64E-01 6159 
rs1799918 19:13002400 0.0213 0.0149 1.52E-01 8.45E-01 5413 
rs958483 19:33759240 0.0276 0.0552 6.17E-01 6.00E-01 380 
rs6014993 20:55991637 -0.0161 0.0138 2.44E-01 9.56E-01 6083 
rs4820079 22:32879617 0.0182 0.0122 1.35E-01 7.92E-01 7934 
rs855791 22:37462936 0.0755 0.0167 6.00E-06 3.44E-01 4300 









Table 25. MCH univariate results for combined-phenotype lead SNPs in African Americans. 
rsid Chr:Pos Beta SE p-value Het p-value effN 
rs61523591 2:46372781 0.0566 0.0464 2.23E-01 3.78E-01 2888 
rs73210009 3:195830276 -0.1646 0.0481 6.25E-04 3.03E-01 2767 
rs2361016 3:24341268 0.0572 0.0494 2.47E-01 5.77E-01 2580 
rs218265 4:55408999 0.1789 0.0448 6.57E-05 2.46E-01 3031 
rs4535497 5:1107428 -0.0468 0.0409 2.52E-01 3.01E-01 3611 
rs3749748 5:127350549 0.0378 0.0883 6.69E-01 3.97E-03 869 
rs2032451 6:26092170 -0.1077 0.1086 3.21E-01 6.50E-01 560 
rs1800562 6:26093141 -0.5163 0.1995 9.66E-03 2.94E-01 159 
rs11964516 6:41860252 0.1168 0.0534 2.87E-02 3.29E-02 2207 
rs13203155 6:109614844 -0.0504 0.0392 1.99E-01 4.11E-01 4132 
rs35786788 6:135419042 -0.2935 0.0749 8.95E-05 5.29E-01 1144 
rs590856 6:139844429 0.1514 0.0401 1.58E-04 8.70E-01 3943 
rs7385804 7:100235970 -0.1044 0.0424 1.38E-02 3.30E-01 3462 
rs10253736 7:151415256 0.0079 0.0576 8.91E-01 1.53E-01 1896 
rs12718598 7:50428445 0.0801 0.0387 3.84E-02 5.90E-02 4147 
rs28832309 7:80319938 0.039 0.0702 5.78E-01 5.69E-01 1297 
rs2519093 9:136141870 -0.04 0.0614 5.15E-01 7.60E-01 1639 
rs7853365 9:4855858 -0.1307 0.0549 1.71E-02 8.50E-01 2079 
rs34793991 10:46080590 0.1633 0.1369 2.33E-01 3.03E-02 334 
rs17476364 10:71094504 0.1551 0.1614 3.36E-01 4.48E-01 254 
rs33930165 11:5248233 1.2985 0.2005 9.32E-11 2.59E-01 164 
rs28456 11:61589481 -0.1014 0.0543 6.18E-02 8.06E-01 2113 
rs12320749 12:4331647 0.1023 0.0452 2.38E-02 3.81E-01 3007 
rs597808 12:111973358 -0.1152 0.0712 1.06E-01 4.90E-01 1413 
rs8013143 14:23494277 -0.0835 0.047 7.58E-02 2.35E-01 3051 
rs11621325 14:65472241 0.0679 0.0399 8.89E-02 2.78E-01 3868 
rs4887023 15:78535437 0.0255 0.039 5.14E-01 6.03E-01 4141 
rs60125383 16:176446 0.1999 0.0388 2.55E-07 1.90E-01 4031 
rs8051004 16:198835 -0.1828 0.0676 6.84E-03 9.09E-01 1486 
rs115415087 16:205132 -0.8952 0.1455 7.62E-10 7.45E-02 289 
rs145546625 16:220583 -0.3128 0.3939 4.27E-01 1.00E+00 35 
rs55932218 16:221151 -0.5021 0.0893 1.88E-08 9.42E-02 863 
rs8058016 16:228786 1.8882 0.264 8.50E-13 3.07E-02 95 
rs61743947 16:240000 -- -- -- -- -- 
rs145752042 16:267208 -2.2974 0.4062 1.55E-08 1.00E+00 39 




rs9924561 16:314780 1.4824 0.0624 7.95E-125 3.29E-11 1487 
rs2608604 16:88849421 0.0413 0.0413 3.17E-01 6.49E-01 3630 
rs4890634 18:43854259 0.083 0.0389 3.27E-02 2.43E-02 4141 
rs71176524 19:2177925 0.0774 0.039 4.73E-02 3.64E-01 4110 
rs919797 19:4498157 -0.0589 0.0433 1.74E-01 8.11E-01 3371 
rs1799918 19:13002400 -0.1185 0.047 1.18E-02 6.00E-01 2911 
rs958483 19:33759240 0.2607 0.203 1.99E-01 9.00E-01 169 
rs6014993 20:55991637 0.101 0.044 2.16E-02 3.05E-01 3276 
rs4820079 22:32879617 0.0812 0.0385 3.46E-02 8.76E-01 4270 
rs855791 22:37462936 0.1912 0.0531 3.20E-04 5.96E-01 2266 









Table 26. MCHC univariate results for combined-phenotype lead SNPs in African 
Americans. 
rsid Chr:Pos Beta SE p-value Het p-value effN 
rs61523591 2:46372781 0.0082 0.0145 5.71E-01 3.70E-01 5328 
rs73210009 3:195830276 -0.0359 0.015 1.64E-02 9.74E-01 5151 
rs2361016 3:24341268 0.0101 0.0154 5.11E-01 3.57E-01 4776 
rs218265 4:55408999 0.0366 0.014 8.80E-03 7.02E-01 5614 
rs4535497 5:1107428 0.0073 0.0128 5.69E-01 7.02E-02 6685 
rs3749748 5:127350549 0.0479 0.0271 7.77E-02 3.79E-02 1647 
rs2032451 6:26092170 -0.0664 0.0335 4.72E-02 6.37E-01 1056 
rs1800562 6:26093141 -0.1359 0.056 1.51E-02 5.89E-01 403 
rs11964516 6:41860252 0.0349 0.0168 3.79E-02 3.68E-01 4032 
rs13203155 6:109614844 -0.0156 0.0122 2.01E-01 8.78E-01 7667 
rs35786788 6:135419042 -0.0531 0.0233 2.28E-02 4.26E-01 2109 
rs590856 6:139844429 -0.0056 0.0125 6.52E-01 3.36E-01 7368 
rs7385804 7:100235970 -0.0191 0.0131 1.46E-01 8.50E-01 6484 
rs10253736 7:151415256 -0.0016 0.0178 9.29E-01 8.37E-01 3510 
rs12718598 7:50428445 0.0099 0.0121 4.13E-01 6.39E-01 7700 
rs28832309 7:80319938 0.0419 0.0222 5.93E-02 1.74E-02 2334 
rs2519093 9:136141870 -0.0041 0.019 8.29E-01 5.88E-01 3073 
rs7853365 9:4855858 -0.0266 0.0171 1.21E-01 3.87E-01 3835 
rs34793991 10:46080590 0.0725 0.0411 7.81E-02 5.73E-01 694 
rs17476364 10:71094504 -0.0362 0.0488 4.58E-01 9.29E-01 502 
rs33930165 11:5248233 -0.7731 0.0663 1.98E-31 3.78E-10 269 
rs28456 11:61589481 0.0116 0.0169 4.94E-01 8.24E-01 4070 
rs12320749 12:4331647 0.0262 0.0142 6.47E-02 8.51E-01 5628 
rs597808 12:111973358 -0.0417 0.0222 5.99E-02 7.42E-01 2590 
rs8013143 14:23494277 -0.0195 0.0146 1.84E-01 4.34E-01 5632 
rs11621325 14:65472241 0.0029 0.0125 8.13E-01 5.09E-01 7227 
rs4887023 15:78535437 0.0073 0.0121 5.45E-01 3.94E-01 7692 
rs60125383 16:176446 0.0402 0.0128 1.66E-03 2.79E-02 7523 
rs8051004 16:198835 -0.0723 0.0218 9.13E-04 4.32E-01 2774 
rs115415087 16:205132 -0.158 0.0491 1.29E-03 1.32E-01 544 
rs145546625 16:220583 -0.1102 0.1047 2.92E-01 1.00E+00 145 
rs55932218 16:221151 -0.1049 0.0282 1.95E-04 3.56E-01 1687 
rs8058016 16:228786 0.2459 0.0778 1.57E-03 5.11E-01 291 
rs61743947 16:240000 0.8707 0.1429 1.10E-09 1.00E+00 65 
rs145752042 16:267208 -0.3627 0.1127 1.28E-03 1.13E-01 116 




rs9924561 16:314780 0.3569 0.0199 1.19E-71 4.76E-07 2731 
rs2608604 16:88849421 -0.0222 0.0128 8.40E-02 9.70E-01 6763 
rs4890634 18:43854259 -0.0059 0.0122 6.26E-01 5.04E-01 7653 
rs71176524 19:2177925 0.0108 0.0122 3.73E-01 6.07E-01 7637 
rs919797 19:4498157 -0.0127 0.0134 3.45E-01 3.18E-01 6225 
rs1799918 19:13002400 -0.0237 0.0146 1.04E-01 4.29E-01 5409 
rs958483 19:33759240 0.0191 0.0575 7.39E-01 7.17E-01 366 
rs6014993 20:55991637 -4.0E-04 0.0136 9.79E-01 9.21E-01 6088 
rs4820079 22:32879617 0.0091 0.012 4.46E-01 3.54E-01 7951 
rs855791 22:37462936 0.0494 0.0166 2.85E-03 7.30E-01 4227 










Table 27. MCV univariate results for combined-phenotype lead SNPs in African 
Americans. 
rsid Chr:Pos Beta SE p-value Het p-value effN 
rs61523591 2:46372781 0.1542 0.1224 2.08E-01 6.40E-01 2890 
rs73210009 3:195830276 -0.403 0.1269 1.50E-03 2.66E-01 2750 
rs2361016 3:24341268 0.1562 0.1299 2.29E-01 5.05E-01 2570 
rs218265 4:55408999 0.4793 0.1178 4.70E-05 3.29E-01 3035 
rs4535497 5:1107428 -0.1628 0.1077 1.31E-01 4.56E-01 3599 
rs3749748 5:127350549 0.1053 0.2349 6.54E-01 5.40E-03 852 
rs2032451 6:26092170 -0.2839 0.2891 3.26E-01 2.69E-01 548 
rs1800562 6:26093141 -1.0343 0.5235 4.82E-02 3.58E-01 159 
rs11964516 6:41860252 0.2896 0.1406 3.94E-02 5.27E-02 2207 
rs13203155 6:109614844 -0.1597 0.1033 1.22E-01 4.98E-01 4124 
rs35786788 6:135419042 -0.8157 0.199 4.15E-05 5.81E-01 1126 
rs590856 6:139844429 0.462 0.1056 1.22E-05 7.72E-01 3930 
rs7385804 7:100235970 -0.2341 0.1117 3.62E-02 2.97E-01 3438 
rs10253736 7:151415256 0.0513 0.1523 7.36E-01 1.37E-01 1882 
rs12718598 7:50428445 0.2487 0.1019 1.46E-02 1.44E-01 4140 
rs28832309 7:80319938 0.0983 0.1838 5.93E-01 6.65E-01 1307 
rs2519093 9:136141870 -0.0763 0.1625 6.39E-01 8.57E-01 1628 
rs7853365 9:4855858 -0.3284 0.1449 2.34E-02 7.74E-01 2070 
rs34793991 10:46080590 0.5288 0.361 1.43E-01 2.08E-02 328 
rs17476364 10:71094504 0.7095 0.4279 9.73E-02 1.78E-01 245 
rs33930165 11:5248233 5.4646 0.521 9.64E-26 1.36E-08 166 
rs28456 11:61589481 -0.2596 0.144 7.13E-02 9.51E-01 2093 
rs12320749 12:4331647 0.3063 0.1185 9.75E-03 3.07E-01 2996 
rs597808 12:111973358 -0.3308 0.19 8.16E-02 4.17E-01 1372 
rs8013143 14:23494277 -0.1989 0.1244 1.10E-01 5.82E-02 3020 
rs11621325 14:65472241 0.1495 0.1051 1.55E-01 1.66E-01 3862 
rs4887023 15:78535437 0.078 0.1024 4.46E-01 6.23E-01 4133 
rs60125383 16:176446 0.5133 0.1023 5.19E-07 2.37E-01 4020 
rs8051004 16:198835 -0.3683 0.1776 3.81E-02 7.18E-01 1498 
rs115415087 16:205132 -2.6558 0.3868 6.61E-12 2.49E-01 289 
rs145546625 16:220583 -0.7876 1.1431 4.91E-01 1.00E+00 35 
rs55932218 16:221151 -1.2094 0.2346 2.54E-07 1.21E-01 872 
rs8058016 16:228786 4.5317 0.6691 1.26E-11 4.19E-02 94 
rs61743947 16:240000 -- -- -- -- -- 




rs60616598 16:297264 0.9493 0.1413 1.84E-11 5.32E-01 2409 
rs9924561 16:314780 3.6686 0.1643 1.80E-110 1.27E-07 1493 
rs2608604 16:88849421 0.2453 0.1088 2.42E-02 5.90E-01 3620 
rs4890634 18:43854259 0.1892 0.1025 6.48E-02 8.32E-02 4135 
rs71176524 19:2177925 0.1844 0.1027 7.26E-02 3.11E-01 4102 
rs919797 19:4498157 -0.1647 0.1145 1.50E-01 8.15E-01 3365 
rs1799918 19:13002400 -0.2717 0.1237 2.81E-02 3.95E-01 2902 
rs958483 19:33759240 0.9266 0.5418 8.72E-02 9.45E-01 164 
rs6014993 20:55991637 0.3728 0.116 1.31E-03 1.79E-01 3267 
rs4820079 22:32879617 0.201 0.1015 4.76E-02 8.48E-01 4261 
rs855791 22:37462936 0.427 0.1406 2.39E-03 7.96E-01 2246 








Table 28. RBCC univariate results for combined-phenotype lead SNPs in African 
Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0305 0.0088 5.41E-04 6.56E-01 2887 
rs73210009 3:195830276 0.0131 0.0091 1.53E-01 4.09E-01 2751 
rs2361016 3:24341268 -0.0148 0.0094 1.18E-01 9.73E-02 2567 
rs218265 4:55408999 -0.0282 0.0085 9.15E-04 1.46E-01 3034 
rs4535497 5:1107428 0.0072 0.0078 3.53E-01 9.49E-01 3603 
rs3749748 5:127350549 -0.003 0.0169 8.57E-01 3.81E-02 854 
rs2032451 6:26092170 -0.0325 0.0208 1.17E-01 5.41E-01 546 
rs1800562 6:26093141 -0.0697 0.0383 6.90E-02 1.28E-01 160 
rs11964516 6:41860252 -0.0109 0.0101 2.81E-01 3.86E-01 2212 
rs13203155 6:109614844 0.0189 0.0074 1.11E-02 5.11E-01 4124 
rs35786788 6:135419042 0.0578 0.0143 5.47E-05 9.98E-01 1129 
rs590856 6:139844429 -0.0133 0.0076 8.07E-02 5.53E-01 3931 
rs7385804 7:100235970 0.0183 0.0081 2.33E-02 2.55E-01 3434 
rs10253736 7:151415256 0.0154 0.011 1.60E-01 4.85E-01 1878 
rs12718598 7:50428445 -0.0154 0.0073 3.60E-02 2.54E-01 4140 
rs28832309 7:80319938 -0.006 0.0132 6.52E-01 2.31E-01 1311 
rs2519093 9:136141870 0.0343 0.0117 3.49E-03 6.73E-01 1627 
rs7853365 9:4855858 0.0113 0.0104 2.79E-01 1.85E-01 2074 
rs34793991 10:46080590 0.0051 0.0262 8.47E-01 8.38E-02 328 
rs17476364 10:71094504 0.0147 0.0311 6.37E-01 6.26E-01 246 
rs33930165 11:5248233 -0.1743 0.0384 5.79E-06 2.39E-01 168 
rs28456 11:61589481 0.0217 0.0104 3.65E-02 9.80E-01 2102 
rs12320749 12:4331647 -0.018 0.0085 3.47E-02 1.47E-01 2995 
rs597808 12:111973358 0.004 0.0137 7.70E-01 4.74E-01 1365 
rs8013143 14:23494277 0.0036 0.009 6.88E-01 9.42E-01 3023 
rs11621325 14:65472241 4.0E-04 0.0076 9.57E-01 9.17E-01 3864 
rs4887023 15:78535437 -0.0046 0.0074 5.35E-01 6.92E-01 4135 
rs60125383 16:176446 -0.0183 0.0078 1.96E-02 2.31E-01 4023 
rs8051004 16:198835 0.0037 0.0135 7.86E-01 7.66E-01 1495 
rs115415087 16:205132 0.1389 0.0296 2.74E-06 2.48E-01 288 
rs145546625 16:220583 -0.0964 0.081 2.34E-01 1.00E+00 35 
rs55932218 16:221151 0.0499 0.018 5.51E-03 3.20E-02 867 
rs8058016 16:228786 -0.1065 0.0513 3.78E-02 4.43E-03 94 
rs61743947 16:240000 -- -- -- -- -- 
rs145752042 16:267208 0.1766 0.0788 2.51E-02 1.00E+00 39 




rs9924561 16:314780 -0.1622 0.0121 6.98E-41 4.42E-02 1490 
rs2608604 16:88849421 -0.0093 0.0079 2.35E-01 3.66E-01 3615 
rs4890634 18:43854259 0.0014 0.0074 8.50E-01 5.23E-01 4134 
rs71176524 19:2177925 -0.0181 0.0074 1.44E-02 7.69E-01 4103 
rs919797 19:4498157 0.01 0.0082 2.27E-01 9.73E-01 3381 
rs1799918 19:13002400 0.0314 0.0089 4.27E-04 9.52E-01 2905 
rs958483 19:33759240 -0.0345 0.0396 3.84E-01 3.33E-01 163 
rs6014993 20:55991637 -0.0228 0.0083 6.21E-03 1.90E-01 3277 
rs4820079 22:32879617 -0.0133 0.0073 6.84E-02 8.46E-01 4263 
rs855791 22:37462936 -0.0163 0.0102 1.09E-01 3.04E-01 2248 










Table 29. RDW univariate results for combined-phenotype lead SNPs in African Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0107 0.0257 6.78E-01 2.01E-01 2039 
rs73210009 3:195830276 0.0175 0.0267 5.12E-01 1.58E-01 1983 
rs2361016 3:24341268 -0.0211 0.0273 4.39E-01 7.00E-01 1818 
rs218265 4:55408999 -0.0086 0.0246 7.27E-01 2.64E-01 2143 
rs4535497 5:1107428 0.0042 0.0225 8.52E-01 4.33E-01 2710 
rs3749748 5:127350549 0.1124 0.0481 1.93E-02 4.53E-02 641 
rs2032451 6:26092170 0.0167 0.0585 7.75E-01 5.89E-01 416 
rs1800562 6:26093141 0.3059 0.1278 1.66E-02 6.14E-01 94 
rs11964516 6:41860252 -0.0731 0.0296 1.36E-02 2.08E-01 1540 
rs13203155 6:109614844 0.011 0.0217 6.13E-01 9.15E-01 2908 
rs35786788 6:135419042 0.1422 0.0408 4.88E-04 9.50E-01 827 
rs590856 6:139844429 -0.0267 0.0223 2.31E-01 2.05E-01 2798 
rs7385804 7:100235970 0.0206 0.0232 3.76E-01 2.56E-01 2506 
rs10253736 7:151415256 0.0749 0.0317 1.82E-02 4.12E-01 1360 
rs12718598 7:50428445 0.0031 0.0216 8.85E-01 2.22E-01 2917 
rs28832309 7:80319938 -0.1954 0.0391 5.74E-07 1.91E-01 895 
rs2519093 9:136141870 -0.0114 0.0339 7.36E-01 8.45E-01 1158 
rs7853365 9:4855858 -0.0162 0.0304 5.94E-01 2.22E-01 1458 
rs34793991 10:46080590 0.0579 0.0808 4.74E-01 8.20E-01 224 
rs17476364 10:71094504 -0.1145 0.1092 2.94E-01 2.53E-01 148 
rs33930165 11:5248233 -0.4732 0.1397 7.04E-04 4.24E-01 77 
rs28456 11:61589481 -0.0397 0.0305 1.92E-01 2.61E-01 1489 
rs12320749 12:4331647 -0.0124 0.0253 6.26E-01 1.12E-02 2109 
rs597808 12:111973358 0.0602 0.039 1.23E-01 9.75E-01 1042 
rs8013143 14:23494277 0.0911 0.0258 4.19E-04 8.63E-01 2216 
rs11621325 14:65472241 -0.0079 0.022 7.21E-01 9.36E-01 2733 
rs4887023 15:78535437 -0.0577 0.0216 7.55E-03 4.46E-01 2918 
rs60125383 16:176446 -0.0508 0.0219 2.03E-02 4.43E-01 2817 
rs8051004 16:198835 0.0237 0.0373 5.24E-01 3.85E-01 1006 
rs115415087 16:205132 0.0301 0.1029 7.70E-01 6.01E-01 135 
rs145546625 16:220583 0.2264 0.1798 0.208 1 31.7 
rs55932218 16:221151 0.1392 0.0481 3.79E-03 3.01E-01 597 
rs8058016 16:228786 -0.0124 0.0253 6.26E-01 1.12E-02 2109 
rs61743947 16:240000 -- -- -- -- -- 




rs60616598 16:297264 0.0911 0.0258 4.19E-04 8.63E-01 2216 
rs9924561 16:314780 -0.216 0.0367 4.07E-09 1.83E-03 1006 
rs2608604 16:88849421 0.0081 0.0226 7.18E-01 2.40E-01 2638 
rs4890634 18:43854259 -0.071 0.0216 9.84E-04 8.93E-02 2912 
rs71176524 19:2177925 -0.0229 0.0217 2.92E-01 9.35E-01 2899 
rs919797 19:4498157 0.0332 0.024 1.66E-01 5.54E-01 2394 
rs1799918 19:13002400 -0.0114 0.026 6.62E-01 1.19E-01 2072 
rs958483 19:33759240 0.016 0.1183 8.93E-01 8.22E-01 115 
rs6014993 20:55991637 -0.0369 0.0244 1.30E-01 9.38E-01 2307 
rs4820079 22:32879617 -0.0033 0.0214 8.76E-01 7.16E-01 3008 
rs855791 22:37462936 -0.0985 0.0292 7.57E-04 3.29E-01 1648 








Table 30. HCT univariate results for combined-phenotype lead SNPs in Hispanics/Latinos. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.2471 0.0457 6.54E-08 9.42E-02 5141 
rs73210009 3:195830276 -0.085 0.0348 1.46E-02 5.09E-01 9127 
rs2361016 3:24341268 0.0331 0.0397 4.04E-01 6.42E-01 7212 
rs218265 4:55408999 -0.0583 0.0364 1.09E-01 9.94E-01 8845 
rs4535497 5:1107428 0.0065 0.0339 8.48E-01 7.87E-01 9409 
rs3749748 5:127350549 -0.0581 0.0441 1.88E-01 1.14E-01 5611 
rs2032451 6:26092170 -0.2331 0.0507 4.19E-06 8.49E-01 4314 
rs1800562 6:26093141 -0.1798 0.123 1.44E-01 7.97E-01 772 
rs11964516 6:41860252 0.0959 0.0434 2.73E-02 2.05E-01 5706 
rs13203155 6:109614844 0.0989 0.0357 5.66E-03 7.17E-01 8903 
rs35786788 6:135419042 0.2122 0.0455 3.04E-06 1.94E-01 5315 
rs590856 6:139844429 0.1066 0.0331 1.29E-03 8.45E-01 9990 
rs12718598 7:50428445 -0.0186 0.033 5.72E-01 9.75E-01 10072 
rs28832309 7:80319938 0.154 0.1563 3.25E-01 3.71E-01 534 
rs7385804 7:100235970 0.1541 0.0352 1.20E-05 3.84E-01 8629 
rs10253736 7:151415256 0.2062 0.0411 5.30E-07 6.44E-02 6385 
rs7853365 9:4855858 0.0185 0.0418 6.59E-01 3.81E-01 6226 
rs2519093 9:136141870 0.2441 0.0455 8.27E-08 5.44E-01 5290 
rs34793991 10:46080590 -0.0931 0.0829 2.61E-01 3.81E-01 1573 
rs17476364 10:71094504 0.3816 0.0658 6.52E-09 7.65E-01 2482 
rs33930165 11:5248233 1.7854 0.482 2.12E-04 1.00E+00 45 
rs28456 11:61589481 0.1288 0.0347 2.03E-04 2.96E-01 10257 
rs12320749 12:4331647 -0.051 0.0386 1.87E-01 6.24E-02 7255 
rs597808 12:111973358 -0.0812 0.0368 2.72E-02 1.09E-01 8386 
rs8013143 14:23494277 0.031 0.037 4.02E-01 8.93E-01 8645 
rs11621325 14:65472241 0.0277 0.0335 4.09E-01 6.60E-01 9500 
rs4887023 15:78535437 -0.0645 0.0345 6.14E-02 6.70E-01 9217 
rs60125383 16:176446 0.018 0.0367 6.24E-01 7.27E-01 9258 
rs115415087 16:205132 -0.0209 0.4044 9.59E-01 4.26E-01 109 
rs145546625 16:220583 0.1657 0.069 1.64E-02 7.88E-03 2600 
rs55932218 16:221151 0.0619 0.1991 7.56E-01 5.96E-01 394 
rs8058016 16:228786 0.1547 0.408 7.05E-01 3.56E-01 110 
rs530159671 16:250184 0.4649 0.1949 1.71E-02 1.76E-01 282 
rs60616598 16:297264 0.0544 0.1044 6.02E-01 3.33E-01 1411 
rs9924561 16:314780 0.2802 0.155 7.06E-02 7.43E-01 530 




rs4890634 18:43854259 0.0297 0.0349 3.94E-01 5.76E-02 8832 
rs71176524 19:2177925 -0.1495 0.0332 6.63E-06 5.59E-01 9885 
rs919797 19:4498157 -0.0803 0.0326 1.37E-02 4.58E-01 10045 
rs1799918 19:13002400 0.0323 0.0337 3.38E-01 5.89E-01 9710 
rs958483 19:33759240 -0.1993 0.0637 1.75E-03 9.16E-01 2566 
rs6014993 20:55991637 0.039 0.0342 2.54E-01 1.26E-01 9042 
rs4820079 22:32879617 0.056 0.0323 8.27E-02 1.92E-01 10226 
rs855791 22:37462936 0.2407 0.0331 3.68E-13 2.68E-01 10066 










Table 31. HGB univariate results for combined-phenotype lead SNPs in Hispanics/Latinos. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0774 0.0159 1.20E-06 4.21E-02 5136 
rs73210009 3:195830276 -0.0371 0.012 1.93E-03 2.07E-01 9129 
rs2361016 3:24341268 0.023 0.0138 9.44E-02 7.19E-01 7212 
rs218265 4:55408999 -0.0117 0.0124 3.45E-01 9.17E-01 8848 
rs4535497 5:1107428 0.011 0.0116 3.46E-01 5.29E-01 9405 
rs3749748 5:127350549 -0.0185 0.0153 2.26E-01 2.39E-01 5616 
rs2032451 6:26092170 -0.1217 0.0175 3.32E-12 9.62E-01 4312 
rs1800562 6:26093141 -0.0987 0.0414 1.72E-02 4.64E-01 771 
rs11964516 6:41860252 0.0385 0.015 1.02E-02 3.03E-01 5711 
rs13203155 6:109614844 0.0156 0.0123 2.06E-01 7.12E-01 8899 
rs35786788 6:135419042 0.0515 0.0155 9.18E-04 1.47E-01 5318 
rs590856 6:139844429 0.0329 0.0114 3.94E-03 7.57E-01 9981 
rs12718598 7:50428445 -0.0101 0.0114 3.75E-01 9.97E-01 10066 
rs28832309 7:80319938 0.1424 0.0544 8.86E-03 1.17E-01 530 
rs7385804 7:100235970 0.0338 0.0121 5.20E-03 6.07E-01 8619 
rs10253736 7:151415256 0.0786 0.0141 2.70E-08 9.27E-02 6381 
rs7853365 9:4855858 0.009 0.0144 5.30E-01 4.23E-01 6225 
rs2519093 9:136141870 0.0973 0.0157 6.56E-10 8.98E-01 5295 
rs34793991 10:46080590 -0.0131 0.0285 6.46E-01 3.88E-01 1576 
rs17476364 10:71094504 0.14 0.0227 6.45E-10 9.56E-01 2487 
rs33930165 11:5248233 -0.1972 0.1689 2.43E-01 1.00E+00 47 
rs28456 11:61589481 0.0504 0.012 2.64E-05 3.22E-01 10252 
rs12320749 12:4331647 -0.03 0.0133 2.40E-02 3.68E-02 7246 
rs597808 12:111973358 -0.0268 0.0127 3.50E-02 4.46E-02 8386 
rs8013143 14:23494277 0.0061 0.0128 6.35E-01 7.38E-01 8623 
rs11621325 14:65472241 0.0238 0.0116 3.97E-02 7.70E-01 9496 
rs4887023 15:78535437 -0.0087 0.0119 4.66E-01 6.18E-01 9217 
rs60125383 16:176446 0.021 0.0128 1.01E-01 5.49E-01 9250 
rs115415087 16:205132 -0.1625 0.1506 2.81E-01 3.66E-01 112 
rs145546625 16:220583 0.0715 0.024 2.89E-03 3.72E-02 2595 
rs55932218 16:221151 -0.0432 0.0701 5.38E-01 6.15E-01 389 
rs8058016 16:228786 0.2219 0.1474 1.32E-01 4.73E-01 115 
rs530159671 16:250184 0.3677 0.0689 9.46E-08 4.90E-01 285 
rs60616598 16:297264 0.1003 0.0378 7.88E-03 1.42E-01 1411 
rs9924561 16:314780 0.3025 0.0533 1.41E-08 5.60E-01 526 




rs4890634 18:43854259 0.0106 0.0121 3.83E-01 1.50E-01 8827 
rs71176524 19:2177925 -0.0445 0.0114 9.04E-05 7.88E-01 9879 
rs919797 19:4498157 -0.0342 0.0113 2.46E-03 3.10E-01 10039 
rs1799918 19:13002400 0.0044 0.0116 7.02E-01 7.68E-01 9706 
rs958483 19:33759240 -0.065 0.0219 2.98E-03 9.35E-01 2561 
rs6014993 20:55991637 0.0233 0.0118 4.91E-02 6.94E-02 9043 
rs4820079 22:32879617 0.0198 0.0112 7.60E-02 1.89E-01 10220 
rs855791 22:37462936 0.12 0.0115 1.51E-25 2.73E-02 10061 








Table 32. MCH univariate results for combined-phenotype lead SNPs in Hispanics/ Latinos. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0647 0.0334 5.26E-02 9.62E-01 4340 
rs73210009 3:195830276 -0.1151 0.0249 4.00E-06 3.61E-01 7572 
rs2361016 3:24341268 0.1089 0.0285 1.31E-04 3.37E-01 6034 
rs218265 4:55408999 0.2169 0.0262 1.23E-16 8.85E-01 7405 
rs4535497 5:1107428 -0.0279 0.0246 2.56E-01 6.23E-01 7887 
rs3749748 5:127350549 0.0059 0.032 8.53E-01 7.85E-01 4655 
rs2032451 6:26092170 -0.3049 0.0366 8.41E-17 4.58E-01 3575 
rs1800562 6:26093141 -0.3156 0.085 2.05E-04 3.08E-01 641 
rs11964516 6:41860252 0.2021 0.0306 3.75E-11 2.71E-02 4773 
rs13203155 6:109614844 -0.1263 0.0252 5.13E-07 6.45E-01 7454 
rs35786788 6:135419042 -0.2348 0.0332 1.45E-12 1.88E-01 4359 
rs590856 6:139844429 0.1649 0.024 6.20E-12 5.50E-02 8408 
rs12718598 7:50428445 0.1351 0.0235 8.75E-09 3.66E-01 8451 
rs28832309 7:80319938 0.1074 0.1066 3.14E-01 2.14E-01 467 
rs7385804 7:100235970 -0.0994 0.0251 7.69E-05 3.13E-01 7279 
rs10253736 7:151415256 0.0165 0.0295 5.75E-01 4.14E-01 5296 
rs7853365 9:4855858 -0.1547 0.0302 3.15E-07 6.76E-01 5151 
rs2519093 9:136141870 0.0273 0.0331 4.10E-01 2.00E-01 4349 
rs34793991 10:46080590 0.2005 0.0615 1.11E-03 4.04E-01 1261 
rs17476364 10:71094504 0.11 0.0472 1.98E-02 4.05E-01 2021 
rs33930165 11:5248233 1.1857 0.3004 7.92E-05 1.00E+00 47 
rs28456 11:61589481 -0.0255 0.0252 3.11E-01 4.57E-02 8592 
rs12320749 12:4331647 0.0661 0.0275 1.61E-02 8.78E-01 6147 
rs597808 12:111973358 0.0389 0.0267 1.45E-01 9.30E-01 6884 
rs8013143 14:23494277 -0.0459 0.0261 7.80E-02 8.21E-01 7421 
rs11621325 14:65472241 0.1174 0.0242 1.18E-06 3.05E-02 7961 
rs4887023 15:78535437 0.0279 0.0242 2.48E-01 8.23E-01 7686 
rs60125383 16:176446 0.0842 0.0258 1.10E-03 1.09E-01 7822 
rs115415087 16:205132 -1.2073 0.3275 2.27E-04 5.86E-01 120 
rs145546625 16:220583 4.31E-01 0.0481 3.18E-19 9.26E-01 2207 
rs55932218 16:221151 -0.4085 0.1406 3.67E-03 2.86E-01 348 
rs8058016 16:228786 1.6928 0.2823 2.03E-09 5.61E-01 125 
rs530159671 16:250184 1.8413 0.1684 8.22E-28 9.88E-02 209 
rs60616598 16:297264 5.02E-01 0.0795 2.73E-10 2.23E-01 1326 
rs9924561 16:314780 1.6572 0.1138 4.70E-48 8.41E-01 469 




rs4890634 18:43854259 0.0754 0.0252 2.75E-03 6.30E-01 7412 
rs71176524 19:2177925 0.004 0.0237 8.65E-01 8.17E-01 8301 
rs919797 19:4498157 -0.0792 0.0236 7.73E-04 5.32E-01 8435 
rs1799918 19:13002400 -0.1041 0.0239 1.39E-05 4.82E-01 8115 
rs958483 19:33759240 0.1217 0.0457 7.79E-03 9.29E-01 2163 
rs6014993 20:55991637 0.124 0.0242 2.99E-07 6.91E-01 7566 
rs4820079 22:32879617 0.0464 0.0233 4.65E-02 6.37E-01 8588 
rs855791 22:37462936 0.334 0.0238 9.06E-45 6.24E-01 8433 








Table 33. MCHC univariate results for combined-phenotype lead SNPs in Hispanics/ Latinos. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.0093 0.015 5.35E-01 7.63E-01 5313 
rs73210009 3:195830276 -0.0288 0.0116 1.28E-02 5.27E-01 9077 
rs2361016 3:24341268 0.0155 0.0129 2.30E-01 8.62E-01 7384 
rs218265 4:55408999 0.0197 0.0122 1.08E-01 1.37E-01 8606 
rs4535497 5:1107428 0.0211 0.0112 5.97E-02 6.70E-01 9442 
rs3749748 5:127350549 -0.0106 0.0145 4.66E-01 1.14E-01 5615 
rs2032451 6:26092170 -0.1154 0.0172 1.80E-11 9.13E-01 4194 
rs1800562 6:26093141 -0.0907 0.0407 2.57E-02 5.20E-02 744 
rs11964516 6:41860252 0.0091 0.0144 5.28E-01 2.51E-01 5732 
rs13203155 6:109614844 -0.0524 0.0116 6.34E-06 6.44E-01 9074 
rs35786788 6:135419042 -0.0548 0.015 2.53E-04 3.31E-01 5282 
rs590856 6:139844429 -0.0132 0.0111 2.32E-01 2.73E-01 10066 
rs12718598 7:50428445 0.0024 0.0109 8.28E-01 3.63E-01 10111 
rs28832309 7:80319938 0.1232 0.0466 8.19E-03 3.19E-03 674 
rs7385804 7:100235970 -0.032 0.0116 5.97E-03 2.55E-01 8704 
rs10253736 7:151415256 0.0134 0.0136 3.25E-01 8.52E-01 6484 
rs7853365 9:4855858 -0.0108 0.0138 4.35E-01 8.92E-01 6152 
rs2519093 9:136141870 0.0097 0.0152 5.24E-01 1.61E-01 5235 
rs34793991 10:46080590 0.0612 0.027 2.32E-02 8.24E-01 1582 
rs17476364 10:71094504 0.024 0.022 2.74E-01 1.14E-01 2426 
rs33930165 11:5248233 -1.9802 0.1917 5.06E-25 1.00E+00 47 
rs28456 11:61589481 -8.00E-04 0.0116 9.47E-01 3.09E-02 10202 
rs12320749 12:4331647 -0.0256 0.0127 4.30E-02 7.61E-01 7289 
rs597808 12:111973358 -0.0058 0.0123 6.39E-01 5.78E-01 8397 
rs8013143 14:23494277 -0.0129 0.0121 2.87E-01 2.24E-01 9050 
rs11621325 14:65472241 0.0234 0.0111 3.56E-02 6.26E-01 9465 
rs4887023 15:78535437 0.0219 0.0113 5.20E-02 5.02E-01 9209 
rs60125383 16:176446 0.0274 0.0117 1.96E-02 1.43E-01 9402 
rs115415087 16:205132 -0.3316 0.1199 5.70E-03 9.07E-01 147 
rs145546625 16:220583 0.0508 0.0234 2.98E-02 6.94E-01 2414 
rs55932218 16:221151 -0.1332 0.0587 2.32E-02 4.16E-01 507 
rs8058016 16:228786 0.304 0.1113 6.30E-03 9.68E-01 164 
rs530159671 16:250184 0.4165 0.0658 2.45E-10 4.51E-02 292 
rs60616598 16:297264 1.67E-01 0.0314 1.02E-07 6.45E-01 1790 
rs9924561 16:314780 0.4657 0.047 3.95E-23 2.79E-01 671 




rs4890634 18:43854259 0.0024 0.0117 8.35E-01 9.20E-02 8849 
rs71176524 19:2177925 0.0123 0.0109 2.59E-01 9.64E-01 9907 
rs919797 19:4498157 -0.0186 0.0109 8.85E-02 7.23E-01 10056 
rs1799918 19:13002400 -0.0105 0.0113 3.51E-01 7.97E-01 9582 
rs958483 19:33759240 0.0026 0.0213 9.03E-01 9.16E-01 2532 
rs6014993 20:55991637 0.0025 0.0114 8.29E-01 2.85E-01 9049 
rs4820079 22:32879617 0.0048 0.0107 6.52E-01 2.78E-01 10241 
rs855791 22:37462936 0.0969 0.0109 8.10E-19 4.43E-02 10025 







Table 34. MCV univariate results for combined-phenotype lead SNPs in Hispanics/ Latinos. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.1176 0.0914 1.98E-01 3.65E-01 4355 
rs73210009 3:195830276 -0.266 0.0677 8.60E-05 8.66E-01 7560 
rs2361016 3:24341268 0.249 0.0772 1.26E-03 2.64E-01 6046 
rs218265 4:55408999 0.5696 0.0711 1.10E-15 5.80E-01 7378 
rs4535497 5:1107428 -0.1723 0.0673 1.05E-02 9.03E-01 7884 
rs3749748 5:127350549 0.0243 0.0861 7.78E-01 8.84E-01 4651 
rs2032451 6:26092170 -0.6137 0.0986 4.92E-10 3.30E-01 3564 
rs1800562 6:26093141 -0.6912 0.2359 3.39E-03 8.72E-01 641 
rs11964516 6:41860252 0.5113 0.0848 1.65E-09 5.26E-02 4770 
rs13203155 6:109614844 -0.2387 0.0688 5.22E-04 9.48E-01 7468 
rs35786788 6:135419042 -0.5334 0.0904 3.68E-09 8.17E-02 4355 
rs590856 6:139844429 0.5344 0.0648 1.70E-16 2.01E-02 8406 
rs12718598 7:50428445 0.3519 0.0641 3.96E-08 4.29E-01 8447 
rs28832309 7:80319938 -0.0531 0.2855 8.53E-01 6.42E-01 476 
rs7385804 7:100235970 -0.1934 0.0682 4.54E-03 1.96E-01 7279 
rs10253736 7:151415256 -0.0149 0.0803 8.52E-01 3.96E-01 5301 
rs7853365 9:4855858 -0.4638 0.0819 1.52E-08 7.80E-01 5139 
rs2519093 9:136141870 -0.0341 0.0909 7.08E-01 4.30E-01 4345 
rs34793991 10:46080590 0.5509 0.1662 9.21E-04 4.04E-01 1262 
rs17476364 10:71094504 0.2795 0.1283 2.94E-02 9.96E-01 2016 
rs33930165 11:5248233 8.3913 0.8275 3.64E-24 1.00E+00 47 
rs28456 11:61589481 -0.165 0.0684 1.58E-02 9.98E-02 8579 
rs12320749 12:4331647 0.2975 0.0748 7.04E-05 7.74E-01 6144 
rs597808 12:111973358 0.1141 0.0726 1.16E-01 9.90E-01 6882 
rs8013143 14:23494277 -0.1229 0.0711 8.39E-02 5.63E-01 7448 
rs11621325 14:65472241 0.2378 0.0654 2.76E-04 1.98E-01 7949 
rs4887023 15:78535437 -0.0331 0.0661 6.16E-01 9.91E-01 7682 
rs60125383 16:176446 0.1691 0.0713 1.78E-02 1.52E-01 7829 
rs115415087 16:205132 -2.5876 0.8153 1.51E-03 5.34E-01 117 
rs145546625 16:220583 1.15E+00 0.1308 1.15E-18 8.69E-01 2193 
rs55932218 16:221151 -0.9119 0.3806 1.66E-02 2.09E-01 360 
rs8058016 16:228786 4.2379 0.7427 1.16E-08 5.89E-01 128 
rs530159671 16:250184 3.9345 0.4835 4.06E-16 7.06E-02 208 
rs60616598 16:297264 1.08E+00 0.2002 6.78E-08 6.48E-01 1316 
rs9924561 16:314780 3.6573 0.2989 1.99E-34 9.54E-01 475 




rs4890634 18:43854259 0.1496 0.0687 2.94E-02 7.53E-01 7406 
rs71176524 19:2177925 -0.0408 0.0644 5.27E-01 6.91E-01 8295 
rs919797 19:4498157 -0.1943 0.0634 2.18E-03 7.07E-01 8427 
rs1799918 19:13002400 -0.3003 0.0665 6.37E-06 2.99E-01 8089 
rs958483 19:33759240 0.2661 0.124 3.19E-02 9.95E-01 2152 
rs6014993 20:55991637 0.3289 0.0661 6.41E-07 6.97E-01 7561 
rs4820079 22:32879617 0.0965 0.0644 1.34E-01 2.38E-01 8580 
rs855791 22:37462936 0.6533 0.0644 3.55E-24 7.11E-01 8420 









Table 35. RBCC univariate results for combined-phenotype lead SNPs in Hispanics/ Latinos. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0166 0.0062 7.00E-03 1.85E-01 4335 
rs73210009 3:195830276 9.00E-04 0.0046 8.49E-01 8.56E-01 7570 
rs2361016 3:24341268 -0.0151 0.0053 4.32E-03 9.07E-01 6023 
rs218265 4:55408999 -0.035 0.0048 4.24E-13 6.68E-01 7429 
rs4535497 5:1107428 0.012 0.0045 7.32E-03 7.40E-01 7889 
rs3749748 5:127350549 -0.0112 0.0058 5.48E-02 4.67E-01 4649 
rs2032451 6:26092170 0.0086 0.0067 1.95E-01 3.14E-01 3578 
rs1800562 6:26093141 0.0176 0.0163 2.80E-01 8.27E-01 642 
rs11964516 6:41860252 -0.0175 0.0057 2.09E-03 3.90E-02 4765 
rs13203155 6:109614844 0.0234 0.0048 9.96E-07 8.83E-01 7447 
rs35786788 6:135419042 0.059 0.006 1.32E-22 8.44E-01 4357 
rs590856 6:139844429 -0.0141 0.0044 1.45E-03 5.96E-01 8410 
rs12718598 7:50428445 -0.0219 0.0044 8.26E-07 8.03E-01 8454 
rs28832309 7:80319938 0.0148 0.0202 4.63E-01 4.26E-02 462 
rs7385804 7:100235970 0.0271 0.0047 6.61E-09 2.36E-02 7287 
rs10253736 7:151415256 0.0176 0.0054 1.22E-03 1.79E-01 5285 
rs7853365 9:4855858 0.0223 0.0057 8.32E-05 3.84E-01 5150 
rs2519093 9:136141870 0.0233 0.0061 1.31E-04 4.27E-01 4355 
rs34793991 10:46080590 -0.0429 0.0113 1.40E-04 6.55E-01 1255 
rs17476364 10:71094504 0.0291 0.0088 9.10E-04 5.52E-01 2014 
rs33930165 11:5248233 -0.2773 0.0544 3.38E-07 1.00E+00 45 
rs28456 11:61589481 0.0192 0.0046 3.09E-05 9.02E-01 8603 
rs12320749 12:4331647 -0.0253 0.0051 8.90E-07 1.70E-01 6155 
rs597808 12:111973358 -0.0168 0.005 7.98E-04 7.20E-02 6881 
rs8013143 14:23494277 0.0072 0.0049 1.44E-01 9.39E-01 7420 
rs11621325 14:65472241 -0.0106 0.0044 1.61E-02 2.36E-01 7970 
rs4887023 15:78535437 -0.0046 0.0046 3.20E-01 8.74E-01 7688 
rs60125383 16:176446 -0.0097 0.0047 3.92E-02 7.98E-01 7824 
rs115415087 16:205132 0.1533 0.0471 1.13E-03 1.23E-01 112 
rs145546625 16:220583 -3.97E-02 0.0092 1.48E-05 5.67E-02 2214 
rs55932218 16:221151 0.0596 0.0262 2.27E-02 9.08E-01 345 
rs8058016 16:228786 -0.205 0.046 8.49E-06 3.33E-02 107 
rs530159671 16:250184 -0.2008 0.0321 3.98E-10 6.71E-01 206 
rs60616598 16:297264 -5.34E-02 0.0125 1.98E-05 1.19E-01 1263 
rs9924561 16:314780 -0.1622 0.021 9.93E-15 5.46E-01 461 




rs4890634 18:43854259 -0.0055 0.0046 2.38E-01 1.36E-01 7421 
rs71176524 19:2177925 -0.0175 0.0044 7.18E-05 6.98E-01 8307 
rs919797 19:4498157 -0.0014 0.0044 7.47E-01 6.13E-01 8442 
rs1799918 19:13002400 0.0182 0.0045 4.33E-05 5.97E-01 8128 
rs958483 19:33759240 -0.0423 0.0084 5.40E-07 9.79E-01 2170 
rs6014993 20:55991637 -0.009 0.0046 5.10E-02 3.13E-01 7566 
rs4820079 22:32879617 -0.0013 0.0043 7.60E-01 1.96E-02 8593 
rs855791 22:37462936 -0.0062 0.0044 1.64E-01 9.34E-01 8443 









Table 36. RDW univariate results for combined-phenotype lead SNPs in 
Hispanics/Latinos. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.0029 0.015 8.48E-01 3.17E-01 4329 
rs73210009 3:195830276 0.058 0.0114 3.34E-07 6.80E-01 7509 
rs2361016 3:24341268 -0.0333 0.0129 9.70E-03 8.91E-01 6002 
rs218265 4:55408999 -0.0156 0.0117 1.80E-01 5.74E-01 7348 
rs4535497 5:1107428 0.0763 0.0112 8.49E-12 3.59E-01 7836 
rs3749748 5:127350549 0.1173 0.0143 2.65E-16 2.29E-02 4623 
rs2032451 6:26092170 0.1119 0.0165 1.20E-11 8.53E-02 3532 
rs1800562 6:26093141 0.0725 0.0393 6.52E-02 5.22E-01 630 
rs11964516 6:41860252 -0.0313 0.0141 2.60E-02 8.91E-02 4735 
rs13203155 6:109614844 0.0379 0.0115 9.72E-04 2.68E-01 7414 
rs35786788 6:135419042 0.0685 0.0149 4.08E-06 3.71E-02 4324 
rs590856 6:139844429 0.0027 0.0108 8.01E-01 2.91E-01 8352 
rs12718598 7:50428445 -0.0133 0.0106 2.10E-01 1.90E-01 8393 
rs28832309 7:80319938 -0.2112 0.0471 7.17E-06 7.03E-01 467 
rs7385804 7:100235970 0.034 0.0115 3.02E-03 6.35E-01 7240 
rs10253736 7:151415256 0.0026 0.0134 8.44E-01 4.21E-01 5266 
rs7853365 9:4855858 0.0374 0.0136 5.81E-03 6.24E-01 5104 
rs2519093 9:136141870 -0.0252 0.0149 9.01E-02 4.63E-01 4314 
rs34793991 10:46080590 -0.0065 0.0277 8.14E-01 7.75E-01 1252 
rs17476364 10:71094504 0.0337 0.0213 1.14E-01 3.01E-01 2001 
rs33930165 11:5248233 -0.5124 0.1381 2.07E-04 1.00E+00 45 
rs28456 11:61589481 -0.0258 0.0113 2.17E-02 2.56E-01 8530 
rs12320749 12:4331647 -0.0078 0.0124 5.28E-01 6.34E-02 6106 
rs597808 12:111973358 0.0014 0.012 9.07E-01 2.30E-01 6827 
rs8013143 14:23494277 0.0961 0.0118 3.03E-16 4.88E-01 7397 
rs11621325 14:65472241 -0.0157 0.011 1.53E-01 3.54E-01 7903 
rs4887023 15:78535437 -0.0531 0.011 1.44E-06 1.84E-01 7629 
rs60125383 16:176446 -0.0025 0.0122 8.38E-01 4.32E-01 7769 
rs115415087 16:205132 0.172 0.1247 1.68E-01 3.76E-01 116 
rs145546625 16:220583 -0.0789 0.0226 4.83E-04 5.01E-01 2195 
rs55932218 16:221151 0.1668 0.063 8.16E-03 7.52E-01 342 
rs8058016 16:228786 -0.1555 0.0339 4.47E-06 9.09E-01 1317 
rs530159671 16:250184 -0.3628 0.0719 4.59E-07 4.04E-01 205 
rs60616598 16:297264 -0.1599 0.0338 2.17E-06 8.97E-01 1314 
rs9924561 16:314780 -0.349 0.0473 1.65E-13 4.34E-01 454 




rs4890634 18:43854259 -0.0626 0.0113 2.97E-08 2.28E-01 7359 
rs71176524 19:2177925 -0.0119 0.0106 2.64E-01 9.16E-01 8244 
rs919797 19:4498157 -0.0081 0.0108 4.53E-01 4.05E-01 8378 
rs1799918 19:13002400 0.0023 0.0109 8.33E-01 8.50E-01 8050 
rs958483 19:33759240 0.0136 0.0201 5.00E-01 2.64E-01 2153 
rs6014993 20:55991637 -0.0172 0.0111 1.23E-01 6.63E-01 7511 
rs4820079 22:32879617 -0.022 0.0104 3.48E-02 2.44E-01 8528 
rs855791 22:37462936 -0.0981 0.0107 6.95E-20 4.06E-01 8374 









Table 37. HCT univariate results for combined-phenotype lead SNPs in European 
Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.2237 0.0334 2.1E-11 2.6E-01 7339 
rs2361016 3:24341268 0.0191 0.0262 4.6E-01 4.4E-02 11798 
rs73210009 3:195830276 -0.0254 0.0243 3.0E-01 7.5E-02 13552 
rs218265 4:55408999 -0.1088 0.0337 1.2E-03 8.5E-01 7085 
rs4535497 5:1107428 0.0074 0.0256 7.7E-01 3.4E-01 12414 
rs3749748 5:127350549 0.0453 0.0275 9.9E-02 1.1E-01 10754 
rs2032451 6:26092170 -0.2134 0.0328 7.4E-11 1.0E+00 7610 
rs1800562 6:26093141 -0.3819 0.0491 7.4E-15 6.0E-02 3361 
rs11964516 6:41860252 0.0513 0.0312 1.0E-01 1.7E-01 8289 
rs13203155 6:109614844 0.0861 0.0237 2.8E-04 8.5E-02 14583 
rs35786788 6:135419042 0.2012 0.027 9.4E-14 4.4E-01 11170 
rs590856 6:139844429 0.0423 0.0238 7.5E-02 7.8E-01 14429 
rs12718598 7:50428445 0.0038 0.0239 8.7E-01 9.5E-01 14121 
rs7385804 7:100235970 0.1201 0.0249 1.4E-06 6.5E-01 13046 
rs10253736 7:151415256 0.1593 0.0272 4.7E-09 6.3E-01 10738 
rs7853365 9:4855858 -0.0061 0.0294 8.4E-01 6.4E-01 9469 
rs2519093 9:136141870 0.1718 0.0301 1.1E-08 7.3E-01 8826 
rs34793991 10:46080590 0.0056 0.0481 9.1E-01 5.0E-01 3517 
rs17476364 10:71094504 0.361 0.0422 1.1E-17 1.6E-01 4433 
rs28456 11:61589481 0.1126 0.0262 1.7E-05 2.4E-01 11738 
rs12320749 12:4331647 -0.1008 0.0294 6.0E-04 9.6E-01 9247 
rs597808 12:111973358 -0.1679 0.0241 3.1E-12 5.6E-01 14096 
rs8013143 14:23494277 -0.0353 0.0264 1.8E-01 5.7E-01 11487 
rs11621325 14:65472241 -0.0141 0.0241 5.6E-01 7.6E-01 14041 
rs4887023 15:78535437 -0.0557 0.0244 2.3E-02 5.7E-01 13799 
rs2608604 16:88849421 -0.0786 0.0262 2.7E-03 4.4E-01 11677 
rs4890634 18:43854259 0.0408 0.0272 1.3E-01 2.5E-01 11039 
rs71176524 19:2177925 -0.1057 0.0252 2.8E-05 1.3E-01 12760 
rs919797 19:4498157 -0.033 0.0251 1.9E-01 3.9E-01 13216 
rs1799918 19:13002400 0.0662 0.0251 8.4E-03 5.5E-01 12735 
rs958483 19:33759240 -0.078 0.0545 1.5E-01 7.6E-01 2692 
rs6014993 20:55991637 0.0336 0.0244 1.7E-01 1.0E+00 13367 
rs4820079 22:32879617 0.0465 0.0235 4.8E-02 2.1E-01 14738 
rs855791 22:37462936 0.2288 0.0243 4.7E-21 3.8E-01 13718 





Table 38. HGB univariate results for combined-phenotype lead SNPs in European 
Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0781 0.0113 4.0E-12 1.4E-01 7333 
rs2361016 3:24341268 0.0079 0.0088 3.7E-01 5.7E-02 11802 
rs73210009 3:195830276 -0.0213 0.0082 9.4E-03 2.1E-01 13549 
rs218265 4:55408999 -0.0301 0.0114 8.0E-03 8.5E-01 7088 
rs4535497 5:1107428 0.0129 0.0087 1.4E-01 1.3E-01 12413 
rs3749748 5:127350549 0.0114 0.0093 2.2E-01 2.4E-01 10752 
rs2032451 6:26092170 -0.1002 0.011 1.2E-19 8.6E-01 7609 
rs1800562 6:26093141 -0.1697 0.0166 1.2E-24 9.6E-02 3360 
rs11964516 6:41860252 0.0159 0.0105 1.3E-01 1.7E-01 8284 
rs13203155 6:109614844 0.015 0.008 6.0E-02 8.1E-02 14581 
rs35786788 6:135419042 0.0499 0.0091 4.3E-08 5.4E-01 11168 
rs590856 6:139844429 0.0157 0.008 5.0E-02 4.4E-01 14427 
rs12718598 7:50428445 0.0062 0.0081 4.4E-01 8.6E-01 14118 
rs7385804 7:100235970 0.0336 0.0084 6.5E-05 7.6E-01 13043 
rs10253736 7:151415256 0.0562 0.0092 1.0E-09 6.7E-01 10736 
rs7853365 9:4855858 -0.0048 0.0099 6.3E-01 5.3E-01 9460 
rs2519093 9:136141870 0.0611 0.0102 1.9E-09 9.2E-01 8811 
rs34793991 10:46080590 0.0117 0.0162 4.7E-01 2.8E-01 3511 
rs17476364 10:71094504 0.126 0.0142 8.7E-19 1.8E-01 4433 
rs28456 11:61589481 0.0399 0.0088 6.4E-06 1.0E-01 11741 
rs12320749 12:4331647 -0.032 0.0099 1.3E-03 6.5E-01 9239 
rs597808 12:111973358 -0.0621 0.0081 2.1E-14 3.6E-01 14093 
rs8013143 14:23494277 -0.0201 0.0089 2.4E-02 7.4E-01 11493 
rs11621325 14:65472241 0.0021 0.0081 8.0E-01 6.2E-01 14039 
rs4887023 15:78535437 -0.0185 0.0082 2.5E-02 6.4E-01 13797 
rs2608604 16:88849421 -0.0386 0.0089 1.3E-05 4.1E-01 11677 
rs4890634 18:43854259 0.0202 0.0092 2.7E-02 4.1E-02 11037 
rs71176524 19:2177925 -0.0325 0.0085 1.4E-04 9.6E-02 12758 
rs919797 19:4498157 -0.0219 0.0085 9.9E-03 4.8E-01 13214 
rs1799918 19:13002400 0.0179 0.0085 3.5E-02 6.4E-01 12727 
rs958483 19:33759240 -0.0269 0.0184 1.4E-01 3.9E-01 2696 
rs6014993 20:55991637 0.0161 0.0082 5.0E-02 9.6E-01 13364 
rs4820079 22:32879617 0.0203 0.0079 1.1E-02 3.5E-01 14736 
rs855791 22:37462936 0.0993 0.0082 8.5E-34 4.9E-01 13716 







Table 39. MCH univariate results for combined-phenotype lead SNPs in European 
Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.0375 0.0282 1.8E-01 2.2E-01 3691 
rs2361016 3:24341268 0.1096 0.0223 8.7E-07 9.7E-01 5838 
rs73210009 3:195830276 -0.0899 0.0209 1.7E-05 6.7E-01 6583 
rs218265 4:55408999 0.1677 0.0285 4.0E-09 7.0E-01 3515 
rs4535497 5:1107428 -0.0795 0.0216 2.3E-04 8.0E-02 6173 
rs3749748 5:127350549 -0.0379 0.0234 1.1E-01 5.0E-01 5376 
rs2032451 6:26092170 -0.2824 0.0276 1.4E-24 6.3E-03 3789 
rs1800562 6:26093141 -0.4866 0.041 1.9E-32 6.5E-01 1685 
rs11964516 6:41860252 0.1818 0.0266 8.3E-12 2.4E-01 4095 
rs13203155 6:109614844 -0.1176 0.02 3.9E-09 4.1E-01 7272 
rs35786788 6:135419042 -0.3501 0.0227 1.4E-53 4.8E-01 5567 
rs590856 6:139844429 0.0799 0.0199 5.8E-05 8.2E-01 7236 
rs12718598 7:50428445 0.1096 0.0205 9.1E-08 5.7E-02 6939 
rs7385804 7:100235970 -0.1347 0.0214 3.0E-10 1.3E-01 6385 
rs10253736 7:151415256 0.0334 0.0229 1.4E-01 9.7E-01 5360 
rs7853365 9:4855858 -0.1314 0.0248 1.2E-07 2.9E-01 4752 
rs2519093 9:136141870 0.0324 0.0258 2.1E-01 5.5E-01 4341 
rs34793991 10:46080590 0.2159 0.0407 1.1E-07 5.3E-01 1753 
rs17476364 10:71094504 0.1356 0.0362 1.8E-04 4.1E-01 2191 
rs28456 11:61589481 -0.0025 0.0224 9.1E-01 7.1E-01 5782 
rs12320749 12:4331647 0.0489 0.0249 4.9E-02 6.2E-01 4661 
rs597808 12:111973358 -0.0585 0.0207 4.6E-03 1.6E-02 6937 
rs8013143 14:23494277 -0.0232 0.0229 3.1E-01 5.1E-01 5562 
rs11621325 14:65472241 0.0851 0.0203 2.8E-05 7.8E-01 7002 
rs4887023 15:78535437 0.0441 0.0207 3.3E-02 4.9E-01 6875 
rs2608604 16:88849421 -0.0077 0.0227 7.3E-01 9.6E-01 5737 
rs4890634 18:43854259 0.1034 0.0229 6.3E-06 2.0E-01 5510 
rs71176524 19:2177925 0.0022 0.0216 9.2E-01 1.8E-02 6335 
rs919797 19:4498157 -0.1342 0.0221 1.2E-09 5.5E-01 6208 
rs1799918 19:13002400 -0.1251 0.0217 7.7E-09 1.5E-01 6180 
rs958483 19:33759240 0.1523 0.0472 1.3E-03 2.1E-01 1378 
rs6014993 20:55991637 0.1063 0.0206 2.6E-07 9.8E-01 6770 
rs4820079 22:32879617 0.1072 0.0198 6.4E-08 4.0E-01 7343 
rs855791 22:37462936 0.2731 0.0205 1.6E-40 9.5E-01 6883 









Table 40. MCHC univariate results for combined-phenotype lead SNPs in 
European Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0023 0.0108 8.3E-01 1.3E-01 7350 
rs2361016 3:24341268 0.0059 0.0085 4.9E-01 3.4E-01 11779 
rs73210009 3:195830276 -0.0219 0.0079 5.4E-03 6.7E-01 13535 
rs218265 4:55408999 0.0147 0.0109 1.8E-01 8.5E-01 7088 
rs4535497 5:1107428 0.0267 0.0083 1.3E-03 2.3E-01 12422 
rs3749748 5:127350549 -0.019 0.0089 3.2E-02 4.5E-01 10738 
rs2032451 6:26092170 -0.0798 0.0106 4.1E-14 9.1E-04 7601 
rs1800562 6:26093141 -0.1247 0.0159 4.5E-15 7.8E-01 3348 
rs11964516 6:41860252 0.0032 0.0101 7.5E-01 9.5E-01 8276 
rs13203155 6:109614844 -0.0322 0.0076 2.5E-05 2.4E-01 14568 
rs35786788 6:135419042 -0.0442 0.0087 4.3E-07 9.9E-01 11156 
rs590856 6:139844429 -0.0038 0.0077 6.2E-01 6.3E-03 14422 
rs12718598 7:50428445 0.0088 0.0077 2.6E-01 1.1E-01 14112 
rs7385804 7:100235970 -0.0168 0.0081 3.7E-02 4.9E-01 13032 
rs10253736 7:151415256 0.0083 0.0088 3.4E-01 9.2E-01 10731 
rs7853365 9:4855858 0.0013 0.0095 8.9E-01 4.1E-01 9445 
rs2519093 9:136141870 0.0205 0.0098 3.5E-02 6.7E-01 8820 
rs34793991 10:46080590 0.0179 0.0156 2.5E-01 7.9E-01 3509 
rs17476364 10:71094504 0.0127 0.0137 3.6E-01 5.3E-01 4405 
rs28456 11:61589481 0.0082 0.0085 3.3E-01 9.7E-01 11701 
rs12320749 12:4331647 0.0033 0.0095 7.3E-01 7.3E-01 9251 
rs597808 12:111973358 -0.0109 0.0078 1.6E-01 4.1E-02 14087 
rs8013143 14:23494277 -0.0139 0.0085 1.0E-01 7.1E-01 11496 
rs11621325 14:65472241 0.0144 0.0078 6.5E-02 2.1E-01 14022 
rs4887023 15:78535437 0.0028 0.0079 7.2E-01 2.2E-01 13793 
rs2608604 16:88849421 -0.0436 0.0085 3.2E-07 6.3E-01 11654 
rs4890634 18:43854259 0.0225 0.0088 1.0E-02 3.1E-01 11023 
rs71176524 19:2177925 0.0068 0.0082 4.1E-01 7.3E-01 12750 
rs919797 19:4498157 -0.0372 0.0082 5.2E-06 6.1E-01 13211 
rs1799918 19:13002400 -0.0143 0.0082 8.0E-02 6.5E-01 12713 
rs958483 19:33759240 0.0308 0.0178 8.5E-02 2.8E-01 2672 
rs6014993 20:55991637 0.0024 0.0079 7.6E-01 6.0E-01 13358 
rs4820079 22:32879617 0.0113 0.0076 1.4E-01 7.1E-01 14728 
rs855791 22:37462936 0.0578 0.0079 1.9E-13 2.3E-01 13709 





Table 41. MCV univariate results for combined-phenotype lead SNPs in European 
Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.1305 0.072 7.0E-02 3.2E-01 3696 
rs2361016 3:24341268 0.2767 0.0569 1.2E-06 9.5E-01 5831 
rs73210009 3:195830276 -0.2064 0.0531 1.0E-04 5.7E-01 6581 
rs218265 4:55408999 0.4577 0.0728 3.1E-10 9.5E-01 3507 
rs4535497 5:1107428 -0.3103 0.0547 1.4E-08 1.5E-02 6171 
rs3749748 5:127350549 -0.0686 0.0597 2.5E-01 6.4E-01 5378 
rs2032451 6:26092170 -0.6301 0.0706 4.2E-19 7.0E-02 3788 
rs1800562 6:26093141 -0.9763 0.1049 1.3E-20 4.3E-01 1685 
rs11964516 6:41860252 0.4834 0.0678 1.0E-12 6.8E-01 4099 
rs13203155 6:109614844 -0.3076 0.051 1.7E-09 5.3E-01 7269 
rs35786788 6:135419042 -0.8698 0.058 7.8E-51 5.1E-01 5568 
rs590856 6:139844429 0.2761 0.0507 5.0E-08 8.3E-01 7234 
rs12718598 7:50428445 0.3098 0.0523 3.2E-09 1.6E-02 6937 
rs7385804 7:100235970 -0.3308 0.0545 1.3E-09 9.0E-02 6382 
rs10253736 7:151415256 0.058 0.0582 3.2E-01 7.8E-01 5360 
rs7853365 9:4855858 -0.332 0.0633 1.6E-07 3.8E-01 4756 
rs2519093 9:136141870 0.0233 0.0656 7.2E-01 6.8E-01 4351 
rs34793991 10:46080590 0.5839 0.1037 1.8E-08 6.7E-01 1755 
rs17476364 10:71094504 0.3964 0.0922 1.7E-05 7.2E-01 2190 
rs28456 11:61589481 -0.0638 0.0571 2.6E-01 4.3E-01 5777 
rs12320749 12:4331647 0.1462 0.0633 2.1E-02 5.5E-01 4659 
rs597808 12:111973358 -0.1636 0.0527 1.9E-03 2.6E-01 6934 
rs8013143 14:23494277 -0.007 0.0584 9.0E-01 6.8E-01 5556 
rs11621325 14:65472241 0.1908 0.0518 2.3E-04 6.3E-01 7000 
rs4887023 15:78535437 0.1024 0.0529 5.3E-02 8.3E-01 6875 
rs2608604 16:88849421 0.1092 0.0576 5.8E-02 7.1E-01 5733 
rs4890634 18:43854259 0.2733 0.0585 3.0E-06 1.1E-01 5508 
rs71176524 19:2177925 -0.0276 0.055 6.2E-01 5.5E-02 6333 
rs919797 19:4498157 -0.2847 0.0561 3.8E-07 2.8E-01 6206 
rs1799918 19:13002400 -0.2722 0.0551 7.8E-07 4.4E-02 6182 
rs958483 19:33759240 0.3658 0.1206 2.4E-03 4.6E-01 1375 
rs6014993 20:55991637 0.1462 0.0633 2.1E-02 5.5E-01 4659 
rs4820079 22:32879617 -0.007 0.0584 9.0E-01 6.8E-01 5556 
rs855791 22:37462936 0.5782 0.0524 2.5E-28 7.5E-01 6880 








Table 42. RBCC univariate results for combined-phenotype lead SNPs in European 
Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 -0.0266 0.006 8.3E-06 9.5E-01 3699 
rs2361016 3:24341268 -0.0126 0.0047 7.7E-03 2.5E-03 5832 
rs73210009 3:195830276 0.0059 0.0044 1.8E-01 1.6E-01 6580 
rs218265 4:55408999 -0.0446 0.006 1.7E-13 9.4E-01 3513 
rs4535497 5:1107428 0.0148 0.0046 1.2E-03 3.0E-01 6173 
rs3749748 5:127350549 0.0012 0.005 8.1E-01 3.0E-01 5379 
rs2032451 6:26092170 0.0153 0.0059 9.2E-03 3.1E-01 3793 
rs1800562 6:26093141 0.003 0.0087 7.3E-01 8.0E-01 1687 
rs11964516 6:41860252 -0.0255 0.0057 6.6E-06 6.4E-01 4100 
rs13203155 6:109614844 0.0217 0.0042 3.1E-07 4.8E-01 7269 
rs35786788 6:135419042 0.0625 0.0048 3.3E-38 6.3E-01 5565 
rs590856 6:139844429 -0.0188 0.0042 8.1E-06 5.8E-01 7235 
rs12718598 7:50428445 -0.0202 0.0044 3.6E-06 3.1E-01 6938 
rs7385804 7:100235970 0.027 0.0045 3.0E-09 2.8E-02 6383 
rs10253736 7:151415256 0.0189 0.0049 9.9E-05 1.4E-01 5355 
rs7853365 9:4855858 0.014 0.0053 8.0E-03 9.5E-01 4758 
rs2519093 9:136141870 0.0162 0.0055 3.1E-03 2.4E-01 4345 
rs34793991 10:46080590 -0.0394 0.0086 4.8E-06 4.8E-01 1755 
rs17476364 10:71094504 0.0161 0.0077 3.7E-02 5.3E-01 2186 
rs28456 11:61589481 0.0184 0.0048 1.1E-04 5.9E-03 5775 
rs12320749 12:4331647 -0.0199 0.0053 1.6E-04 7.4E-01 4658 
rs597808 12:111973358 -0.0103 0.0044 1.9E-02 9.5E-01 6935 
rs8013143 14:23494277 -0.0029 0.0049 5.5E-01 4.6E-01 5562 
rs11621325 14:65472241 -0.0114 0.0043 7.9E-03 3.9E-01 7001 
rs4887023 15:78535437 -0.0136 0.0044 2.0E-03 2.8E-01 6877 
rs2608604 16:88849421 -0.0197 0.0048 4.4E-05 4.7E-01 5733 
rs4890634 18:43854259 -0.0105 0.0049 3.0E-02 4.6E-01 5510 
rs71176524 19:2177925 -0.0132 0.0046 4.3E-03 6.0E-01 6334 
rs919797 19:4498157 0.0046 0.0047 3.2E-01 9.8E-01 6207 
rs1799918 19:13002400 0.0238 0.0046 2.4E-07 3.8E-01 6180 
rs958483 19:33759240 -0.0465 0.0101 4.1E-06 5.8E-01 1372 
rs6014993 20:55991637 -0.0116 0.0044 8.1E-03 2.9E-01 6769 
rs4820079 22:32879617 -0.0128 0.0042 2.4E-03 8.9E-01 7341 
rs855791 22:37462936 -0.0055 0.0044 2.0E-01 9.4E-01 6882 







Table 43. RDW univariate results for combined-phenotype lead SNPs in European 
Americans. 
rsid Chr:Pos Beta SE p-value 
Het p-
value effN 
rs61523591 2:46372781 0.0291 0.0302 3.4E-01 2.5E-01 1024 
rs2361016 3:24341268 -0.0132 0.0234 5.7E-01 9.8E-01 1678 
rs73210009 3:195830276 0.0473 0.0213 2.7E-02 4.2E-01 2023 
rs218265 4:55408999 0.0286 0.0294 3.3E-01 9.6E-01 1047 
rs4535497 5:1107428 0.1012 0.0216 2.8E-06 8.5E-01 1962 
rs3749748 5:127350549 0.1244 0.0247 4.9E-07 2.9E-01 1505 
rs2032451 6:26092170 0.1544 0.0297 2.0E-07 5.5E-01 1044 
rs1800562 6:26093141 0.2114 0.0447 2.3E-06 8.0E-01 451 
rs11964516 6:41860252 -0.0969 0.0278 4.8E-04 6.1E-01 1174 
rs13203155 6:109614844 0.0352 0.0213 9.8E-02 7.3E-01 2066 
rs35786788 6:135419042 0.1366 0.0236 7.2E-09 1.4E-01 1615 
rs590856 6:139844429 0 0.0211 1.0E+00 1.4E-01 2051 
rs12718598 7:50428445 -0.0121 0.0208 5.6E-01 5.8E-01 2065 
rs7385804 7:100235970 0.0489 0.022 2.6E-02 7.2E-01 1917 
rs10253736 7:151415256 0.0252 0.0236 2.8E-01 1.2E-01 1661 
rs7853365 9:4855858 0.0388 0.0268 1.5E-01 2.1E-01 1300 
rs2519093 9:136141870 -0.0605 0.0267 2.4E-02 4.5E-01 1275 
rs34793991 10:46080590 0.032 0.0434 4.6E-01 5.9E-01 476 
rs17476364 10:71094504 -0.0283 0.0362 4.4E-01 4.6E-01 684 
rs28456 11:61589481 -0.0286 0.023 2.1E-01 9.8E-01 1761 
rs12320749 12:4331647 -2.00E-04 0.0254 9.9E-01 7.3E-01 1405 
rs597808 12:111973358 -8.00E-04 0.0214 9.7E-01 7.7E-01 2044 
rs8013143 14:23494277 0.1114 0.0232 1.6E-06 7.6E-01 1711 
rs11621325 14:65472241 -0.0208 0.0217 3.4E-01 9.7E-01 1995 
rs4887023 15:78535437 -0.099 0.0218 5.6E-06 7.2E-01 1943 
rs2608604 16:88849421 -0.0017 0.0219 9.4E-01 1.3E-01 1842 
rs4890634 18:43854259 -0.0608 0.0245 1.3E-02 2.1E-01 1551 
rs71176524 19:2177925 -0.0485 0.021 2.1E-02 1.2E-01 2026 
rs919797 19:4498157 0.0037 0.0214 8.6E-01 8.7E-01 1997 
rs1799918 19:13002400 0.0486 0.022 2.7E-02 7.9E-02 1895 
rs958483 19:33759240 -0.0818 0.0457 7.4E-02 9.6E-01 446 
rs6014993 20:55991637 0.0032 0.021 8.8E-01 3.9E-01 2015 
rs4820079 22:32879617 -0.0092 0.021 6.6E-01 9.9E-01 2082 
rs855791 22:37462936 -0.1285 0.0214 1.9E-09 3.5E-01 2001 







Table 44. LD proxies by ancestry for rs6573766, associated with RBCC in univariate sensitivity analysis. 
  LD proxy SNPs (r2>0.6) 
Coded allele 
frequency 
p-value in total 
study population 
African 
American Hispanic/ Latino European American Pooled MEGA 
African 
American 
























rs77151393 (r2=0.6) Hispanic/ 
Latino 
0.34 HGB 0.06 
European 
American 
0.2 MCH 0.06 
CHB 
(HapMap) 











   
 














Table 45. LD proxies by ancestry for rs145548796*, associated with MCV in univariate sensitivity analysis. 




p-value in total  




American Pooled MEGA 

















rs543776773 (r2=0.61)  






AMR 0.001 HGB 0.75 
  
EAS 0 MCH 1.20E-07 
  
EUR 0.005 MCHC 0.63 
  








   
           
*coded allele was not detectable in ancestry-specific analyses, values reported are for the ARIC European American sub-population; 
the variant had a CAF of 0.0015 in the pooled MEGA study population and a CAF of 0.0034 in ARIC European Americans. r2 = 









Table 46. Comparison of unadjusted and esv3637548-adjusted trait-specific p-values at HBA1/2 locus on 
chromosome 16 in MEGA-genotyped individuals. 
rsid HCT un HCT adj HGB un HGB adj MCH un MCH adj MCHC un MCHC adj aSPU un aSPU adj 
rs186066503 6.0E-02 7.0E-02 1.0E-01 7.0E-02 5.3E-26 1.5E-28 2.2E-13 4.1E-15 1.0E-11 1.0E-11 
rs145546625 6.0E-02 5.0E-02 2.0E-02 1.0E-02 1.1E-15 1.5E-17 1.8E-01 7.0E-02 1.0E-11 1.0E-11 
rs61743947 4.0E-02 3.0E-02 2.2E-04 4.6E-01 3.9E-10 1.3E-14 2.4E-09 5.7E-11 1.0E-11 1.0E-11 
rs55932218 1.0E-01 6.0E-02 5.0E-03 7.0E-04 5.5E-07 1.6E-11 2.0E-03 3.6E-05 4.5E-06 1.0E-11 
rs142154093 2.0E-02 8.9E-01 3.3E-06 7.0E-03 2.0E-19 3.4E-07 1.5E-07 7.0E-02 1.0E-11 1.3E-06 
rs9924561 1.4E-04 6.9E-01 3.6E-26 4.0E-01 5.8E-158 9.8E-07 9.7E-87 1.1E-04 1.0E-11 1.6E-05 
rs60616598 2.2E-01 3.5E-01 5.9E-04 9.0E-03 2.3E-11 4.0E-05 1.7E-06 4.4E-04 1.0E-11 2.7E-05 
rs76613236 5.5E-01 3.6E-01 3.5E-05 8.8E-01 1.3E-41 3.4E-04 9.6E-14 8.5E-01 1.0E-11 4.5E-04 
rs60125383 4.9E-01 9.3E-01 1.0E-03 1.2E-01 3.8E-09 1.0E-03 4.5E-10 3.0E-04 3.0E-09 3.0E-03 
rs8051004 5.2E-01 6.5E-01 7.5E-01 4.0E-01 5.0E-03 5.0E-03 7.0E-02 6.0E-03 5.0E-02 2.0E-02 
rs8058016 9.0E-03 5.0E-02 2.3E-04 1.0E-01 1.1E-12 1.0E-02 1.2E-04 6.5E-01 1.0E-11 1.2E-01 
rs115415087 4.7E-01 9.0E-02 5.6E-01 3.9E-01 1.4E-09 7.6E-01 1.8E-04 6.1E-01 3.0E-09 1.2E-01 
rs145752042 6.0E-02 7.0E-02 6.0E-02 1.2E-01 1.3E-01 4.6E-01 8.8E-01 4.7E-01 4.0E-02 1.3E-01 
rs530159671 2.0E-02 4.8E-01 1.0E-07 4.6E-01 1.4E-34 8.0E-02 3.7E-11 3.0E-01 1.0E-11 2.6E-01 
rsid MCV un MCV adj RBCC un RBCC adj RDW un RDW adj aSPU un aSPU adj     
rs186066503 8.0E-14 2.6E-15 8.0E-15 3.4E-14 1.5E-06 8.4E-07 1.0E-11 1.0E-11     
rs145546625 3.2E-16 1.3E-17 2.1E-05 1.4E-05 7.0E-03 3.0E-03 1.0E-11 1.0E-11     
rs61743947 2.7E-09 4.3E-13 2.0E-01 1.2E-01 1.5E-05 5.2E-07 1.0E-11 1.0E-11     
rs55932218 2.2E-05 1.2E-08 7.0E-02 3.0E-02 6.2E-06 1.2E-08 4.5E-06 1.0E-11     
rs142154093 2.1E-18 2.4E-07 5.9E-08 5.0E-03 6.1E-07 2.0E-03 1.0E-11 1.3E-06     
rs9924561 2.4E-135 1.1E-04 8.6E-49 2.1E-01 4.9E-06 9.0E-03 1.0E-11 1.6E-05     
rs60616598 2.4E-07 7.0E-03 2.6E-04 4.0E-02 9.3E-09 2.6E-06 1.0E-11 2.7E-05     
rs76613236 1.3E-33 1.9E-04 1.4E-18 2.2E-04 2.2E-12 6.0E-03 1.0E-11 4.5E-04     
rs60125383 8.6E-06 3.0E-02 6.8E-04 7.0E-02 5.0E-02 3.3E-01 3.0E-09 3.0E-03     
rs8051004 3.0E-02 2.0E-02 9.7E-01 9.4E-01 7.2E-01 5.4E-01 5.0E-02 2.0E-02     
rs8058016 1.3E-11 8.0E-03 5.0E-03 4.7E-01 2.0E-02 7.3E-01 1.0E-11 1.2E-01     
rs115415087 6.4E-09 5.8E-01 7.4E-09 2.0E-02 1.6E-01 7.0E-02 3.0E-09 1.2E-01     
rs145752042 1.0E-02 5.0E-02 6.8E-01 8.5E-01 6.1E-01 5.5E-01 4.0E-02 1.3E-01     
rs530159671 2.1E-21 4.0E-02 6.0E-11 3.3E-01 9.9E-08 3.3E-01 1.0E-11 2.6E-01     










Table 47. Shared generalization at previously published index SNPs across seven RBC traits. 
        








27% 48% 35% 43% 39% 
MCH 48% 53% 
MCH:  
9.1% 
67% 88% 67% 66% 
MCHC 32% 42% 30% 
MCHC: 
19% 
32% 24% 60% 








RDW 38% 36% 31% 61% 33% 28% 
RDW:  
27% 
        
*Generalization significance threshold is p<1.07E-04. Top-right side of matrix represents the number 
of variants significant for both traits (numerator) as a proportion of the total number of significant 
variants for the trait in that row (denominator, green/yellow). Bottom-left size of the matrix represents 
the number of variants significant for both traits (numerator) as a proportion of the total number of 







Table 48. Generalization of previously reported association signals and index SNPs to the PAGE 
trans-ethnic study population. 
 















All loci 250 251 223 197 222 126 188 
Trait loci 82 93 129 50 142 73 95 
All index SNPs 104 125 243 111 243 155 114 
Trait index SNPs 48 62 137 40 136 77 47         
Proportion 
       
 
HCT HGB MCH MCHC MCV RBCC RDW 
Trait loci 73 77 60 35 58 41 53 
Trait index SNPs 29 32 33 28 29 26 13 
All loci 53 53 47 42 47 27 40 








Table 49. Generalization of previously reported association signals and index SNPs to the 
PAGE African American population. 
 
Number 
















All loci 171 153 149 143 144 119 101 
Trait loci 47 53 69 29 83 41 43 
All index SNPs 2 19 23 12 28 18 6 
Trait index 
SNPs 
2 11 14 7 13 8 0 
        
Proportion 
       
 
HCT HGB MCH MCHC MCV RBCC RDW 
Trait loci 42 44 32 20 34 23 24 
Trait index SNPs 1 6 3 5 3 3 0 
All loci 36 33 32 30 31 25 21 








Table 50. Generalization of previously reported association signals and index SNPs to the 
PAGE Hispanic/Latino population. 
 
Number 

















All loci 169 180 171 128 193 185 142 
 
Trait loci 63 66 93 31 118 89 77 
 
All index SNPs 44 43 113 40 103 67 65 
 
Trait index SNPs 18 29 65 20 64 38 24 
 
         
Proportion 
        
 
HCT HGB MCH MCHC MCV RBCC RDW 
 
Trait loci 56 55 43 22 48 49 43 
 
Trait index SNPs 11 15 15 14 14 13 7 
 
All loci 36 38 36 27 41 39 30 
 









Table 51. Generalization of previously reported association signals and index SNPs to the 
PAGE European-ancestry population. 
 















All loci 125 136 119 98 124 119 48 
Trait loci 51 67 84 28 84 62 25 
All index SNPs 92 84 165 50 159 81 42 
Trait index SNPs 39 44 95 18 92 42 15         
Proportion 
       
 
HCT HGB MCH MCHC MCV RBCC RDW 
Trait loci 45 55 39 20 34 34 14 
Trait index SNPs 23 22 23 13 20 14 4 
All loci 27 29 25 21 26 25 10 








Table 52. Lead SNPs that are significant eQTLs for genes within 500kb for RBC-relevant 
tissues in GTEx. 
Gene 
Symbol Gencode Id SNP p-value 
GTEx 
alpha Tissue 
ABO ENSG00000175164.9 rs10901252 1.5E-49 4.6E-05 Thyroid 
ABO ENSG00000175164.9 rs10901252 3.1E-16 2.2E-05 Whole Blood 
ABO ENSG00000175164.9 rs10901252 2.8E-07 1.2E-05 Spleen 
CHAF1A ENSG00000167670.11 rs12459922 1.1E-36 3.5E-05 Thyroid 
CHAF1A ENSG00000167670.11 rs12459922 1.6E-08 2.0E-05 Whole Blood 
CHAF1A ENSG00000167670.11 rs12459922 7.1E-07 7.1E-06 Liver 
UBXN6 ENSG00000167671.7 rs12459922 2.8E-44 3.7E-05 Thyroid 
HBS1L ENSG00000112339.10 rs12664956 1.4E-16 7.0E-05 Thyroid 
HBS1L ENSG00000112339.10 rs12664956 9.2E-08 1.2E-05 Liver 
HBS1L ENSG00000112339.10 rs12664956 4.6E-06 3.7E-05 Whole Blood 
CPT1B ENSG00000205560.8 rs140523 1.4E-06 8.3E-05 Thyroid 
ODF3B ENSG00000177989.9 rs140523 4.0E-10 4.6E-05 Whole Blood 
SCO2 ENSG00000130489.8 rs140523 2.5E-06 8.0E-05 Thyroid 
SCO2 ENSG00000130489.8 rs140523 8.9E-06 1.7E-05 Liver 
SCO2 ENSG00000130489.8 rs140523 2.2E-05 4.3E-05 Whole Blood 
TYMP ENSG00000025708.8 rs140523 8.9E-19 4.8E-05 Whole Blood 
FARSA ENSG00000179115.6 rs1799918 7.6E-06 3.8E-05 Whole Blood 
GCDH ENSG00000105607.8 rs1799918 7.6E-12 6.9E-05 Thyroid 
GCDH ENSG00000105607.8 rs1799918 6.6E-08 3.8E-05 Whole Blood 
GCDH ENSG00000105607.8 rs1799918 2.7E-06 1.3E-05 Liver 
SYCE2 ENSG00000161860.7 rs1799918 5.7E-09 5.5E-05 Thyroid 
SYCE2 ENSG00000161860.7 rs1799918 2.8E-06 1.3E-05 Liver 
HFE ENSG00000010704.14 rs2032451 3.9E-10 1.3E-04 Thyroid 
ABO ENSG00000175164.9 rs2519093 4.0E-15 2.2E-05 Whole Blood 
FADS1 ENSG00000149485.12 rs28456 4.2E-13 8.0E-05 Thyroid 
FADS2 ENSG00000134824.9 rs28456 2.1E-27 5.1E-05 Whole Blood 
FADS2 ENSG00000134824.9 rs28456 8.1E-14 7.8E-05 Thyroid 
FADS2 ENSG00000134824.9 rs28456 6.7E-11 2.3E-05 Spleen 
TMEM258 ENSG00000134825.9 rs28456 7.1E-06 4.0E-05 Whole Blood 
MARCH8 ENSG00000165406.11 rs34793991 4.0E-06 1.3E-04 Thyroid 
HBS1L ENSG00000112339.10 rs35786788 4.8E-07 7.0E-05 Thyroid 
HBS1L ENSG00000112339.10 rs35786788 4.4E-06 1.2E-05 Liver 
C18orf25 ENSG00000152242.6 rs4890634 5.1E-06 3.5E-05 Whole Blood 
MOSPD3 ENSG00000106330.7 rs7385804 3.5E-19 5.1E-05 Whole Blood 
TFR2 ENSG00000106327.8 rs7385804 9.7E-11 1.9E-05 Liver 




PRMT5 ENSG00000100462.11 rs8013143 1.1E-08 2.4E-05 Whole Blood 
MPST ENSG00000128309.12 rs855791 8.6E-07 4.6E-05 Thyroid 






 MANUSCRIPT B. GENE-BASED TESTING IN AN 
ANCESTRALLY DIVERSE STUDY POPULATION SUGGESTS COMPLICATED 




Red blood cell (RBC) traits are highly polygenic and moderately heritable traits with a 
broad array of both clinical and research applications. Genetic characterization of these traits 
remain incomplete despite hundreds of reported GWAS loci. Populations of non-European 
ancestry also remain underrepresented in blood trait genetics literature. Therefore, we conducted 
gene-based testing of two variant annotation sets in genotyped and imputed data from 
participants of the multi-ethnic PAGE study (n=29,070). We identified four genes in loci 
previously unreported in the RBC trait association study literature: two specific to MCH 
(IGHV1-3, p=1.2E-07, and CATSPERB, p=4E-08), one specific to RBCC (PPHLN1, p=2.4E-07), 
and a non-coding RNA (RP11-687M24.7) significant for HCT, HGB, MCH, MCHC, RBCC, and 
RDW. The most significant variant within each transcript exhibited a gradient of allele frequency 
by ancestry, being the most common in the African American subpopulation. We additionally 
reported 45 significantly associated genetic transcripts within known RBC trait GWAS loci, all 
but six of which were significantly associated with multiple traits. Our findings suggest that rare 
variants do play a role in RBC development and function, and the improvement in power 
provided by gene-based methods can increase detection of discovery loci driven by rare 




the detection of loci driven by variants that are monomorphic or extremely rare in European-
ancestry study populations. 
 
6.2. Introduction 
Red blood cell (RBC) traits are highly polygenic quantitative phenotypes that describe 
the function and maintenance of RBCs. Hematocrit, hemoglobin, RBC count, and their derived 
traits are utilized clinically to diagnose anemic states, and several RBC traits have been 
associated as prognostic indicators of other chronic diseases8; 107; 260; 632. These traits exhibit 
moderate heritability (20-80%), and insights into the molecular function of genes affecting RBC 
biology has led directly to the development of treatments for hereditary anemias143; 156; 157; 322. 
Identification of genes likely to be affecting RBC trait biology is important to maximize 
understanding of these traits for both research and clinical utilization. 
RBC traits have been extensively evaluated using traditional GWAS methods, identifying 
over 500 loci 31; 301; 348. However, heritability estimates suggest that additional loci remain to be 
found, with the expectation that some heritability may be attributable to rare variants, which are 
more likely to be population-specific than common variants340; 470; 627; 633; 634. Restriction of the 
best-powered GWAS to European- and East Asian-ancestry populations has limited the detection 
of such potentially causal rare variants (minor allele frequency <1%) segregating in African- and 
Amerindian-ancestry populations. In addition to low representation of global ancestries, RBC 
trait GWAS examining rare variants have limited statistical power, particularly when attempting 
to identify loci with modest to moderate effects that are present in a small subset of the study 
population. Gene-based testing improves statistical power to detect such effects by incorporating 




multi-ethnic study population with a large number of previously unexamined rare variants491; 519. 
To address the limitations outlined above, we performed gene-based testing of seven RBC traits 
in over 29,000 participants of the Population Architecture using Genomics and Epidemiology 
(PAGE) study. Our findings emphasize the importance of inclusive study design and evaluation 




6.3.1. Study population 
The PAGE study comprises ancestrally-diverse study populations from United States 
cohorts and biobanks evaluating common complex diseases and accompanying risk factors 
(http://pagestudy.org). This study used data from all Multi-ethnic Genotyping Array (MEGA)-
genotyped (see above) self-reported African American, Asian American, Hispanic/Latino, Native 
American, and “Other” participants from the Hispanic Community Health Study/Study of 
Latinos (HCHC/SOL); the Icahn Mt. Sinai School of Medicine BioME Biobank (BioME); and 
the Women’s Health Initiative (WHI) with phenotype data for one or more RBC traits495; 589; 635. 
Participants were excluded if they met any of the criteria described in Section 4.3.2.  
6.3.2. RBC trait measurement 
RBC traits were measured with hemanalyzers following standardized laboratory 
protocols from blood draws at the earliest available visit for all seven RBC traits (hematocrit 
[HCT], hemoglobin concentration [HGB], mean corpuscular hemoglobin [MCH], MCH 




distribution width [RDW]; Table 3). RBC trait values exceeding four standard deviations from 
the total study population trait mean were excluded. 
6.3.3. Genotyping and Imputation 
All study participants were genotyped on the Illumina Multi-ethnic genotyping array 
(MEGA) and imputed to the 1000 Genomes phase 3 reference panel after application of filtering 
and quality control criteria, as previously described455; 495. Variants with an imputation quality 
score below 0.4 were excluded from analysis. In line with previously published gene-based 
testing efforts, we excluded SNPs which had a minor allele count (MAC) <5—because the 
association may be driven by an ancestral haplotype or outlying phenotypic value rather than a 
genetic association. We also excluded variants with a minor allele frequency (MAF) >0.01 
because variants above that allele frequency are powered to be detected using GWAS methods 
and have already been evaluated in our study population28; 636. Minor allele frequencies (MAFs) 
used for reporting were calculated in MEGA-genotyped WHI African Americans and 
HCHS/SOL Hispanics/Latinos. European MAFs were obtained from the 1000G CEU European-
ancestry population470. 
 
6.3.4. Statistical Methods 
6.3.4.1 Transcript-based variant annotation file design 
Variant annotation files were generated for all autosomal variants with a PAGE MAF 
<0.01 for two different definitions of a genetic transcript using variant-transcript affiliations as 
defined in Ensembl (version 25 GRCh37/hg19), downloaded from BioMart (accessed July 1, 
2019)637. Briefly, transcript start, end, and splice sites were predicted and compared to previous 




coding and noncoding genes (annotation is described in more detail at 
http://ensembl.org/Homo_sapiens/Info/Annotation and 
http://.ensembl.org/info/genome/genebuild/ manual_havana.html). For the first annotation file 
(referred to henceforth as “deleterious”), we restricted to variants annotated as stop-gained, stop-
lost, non-synonymous, and splicing variants. For the second annotation file (henceforth referred 
to as “CADD” in reference to the Combined Annotation Dependent Depletion database), we 
included all variants in the deleterious annotation file plus all synonymous coding variants and 
potential regulatory variants with a scale CADD score >10 classified as upstream, downstream, 
5’UTR, 3’UTR, or intronic variants for the relevant transcript617. CADD scores have been 
calculated and published for 8.6 billion nucleotides in the context of the current reference 
genome (including 1000 Genomes, to which our genotypes are imputed), correlate with relevant 
metrics such as ClinVar pathogenicity, and demonstrate an improvement in predicting 
deleteriousness over other available prediction algorithms such as PolyPhen476. CADD scores are 
particularly useful as a filtering method for rare variants, because functional rare variants are 
expected to have higher effect magnitudes than most common variants, but the vast majority 
have not been molecularly characterized43; 638. Since the raw or unscaled CADD score cannot be 
compared across datasets, we used the scaled PHRED CADD score (representing the rank-order 
by effect magnitude) and filtered on the recommended score of 10 to obtain the top ten percent 
of all variants in the genome. Of note, scores are currently not tissue- or transcript-specific, 
meaning a highly-scored variant may affect transcripts differentially 
(https://cadd.gs.washington.edu, accessed July 5, 2019). Additionally, we note that while non-
coding-RNA (ncRNA)-specific variants were excluded, our annotation file design did not 




6.3.4.2 Gene-based analyses 
Score statistics for individual variants by group were generated in SUGEN in a MASS-
accepted format (see below)616. An additive genetic model of inheritance was assumed, and we 
adjusted for linear effects of age at blood draw, sex, study site or region, and ten ancestral 
principal components23. To identify gene transcripts significantly associated with the seven 
examined RBC traits, we implemented an adaptive method combining variance components and 
burden tests using MASS meta-analysis software 639. The burden test represents the combined 
effect of variant scores within a gene—i.e., the test statistic represents only one genetic variable 
per transcript in the annotation file. The variance components test represents the contribution of 
each participant’s genotype to the proportion of variance of the trait explained by genetic 
variation. In this case, the covariances are calculated for variants within each transcript, for 
which the corresponding test statistic represents a weighted sum of the score statistics for each 
variant499. Within-study weights are applied to the covariance matrix using the beta density 
function Beta(1,25,MAF).  
Transcripts represented by fewer than three variants were excluded because they 
essentially represent single-variant tests rather than group tests44; 636. The maximum number of 
Monte Carlo simulations run in MASS was set to the default of one million; simulations were 
increased to 25 million (simulating a minimum p-value of 4E-08) for transcripts exceeding 1E-5 
to ascertain statistical significance. Gene-based results were presented as the primary findings, 
employing Bonferroni correction assuming 25,000 independent genes for seven traits (p<2.86E-
7). Transcripts were reported as discovery genes if a significant transcript with start and end sites 
≥500kb from a variant previously reported to exceed p<5E-8 for any of the seven RBC traits. 




through review of the NHGRI-EB GWAS Catalog21 as of May 1, 2019. Previously reported 
genes were identified through a PubMed search for exome-chip, exome-sequencing, and whole-
genome sequencing which employed gene-based or sliding-window burden tests.  
6.3.4.3 Gene ontology data 
To help identify shared biological mechanisms underlying significantly associated genes, 
we compared results from both variant annotation sets across all RBC traits using the publicly 
available StringDB resource from Elixir618. StringDB is regularly updated and pulls from 
molecular experimental and GWAS results databases as well as text-mining from the literature. 
Using the standard false discovery rate (FDR) significance threshold of 0.05, we searched for 
biological processes, molecular functions, and cellular components that were overrepresented in 
our set of significantly associated genes (updated Jan 2019, accessed July 1, 2019). Additionally, 
for previously unreported genes we generated networks with modest (0.2) or higher interaction 
scores to visualize potential clusters of proteins significantly associated with one or more traits. 
 
6.4. Results 
The study population comprised 29,070 participants who were predominantly African 
Americans (30%) or Hispanics/Latino (65%) (Table 53). The study population was broadly 
representative with regard to age (ranging from 18 to 90; average age 53 years) and majority 
female (76%). We evaluated a maximum of 108,331 transcripts representing up to 12,399,104 
rare variants in the total study population. The number of variants per transcript ranged from the 
designated minimum of three to 207 (median = 4) for the deleterious variant annotation set and 




6.4.1. Genes previously unreported in RBC trait association studies  
In total, 49 transcripts representing 42 genes were significant for one or more RBC traits 
for one or both annotation sets (Figure 14, Tables 54, 55). Fourteen transcripts were associated 
with only one RBC trait, and MCH (n=37) and MCV (n=36) harbored the largest number of 
associations across all transcripts. Significantly associated transcripts from four genes were 
outside loci previously associated with RBC traits in large-scale genetic studies: CATSPERB, 
IGHV1-3, PPHLN1, and RP11-687M24 (Tables 54, 55). Three of four newly identified 
transcripts exceeded significance for only one trait (RP11-687M24 was significantly associated 
with HCT, HGB, MCV, MCHC, RBCC, and RDW). Three were represented by five or fewer 
variants in their respective masks (the CATSPERB transcript significantly associated with RBCC 
included 38 variants).  
The most significant (“top”) annotated variant had a minor allele frequency >0.1% in all 
significant trait-transcript associations (Tables 56-59). Several of the top variants have been 
reported as index SNPs in RBC trait GWAS, although the transcript containing the variant was 
not always reported as the gene associated with the index SNP in the literature. For the genes 
with multiple significantly associated transcripts in the deleterious annotation set, the top variant 
was the same for all transcripts within the gene in 100% of cases, suggesting that the same 
variants may be functional for multiple transcripts (Tables 58, 59). Approximately 60% of top 
SNPs exceeded traditional genome-wide significance (5E-08), indicating those variants could be 
accounting for most of the association for that trait-transcript combination (Tables 56, 57). 
However, for transcripts significant using the deleterious annotation set, fewer than 10% of 
associations exhibited a decrease over one order of magnitude after conditioning on the top 




variant was the same across all traits approximately half of the time (e.g., n=15/31 for CADD 
annotation set, Tables 56, 57). Of the transcripts representing 38 genes which overlapped with 
known RBC trait GWAS loci, the majority were located in gene-dense regions, particularly the 
regions on chromosomes 11 and 16 referred in which HBB and HBA1/2 are coded, respectively.  
Ancestry differences were also evident in allele frequency differences for top variants 
(Tables 58, 59). On average, African Americans had the highest minor allele frequency in top 
variants (average MAF = 0.0077; approximately one third of variants would been excluded due 
to MAF>1% in an African American-only study population), with Hispanics/Latinos having a 
slightly lower MAF at the same variants (average MAF = 0.0028). Of 75 unique top variants 
across all trait-transcript associations, over 75% were monomorphic in 1000 Genomes European 
or Asian ancestries (EAS, n=68; EUR, n=56; SAS, n=69;  Tables 58, 59). 
6.4.2. Clustering of significant genes 
Consistent with both the molecular and GWAS literature, the first megabase of chromosome 
16—which contains genes coding for multiple hemoglobin subunits as well as FAM234A and 
LUC7L—was highly represented, with 17 genes significant for one or more RBC traits. Of these 
genes, a cluster including LUC7L, ITFG3/FAM234A, RHBDF1, TMEM8A, PDIA2, and RGS11 
exhibited evidence supporting a shared role in RBC physiology (Figure 15). For instance, 
PDIA2, located in a locus recently implicated in alpha-thalassemia, showed evidence of 
association with the adjacent globin cluster on chr16p13.3640. Given the relative proximity of 
these genes and a complicated long-range LD structure regulating alpha-hemoglobin expression 
in this region, additional characterization would be required to separate independent biological 




exhibit a moderate or strong association with any other significant gene or were not available in 
the StringDB gene list (Table 60). 
6.4.3. Overrepresentation of gene ontology or molecular pathways 
Gene ontology and interpretation of biological mechanisms of all significant genes was evaluated 
to determine overlapping pathways. G-protein-coupled receptor activity and oxygen transport 
were overrepresented in our dataset (FDR<0.05, Table 61). None of the previously unreported 




This work reported a gene-based study of seven RBC traits in a multi-ethnic study 
population. We identified four genes which were physically distant from any previously reported 
RBC trait–associated locus. We further reported significant associations with multiple genes in 
known RBC trait loci which differed from the gene reported in the GWAS literature, likely due 
to proximity to a GWAS index SNP. Consistent with RBC trait GWAS and exome-sequencing 
findings, we also found a large overlap in associations across RBC traits. Our results reinforced 
the complexity of RBC traits, as well as highlighting the crucial role ancestrally diverse study 
populations will continue to have in genetic discovery and characterization. Overall, this study 
emphasizes the need to consider the entire spectrum of allelic diversity in global populations 
when attempting to understand the genetic architecture underlying complex traits.  
Notably, we identified four previously unreported genes significantly associated with one 
or more RBC traits, all of which demonstrated contribution from more than one variant to exceed 




more characterization is merited to determine potential underlying contributions to RBC 
phenotypes. For instance, PPHLN1 encodes for periphilin, which has recently been implicated as 
part of the HUSH complex for involvement with epigenetic transcriptional silencing leading to 
heterochromatin formation, a process which is crucial to RBC development in the bone marrow 
as hemoglobin expression is upregulated and nearly all other transcripts are downregulated641-643.  
Of particular relevance to translational research, we found that nearly half of significant 
transcripts in genomic regions previously reported in GWAS were not from the reported gene 
(typically the gene most physically proximal to the index SNP). While canon dictates that the 
index SNP in a GWAS in not necessarily causal and the association may affect a more distant 
gene, this reporting tendency has been sustained over the past decade. GWAS have revealed 
multiple independent associations in both the HBB and HBA1/2 regions, which represent the 
nearly 75% of the associations we identified, but characterization of the functions of most genes 
neighboring the hemoglobin genes has yet to be performed. Our results—especially for smaller 
genes with upstream and downstream variants included in the mask file—cannot be conclusively 
determined to represent the protein-coding gene associated with the associated transcript, 
particularly in areas expected to have multiple overlapping regulatory mechanisms. However, the 
difference between our significant genes and reported GWAS genes reinforces the idea that 
genes other than the most proximal to an index SNP should be considered for functional work.  
This work benefits the RBC trait genetics literature in several ways. First, early gene-
based testing of rare variants was inhibited by poor capture of rare or non-European variants in 
early array design, although sequencing is beginning to address this issue. We were able to 
include millions of rare variants in our annotation sets due in part to use of the MEGA array, 




our variant annotation sets into regulatory regions not captured by standard exome chips495. We 
also benefitted greatly from the diverse ancestral representation of the PAGE study participants, 
as demonstrated by the inclusion of 38 variants that contributed to significant associations and 
were monomorphic in the 1000 Genomes CEU European-ancestry population. Second, 
implementation of the optimal SKAT method is reportedly well powered to identify genes for 
which all variants act in same direction as well as those with variants having both positive and 
negative effects, which is particularly relevant for transcripts including regulatory variants. 
Third, genetic transcripts rather than individual variants as the primary results allows for a more 
precise comparison of results with regard to shared function or physiologic pathway.  
Our study also faced several limitations common to both RBC trait genomics research 
and gene-based testing in general. First, our sample size was limited, although our study 
population was broadly representative of the ancestry groups living in the United States. 
Relatedly, because the number of participants varied by trait, differences in strength of 
association across traits may actually be due to differences in power to detect associations. 
Females were also overrepresented (75%) in our study population—while biological sex is 
associated with the RBC traits we analyzed, we did not have a sufficient number of males to 
perform a sensitivity analysis determining whether sex may be affecting any significant 
associations. Secondly, while the identification of functional variants should be a priority, eQTL 
data for low-frequency or rare SNPs is limited generally, and the limitations become more severe 
for non-European-ancestry variants. Therefore, prioritizing variants identified in our study 
population for additional characterization will be difficult until publicly available functional 
databases are able to be more inclusive. Third, while the capture of rare variants (both genotyped 




methods, whole-genome sequencing will more accurately measure rare variants644. However, this 
effort demonstrates the utility of gene-based testing in diverse populations, providing a platform 
for future testing in larger study populations with sequencing data. Finally, although our 
transcript annotations are designed to represent specific gene isoforms, they are defined by 
physical location within or immediately proximal to the gene of interest. Without additional 
characterization, we cannot be certain that the variants representing any particular transcript are 
not in fact significantly affecting a neighboring gene via a regulatory mechanism. This was 
particularly evident on the short arm of chromosome 16, which contained 214 transcripts in the 
first megabase alone, 26 of which exceeded significance but may be representing complementary 
regulatory effects on the expression of the hemoglobin subunit genes in that region. 
  
6.6. Conclusion 
In conclusion, implementation of gene-based testing enabled the identification of 
multiple new transcripts associated with RBC traits as well as generalizing the associations of 
over three dozen loci previously identified in GWAS. Our work emphasizes the importance of 
inclusive study population design to maximize the benefits of methods developed specifically to 









Figure 13. Number of variants per transcript in deleterious and CADD annotations. 
Green = deleterious annotation set; purple = CADD annotation set. Truncated at x=150 variants 







Figure 14. Genome-wide gene-based results using deleterious (top) and CADD (bottom) masks identifies multiple significant 
transcripts across seven RBC traits.  
Each color represents a p-value < 0.001 for one trait-transcript association as follows: HCT (dark green), HGB (turquoise), MCH 
(light green), MCHC (orange), MCV (dark blue), RBCC (dark yellow), and RDW (pink). Labels indicate each gene with one or 
more trait-transcript associations exceeding genome-wide significance (p<2.8E-07). 
  1         2         3         4          5         6         7         8        9      10       11      12      13       14      15       16       17     18     19     20    21   22 
Chromosome 














Figure 15. Evidence of shared pathways in a cluster of CADD-significant genes.  
Network generated by StringDB for 12 genes with transcripts significantly associated with 
one or more RBC traits. Nodes = significant genes within two degrees of association of a 











































































*The total study population includes self-identified Native American (604), Asian American 
(541), and “Other” (382) study participants. All variables aside from sex presented as the mean 
(standard deviation). g/dL = grams per decliter; pg = picograms; fL = femtoliters; µL = 





Table 54. CADD annotation set transcripts significant in one or more RBC traits in 29,070 PAGE participants. 
Gene Transcript chr:pos vars HCT HGB MCH MCHC MCV RBCC RDW 
RP11-
284F21.10 
ENST00000605886 1:156611458 4 -- 1.0E-
07 
4E-08 4E-08 -- -- 4E-08 
ATP2B2 ENST00000397077 3:10365707 129 4E-08 4E-08 4E-08 -- 4E-08 4E-08 -- 
OSBPL5 ENST00000263650 11:3108346 31 4E-08 4E-08 4E-08 4E-08 -- 4E-08 -- 
OR51E1 ENST00000396952 11:4664650 8 -- -- -- -- 4E-08 -- -- 
MMP26 ENST00000380390 11:4726157 74 4E-08 -- -- -- 4E-08 -- -- 
OR52R1 ENST00000356069 11:4824663 10 -- -- 4E-08 4E-08 4E-08 -- -- 
OR51S1 ENST00000322101 11:4869427 6 -- -- -- -- 4E-08 -- -- 
OR51A4 ENST00000380373 11:4967355 8 4E-08 -- -- -- 4E-08 -- -- 
OR51A2 ENST00000380371 11:4976002 10 -- -- -- 4E-08 4E-08 -- -- 
OR52J1P ENST00000366371 11:5125383 6 -- -- 4E-08 -- 4E-08 -- -- 
HBB ENST00000335295 11:5246694 5 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 
HBB ENST00000380315 11:5246694 4 4E-08 -- 4E-08 4E-08 4E-08 4E-08 4E-08 
*RP11-
687M24.7 
ENST00000560744 11:125058011 5 4E-08 4E-08 4E-08 4E-08 -- 4E-08 4E-08 
*CATSPERB ENST00000557036 14:92047040 38 -- -- 4E-08 -- -- -- -- 
RHBDF1 ENST00000262316 16:108058 15 -- -- 4E-08 -- 4E-08 -- -- 
RHBDF1 ENST00000428730 16:108058 7 -- -- 4E-08 -- 4E-08 -- -- 
RHBDF1 ENST00000450643 16:108058 7 -- -- 4E-08 -- 4E-08 -- -- 
HBQ1 ENST00000199708 16:230452 7 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 
LUC7L ENST00000293872 16:238968 13 -- -- 4E-08 -- -- -- -- 
LUC7L ENST00000429378 16:238968 8 -- -- 1.5E-07 -- -- -- -- 
LUC7L ENST00000442701 16:238968 3 -- -- 4E-08 -- 4E-08 -- -- 
ITFG3 ENST00000301678 16:284545 12 -- -- 4E-08 4E-08 4E-08 4E-08 -- 
ITFG3 ENST00000399932 16:284545 12 -- -- 4E-08 2.0E-07 4E-08 4E-08 -- 
RGS11 ENST00000168869 16:318300 7 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 
RGS11 ENST00000316163 16:318300 20 -- -- 4E-08 -- 4E-08 -- -- 
RGS11 ENST00000359740 16:318300 19 -- -- -- -- 4E-08 -- -- 












PDIA2 ENST00000219406 16:333152 41 -- -- 4E-08 4E-08 4E-08 4E-08 -- 
PDIA2 ENST00000404312 16:333152 41 -- -- 4E-08 4E-08 4E-08 4E-08 -- 
PDIA2 ENST00000435833 16:333152 10 -- -- 4E-08 4E-08 4E-08 4E-08 4E-08 
TMEM8A ENST00000250930 16:420773 14 -- -- 4E-08 -- 4E-08 -- -- 
CAPN15 ENST00000219611 16:577717 27 -- -- 4E-08 -- 4E-08 4E-08 -- 
PIGQ ENST00000026218 16:616995 17 4E-08 4E-08 4E-08 4E-08 -- 4E-08 -- 
PIGQ ENST00000293874 16:616995 6 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 -- 
NHLRC4 ENST00000424439 16:616996 6 -- -- 4E-08 4E-08 4E-08 4E-08 -- 
NHLRC4 ENST00000540585 16:616996 6 -- -- 4E-08 4E-08 4E-08 4E-08 -- 
WDR90 ENST00000293879 16:699311 39 -- -- 4E-08 -- -- -- -- 
BAIAP3 ENST00000397488 16:1383602 23 -- -- 4E-08 4E-08 -- 4E-08 4E-08 
MEIOB ENST00000325962 16:1883984 11 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 4E-08 
TBL3 ENST00000561907 16:2022038 6 -- -- 4E-08 -- -- -- -- 
Chr:pos = chromosome and start site for respective transcript; vars = number of variants included in the transcript in its 
respective annotation file. * indicates gene with transcript start and end sites >500kb from a previously reported RBC 













Table 55. Deleterious annotation set transcripts significant in one or more RBC traits in 29,070 PAGE 
participants. 
Gene Transcript chr:pos vars HCT HGB MCH MCHC MCV RBCC RDW 
OR52R1 ENST00000356069 11:4824663 7 -- -- 4.0E-08 4.0E-08 4.0E-08 -- -- 
OR52R1 ENST00000380382 11:4824663 10 -- -- 1.2E-07 4.0E-08 4.0E-08 -- -- 
OR51A2 ENST00000380371 11:4976002 8 -- -- -- 4.0E-08 4.0E-08 -- -- 
*PPHLN1 ENST00000317560 12:42632249 4 -- -- -- -- -- 2.4E-07 -- 
*IGHV1-3 ENST00000390595 14:106471246 4 -- -- 1.2E-07 -- -- -- -- 
HBQ1 ENST00000199708 16:230452 3 -- -- 4.0E-08 4.0E-08 4.0E-08 4.0E-08 4.0E-08 
LUC7L ENST00000293872 16:238968 5 -- -- 4.0E-08 -- 1.6E-07 -- -- 
LUC7L ENST00000337351 16:238968 5 -- -- 4.0E-08 -- 4.0E-08 -- -- 
LUC7L ENST00000397780 16:238968 5 -- -- 4.0E-08 -- 4.0E-08 -- -- 
LUC7L ENST00000397783 16:238968 5 -- -- 4.0E-08 -- 4.0E-08 -- -- 
LUC7L ENST00000429378 16:238968 3 -- -- -- -- 4.0E-08 -- -- 
ITFG3 ENST00000301678 16:284545 5 -- -- 4.0E-08 4.0E-08 4.0E-08 4.0E-08 4.0E-08 
ITFG3 ENST00000399932 16:284545 5 -- -- 4.0E-08 4.0E-08 4.0E-08 4.0E-08 4.0E-08 
RGS11 ENST00000168869 16:318300 3 -- -- 4.0E-08 -- 4.0E-08 -- -- 
RGS11 ENST00000316163 16:318300 15 -- -- 2.4E-07 -- 4.0E-08 -- -- 
RGS11 ENST00000359740 16:318300 15 -- -- -- -- 4.0E-08 -- -- 
RGS11 ENST00000397770 16:318300 16 -- -- -- -- 4.0E-08 -- -- 
PDIA2 ENST00000219406 16:333152 22 -- -- 4.0E-08 -- -- -- -- 
PDIA2 ENST00000404312 16:333152 22 -- -- 4.0E-08 -- -- -- -- 
PDIA2 ENST00000435833 16:333152 7 -- -- -- -- 4.0E-08 4.0E-08 -- 
NHLRC4 ENST00000424439 16:616996 4 -- -- -- 4.0E-08 4.0E-08 4.0E-08 -- 
NHLRC4 ENST00000540585 16:616996 4 -- -- -- 4.0E-08 -- 4.0E-08 -- 
Chr:pos = chromosome and start site for respective transcript; vars = number of variants included in the transcript 
in its respective annotation file. * indicates gene with transcript start and end sites >500kb from a previously 











Table 56. Top variants and p-values by trait and transcript for CADD variant annotation set significant transcripts. 















































































































































































































































































































































































































































































































































































































Table 57. Top variants and p-values by trait and transcript for deleterious variant annotation set significant transcripts. 

























































































































































































































































































































































































Table 58. Allele frequencies for top variants within CADD annotation set significant transcripts. 
   Coded allele frequency 
Chr:Position rsid 
 






1:156606605 rs115920478  1.16E-02 1.86E-03 0 0 0 
1:156611030 rs115518359  2.04E-02 1.85E-03 0 0 0 
1:156611125 rs59938816  6.08E-03 7.64E-04 0 0 0 
3:10371218 rs191008721  1.82E-05 3.80E-03 0 0 0 
3:10428129 rs35855296  9.34E-04 1.75E-03 0 0.003 0.0112 
3:10448852 rs534601167  2.80E-04 3.37E-03 0 0.003 0 
3:10456310 rs145951267  3.30E-03 3.25E-04 0 0 0 
3:10525459 rs139071992  1.03E-02 1.63E-03 0 0 0 
3:10528178 rs115367728  1.11E-02 1.84E-03 0 0 0 
11:3115015 rs73413562  1.24E-02 1.66E-03 0 0.001 0 
11:3128508 rs142437471  3.07E-03 9.51E-04 0 0 0 
11:3128539 rs77195727  1.98E-02 5.25E-03 0 0 0 
11:3143609 rs6578323  1.98E-02 3.14E-03 0 0 0 
11:4665190 rs17223816  1.38E-03 3.13E-03 0 0.007 0 
11:4674652 rs149616162  1.87E-03 5.85E-03 0 0.0129 0 
11:4675880 rs142765915  1.79E-02 2.28E-03 0.001 0 0 
11:4799877 rs528043612  5.45E-03 1.23E-03 0 0 0 
11:4824752 rs61742567  8.66E-03 1.61E-03 0 0 0 
11:4825022 rs73403015  1.36E-02 5.55E-03 0.001 0 0 
11:4825233 rs75407816  1.36E-02 5.38E-03 0 0 0 
11:4840505 rs149126468  1.33E-02 6.23E-03 0 0.001 0 
11:4869718 rs115882083  8.81E-03 1.14E-03 0 0 0 
11:4870064 rs143546045  1.30E-02 5.76E-03 0 0 0 
11:4958925 rs146130616  7.51E-03 6.44E-03 0 0.001 0 













11:4968058 rs141671097  6.34E-03 1.75E-03 0 0.003 0 
11:4976897 rs80228945  2.09E-02 3.74E-03 0 0 0 
11:4976935 rs148063081  7.50E-03 4.73E-03 0 0 0 
11:4994513 rs115909008  7.50E-03 5.35E-03 0 0 0 
11:5131056 rs114819139  6.94E-03 9.74E-04 0 0 0 
11:5246870 rs113082294  9.88E-04 2.31E-03 0 0.007 0 
11:5248233 rs33930165  1.07E-02 1.95E-03 0 0 0 
11:125058682 rs11219958  2.20E-02 3.94E-03 0 0.001 0.002 
11:125059476 rs143258223  1.83E-03 4.31E-03 0 0.008 0 
11:125060810 rs112487047  2.74E-03 2.97E-04 0 0 0 
14:92075078 rs148993089  8.08E-03 1.18E-03 0 0 0 
16:113648 rs114597905  1.74E-02 2.54E-03 0.001 0 0 
16:114773 rs147906988  1.17E-02 2.46E-03 0 0 0 
16:230724 rs76613236  1.59E-02 3.99E-03 0 0 0 
16:231021 rs144961211  3.21E-03 6.36E-03 0 0.007 0 
16:240000 rs61743947  5.49E-03 6.59E-04 0 0 0 
16:240003 rs144911375  7.09E-03 9.32E-04 0 0 0 
16:309998 rs78001048  4.48E-04 9.24E-03 0.126 0 0.002 
16:314962 rs144091859  1.56E-02 3.90E-03 0 0 0 
16:319299 rs200125295  3.03E-03 2.97E-04 0 0 0 
16:320629 rs77654034  4.48E-04 1.19E-03 0 0.008 0 
16:324075 rs149201684  5.75E-03 9.32E-04 0 0 0 
16:324252 rs145112941  1.64E-03 4.66E-04 0 0 0 
16:336731 rs116969376  6.40E-03 4.45E-03 0 0.0089 0 
16:336898 rs199589252  1.90E-04 4.79E-03 0 0.001 0 
16:336909 rs45512400  1.55E-02 4.77E-03 0 0 0 
16:424251 rs148970260  5.61E-03 7.80E-04 0 0 0 
16:425238 rs144557907  3.36E-03 6.78E-04 0 0 0 












16:597150 rs74003979  1.04E-02 2.13E-03 0 0 0 
16:601533 rs141298471  8.28E-03 1.85E-03 0.001 0 0 
16:602364 rs199859872  1.25E-02 2.72E-03 0 0 0 
16:618214 rs200060251  0 3.18E-03 0 0 0 
16:624108 rs11864607  9.78E-03 2.16E-03 0 0 0 
16:624149 rs56293456  1.97E-02 5.51E-03 0.0079 0.001 0.0266 
16:706763 rs114236636  1.60E-02 2.55E-03 0 0 0 
16:709086 rs138126179  1.84E-02 3.83E-03 0 0 0 
16:712043 rs185839646  8.00E-03 1.08E-03 0 0 0 
16:1381905 rs528548462  4.19E-03 5.56E-04 0 0 0 
16:1392632 rs146826887  1.52E-04 4.31E-03 0 0 0 
16:1397810 rs574931188  1.22E-04 2.16E-03 0 0 0 
16:1906980 rs567425297  4.42E-03 5.59E-04 0 0 0 
16:1910418 rs143362679  1.49E-04 4.07E-03 0 0.003 0 
16:2024200 rs144902773  3.27E-05 3.02E-03 0 0 0 
16:2024263 rs146622601  3.26E-05 3.02E-03 0 0 0 
Chr:Position=chromosome and position in hg19; WHI AfAm = MEGA-genotyped WHI African Americans 
with RBC trait data; HCHSSOL = MEGA-genotyped HCHSSOL Hispanics/Latinos with RBC trait data; 
1000G EAS = 1000 Genomes phase 3 East Asian super population; 1000G EUR = 1000 Genomes phase 3 














Table 59. Allele frequencies for top variants within deleterious annotation set significant transcripts. 













8.66E-03 1.61E-03 0 0 0 
11:4976897 rs80228945 
 
2.09E-02 3.74E-03 0 0 0 
12:42853128 rs187632148 
 
3.29E-03 5.51E-04 0.001 0 0 
14:106471448 rs566505899 
 
6.34E-03 4.54E-03 0.001 0.001 0.0031 
16:230724 rs76613236 
 
1.59E-02 3.99E-03 0 0 0 
16:240000 rs61743947 
 
5.49E-03 6.59E-04 0 0 0 
16:314962 rs144091859 
 
1.56E-02 3.90E-03 0 0 0 
16:324075 rs149201684 
 
5.75E-03 9.32E-04 0 0 0 
16:336898 rs199589252 
 
1.90E-04 4.79E-03 0 0.001 0 
16:618214 rs200060251 
 
0 3.18E-03 0 0 0 
Chr:position= chromosome and position in hg19; WHI AfAm = MEGA-genotyped WHI African Americans with 
RBC trait data; HCHSSOL = MEGA-genotyped HCHSSOL Hispanics/Latinos with RBC trait data; 1000G EAS = 
1000 Genomes phase 3 East Asian super population; 1000G EUR = 1000 Genomes phase 3 European super 















Table 60. Association network of all genes significant for CADD or deleterious annotation sets. 
Gene Associated genes 
OR51E1 CATSPERB 
PIGQ HBB 
HBQ1 HBB, ITFG3, LUC7L 
FAM234A/ ITFG3 HBQ1, PDIA2, RHBDF1, RGS11, TMEM8A, LUC7L 
HBB HBQ1, RHBDF1 
RHBDF1 ITFG3, LUC7L RGS11, PDIA2, HBB, TMEM8A 
RGS11 ITFG3,  RHBDF1, PDIA2, LUC7L, TMEM8A 
TMEM8A ITFG3, RHBDF1, RGS11, LUC7L 
LUC7L ITFG3, RHBDF1, RGS11, PDIA2, HBQ1, TMEM8A,  
OR51S1 OR51A2, OR51A4, OR52R1 
OR51A4 OR51A2, OR52R1, OR51S1 
OR51A2 OR51A4, OR51S1 
OR52R1 OR51A2, OR51A4, OR51S1  
ATP2B2 PDIA2 
BAIAP3 PDIA2 
WDR90 PDIA2, CEP152, RAI1 
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Table 62. P-values that increased after conditioning on a single variant for transcripts 
significantly associated with one or more RBC traits in the deleterious annotation set. 
Gene Transcript 
Conditioned 
variant MCH MCHC MCV RBCC RDW 
PPHLN1 ENST00000317560 12:42853128 -- -- -- 3.2E-07 -- 
PPHLN1 ENST00000317560 12:42792671 -- -- -- 3.2E-07 -- 
LUC7L ENST00000429378 16:230724 -- -- 2.0E-07 -- -- 
LUC7L ENST00000429378 16:314962 -- -- 2.0E-07 -- -- 
LUC7L ENST00000429378 16:618214 -- -- 2.0E-07 -- -- 
RGS11 ENST00000316163 16:230724 4.0E-07 -- N/A -- -- 
RGS11 ENST00000316163 16:314962 4.0E-07 -- N/A -- -- 
RGS11 ENST00000316163 16:618214 4.0E-07 -- N/A -- -- 
RGS11 ENST00000316163 16:240000 4.0E-07 -- N/A -- -- 
RGS11 ENST00000359740 16:230724 -- -- 1.6E-07 -- -- 
RGS11 ENST00000359740 16:314962 -- -- 1.6E-07 -- -- 
RGS11 ENST00000359740 16:618214 -- -- 1.6E-07 -- -- 
RGS11 ENST00000359740 16:240000 -- -- 1.6E-07 -- -- 
RGS11 ENST00000397770 16:230724 -- -- 2.0E-07 -- -- 
RGS11 ENST00000397770 16:314962 -- -- 2.0E-07 -- -- 
RGS11 ENST00000397770 16:618214 -- -- 2.0E-07 -- -- 
RGS11 ENST00000397770 16:240000 -- -- 2.0E-07 -- -- 
N/A = p-value unchanged after conditioning for the respective trait. Note: HCT and HGB excluded from conditional 













7.1. Recapitulations of Specific Aims 
Red blood cell traits are highly complex, clinically relevant, and standardly measured, 
making them ideal for genetic association studies. Molecular characterization and 
experimentation in known red blood cell loci has already been productive in terms of clinical 
application, specifically with regard to anemias with known genetic causes143; 146; 147; 645-647. 
Although RBC biology is moderately well characterized, heritability estimates and suggest there 
are additional sources of genomic contribution to these traits31.  
Although over 500 loci have been convincingly identified for one or more RBC traits, 
previous studies faced multiple limitations. First, previous study populations have been primarily 
of European and East Asian ancestry; such studies are inherently unable to detect African- and 
Amerindian-specific variants unless the study populations are extremely large. Additionally, the 
design of early genotyping arrays made assessment of low-frequency and rare variants difficult, 
which limited the potential for fine-mapping loci of interest435; 495; 597; 648. Finally, while several 
published RBC trait GWAS have been well powered to detect genetic associations, heritability 
estimates suggest that there remain undiscovered genetic loci, motivating additional studies 
employing non-traditional GWAS methods.  
Therefore, the purpose of this doctoral research was to examine RBC traits in a sample 
more representative of the US population, with the aim of identifying previously unreported loci 




employed two different methodological approaches to analyze genotyped and imputed genetic 
variants. First, we assessed whether an anticipated increase in power from studies that leveraged 
correlation in RBC traits allowed for the detection of new RBC trait loci or improved fine-
mapping of known loci using a combined-phenotype approach. Next, we evaluated rare variants 
which traditional methods are underpowered to detect by using a gene-based method for two 
different variant annotation sets. 
We performed this research using data from participants of the Populating Architecture 
using Genomics and Epidemiology (PAGE) study consortium, which incorporates phenotype 
data and imputed genotyped data from participating biobanks and large national cohort studies of 
common complex diseases. RBC trait data was collected and calculated using hemanalyzers and 
standardized complete blood count methods in study-specific labs and harmonized within PAGE, 
and relevant lifestyle and clinical risk factors were collected via interview at the same study visit 
as recorded blood draws. Genotype data were cleaned using standardized quality control 
procedures and imputed to 1000 Genomes Phase III data by the PAGE study coordinating center. 
 
7.2. Main Findings 
We performed these study objectives in up to 68,000 participants of the PAGE study, 
although the number of participants varied by trait. In the first manuscript, we reported 39 loci 
with over 50 independent association signals, with evidence that our findings in conditional 
analyses were due in part to our ancestrally diverse study population. In the second manuscript, 
we identified four discovery loci, demonstrating the relevance of allowing for multiple 
functional-group scenarios to maximize findings in gene-based testing. Both studies showed 




being significant for more than one trait. Our primary findings emphasize the complexity of RBC 
traits by revealing multiple independent signals at several known loci which cannot be 
comprehensively evaluated in European populations. This work also strongly supports the 
expectation, based on previous molecular and population-based studies, that RBC traits share an 
underlying genetic architecture.  
With regard to individual common or low-frequency variants, we found evidence of 
allelic heterogeneity at 19 previously reported loci, confirming independent associations at 
multiple loci that have been previously reported in European-ancestry populations. Within the 
HBA1/2 region, we found 14 conditionally independent associations, 11 of which were 
undetectable in European-ancestry populations, and four of which exhibited independence from a 
known 3.7kb deletion in sensitivity analyses18.  
Our gene-based results also found a large number of transcripts within previously 
reported RBC trait GWAS loci, unsurprisingly given the overlap in study population. Notably, 
we identified four previously unreported genes across all seven traits. We found moderate 
overlap between transcript associations for annotations representing only deleterious coding 
variants versus including regulatory variants, suggesting the benefit of testing multiple types of 
groups for genome-wide gene-based testing. Of 75 lead variants for one or more RBC traits 
within 49 significantly associated transcripts, over 75% were monomorphic in the 1000G EAS, 
EUR, and SAS populations, exemplifying the benefits of study populations including African- 






The PAGE study provided an appreciable improvement in ancestry representation 
compared to previous RBC trait genetics studies. The benefits of an inclusive study population 
involve both improved equity in application of results and improved detection of rare and 
ancestry-specific variants. The ability to measure and evaluate variants that are present in 
African- or Amerindian-ancestry populations but extremely rare or monomorphic in Europeans 
allowed us to detect multiple conditionally independent variants at the HBA1/2 locus in our first 




Our study faced limitations common to genetic analyses of complex traits as well as 
several unique to our analyses. First, several RBC trait GWAS, while not benefitting from the 
methods employed herein, exceeded our study population by tens of thousands of participants, 
which provides an increase in statistical power that we could not match, particularly with the 
gene-based study. Additionally, while our study population improved representation of global 
ancestries compared with previous work, we could not include proportionally representative 
numbers of Native Hawaiians, Pacific Islanders, and Native Americans due to limited phenotype 
data availability, preventing the generalizability of our findings to those groups. We could not 
evaluate low-frequency insertion/deletion variants in our first study, which precluded 
determining whether our lead variants are truly independent of known in/dels. Finally, 
comprehensive characterization of genetic associations requires information on the likely 




available databases having limited availability of relevant data with regard to both tissue type 
and non-European ancestry genetic variation429; 521. 
 
7.5. Overall Conclusions 
Our study results reinforce the benefits of inclusive study design and considering 
methods outside of the arena of traditional GWAS. Over 50 previously reported loci met 
genome-wide significance criteria between the results of both studies, reaffirming the association 
of these loci with RBC traits and calling for additional characterization where it has not yet been 
performed. Particularly regarding loci affected by evolutionary selection in malaria-endemic 
regions with variants known to cause monogenic anemias such as the HBA1/2 locus, our results 
suggest further work remains to successfully identify functional regulatory variants in this 
region. Additionally, our identification of multiple genes supports further examination in a 
molecular context which can elucidate any potential biological mechanisms underlying RBC 
traits.  
Overall, our findings demonstrate that complex traits known to be highly polygenic can 
continue to be characterized via a suite of methods that account for the complete range of genetic 
variation, and that diverse study populations are required for a comprehensive study. Given the 
recent advances in gene-therapy with regard to monogenic blood disorders, all approaches that 
improve characterization of known loci or can identify new candidate functional genes or 
variants should be considered. Findings from both of our studies strongly support the continued 
call for increased representation in publicly available expression and functional databases. 
Additional work is merited to characterize our discovery genes and ancestry-specific variants to 
determine potential function within RBC development and maintenance.   
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APPENDIX: AN INTRODUCTION TO BASIC GENETIC PROCESSES 
All of the processes discussed in this section are portrayed with relevant causal 
relationships in Figure S1. DNA is the beginning molecule for all known coded proteins, making 
it an obvious source of differences in gene products due to genetic variation. Genetic variation 
occurs naturally in every individual from conception through death. Mutations occur during 
meiosis at an average rate of approximately 1x10-8 (approximately 320 per genomic replication), 
whereas somatic mutations have been suggested to occur more frequently649; 650. For a mutation 
to become established within a population, it must:  
1. occur initially as a germline mutation (in order to be heritable);  
2. not preclude reproduction (i.e., the variant cannot cause fatal disease at a prepubescent 
age); and 
3. spread through the population over generations via sexual reproduction.  
Evolutionary selective pressure can shorten the timeframe for a particular variant (as can be seen 
at several mutations at the receptor site in duffy antigen receptor gene, or DARC, which is 
associated with malarial resistance in heterozygotes, which are only found in individuals of 
recent African ancestry)149; 651. This becomes significant when the locus affected by selective 
pressure also affects a physiologic state, either in heterozygotes or (more commonly for 
deleterious phenotypes) homozygotes62; 65; 122; 125; 126; 548; 652. 
Several types of variants affect gene sequences, and these variants may be inherited 
through the germline or occur spontaneously during meiosis after conception. The primary forms 
of genetic variation discussed in this proposal include simple-nucleotide polymorphisms (SNPs, 
also sometimes referred to in other publications as "single nucleotide polymorphisms") 




affect proper expression and maintenance of gene products include chromatin structural 
alterations and epigenetic changes (histone modification or DNAm) that may cause expression 
changes in transcripts with identical genetic sequences (see below). Here we provide a broad 
overview of an extremely complex system with literally hundreds of thousands of processes 
constantly being modulated in each cell in the body.  
 
8.1.   Transcription  
In order for a segment of genomic sequence to eventually become a protein, it must first 
be transcribed from the DNA sequence into messenger RNA (mRNA), which contains the 
nucleotides from which the final protein product can be translated. Note: mitochondrial DNA 
sequence changes can also effect changes in RBC traits, but that is outside the scope of this 
work. Perhaps the best-characterized disease-related genetic changes are coding variants (or 
genetic variants falling in exons), which change the mRNA sequence. Coding changes lead to 
either the same amino acid sequence (synonymous), a changed amino acid sequence 
(nonsynonymous), or an early stop codon (or "premature termination codon", PTC) for the 
resulting protein product. Synonymous coding changes were long considered "silent mutations," 
but evidence has recently come to light that such changes can affect translation by changing the 
post-transcriptional or "secondary" structure of the mRNA653-655. Nonsynonymous changes can 
cause structural changes in the final protein, affect the binding-site affinity at receptor sites, or 
prevent localization of the protein to the appropriate cell structure. PTCs lead to the protein 
product being terminated prematurely during translation, which in turn can cause the product to 
function poorly or be targeted for degradation in the proteasome. Coding variants primarily 
affect the gene in which the variant occurs (exceptions to this general rule have been seen in 




658. The vast majority of genetic disorders that were characterized before the GWAS era were 
identified via candidate-gene studies which identified coding mutations, primarily for monogenic 
disorders but also more recently for highly polygenic diseases such as cancers320; 321.  
 
8.2.   Intronic/intergenic variation 
A large number of cellular processes are also affected by non-coding genetic variants 
involved in regulation due to the disruption of transcription factor binding or other indirect 
regulatory mechanisms469. Work in HaploReg and the GTex consortium has led to estimates that 
a large proportion of variability for complex traits in humans is attributable to regulatory 
mechanisms of gene expression429; 469; 481; 659-661. Noncoding variants in enhancer-, promoter-, 
intronic-, and intergenic regions can affect transcription-factor binding capacity, DNA 
methylation (described below), or chromatin accessibility. These types of variation affect the rate 
and volume of transcription, and can vary by cell type if the gene is differentially expressed by 
tissue307. For example, constitutively expressed tissue-specific transcription factors (TFs) are 
frequently involved in the promotion or repression of gene transcription, and disruption of TF 
binding will likely affect the efficiency of mRNA transcription. Consensus sequence specificity 
varies by TF, with binding by TFs requiring high specificity being more dramatically affected by 
changes in relevant consensus sequences660; 662; 663.  
Splice-site variation in particular merits discussion as a type of noncoding mutation that 
can exhibit a large effect on the final gene product. Variation within or proximal to the splice 
nucleotide can lead to exon skipping; inappropriate inclusion of introns in the mRNA (which 
may subsequently cause the mRNA to be targeted for NMD); or isoform switching, all of which 




inclusion of nucleotides does not lead to the final mRNA being out of frame, the resulting 
protein product is likely to suffer from misfolding in the tertiary structure. Of note, PTCs may be 
introduced by exon skipping or intron inclusion, leading to truncated protein products. 
Spliceosome variation can contribute to dramatic changes in the level of transcript available for 
translation in any cell type. However, RBCs in particular are vulnerable to the effects of splice 
variants because post-enucleation translation is minimal, meaning defective transcripts cannot be 
replaced in mature RBCs665. 
 
8.3.   Epigenetic modification 
While nucleotide variation is relatively straightforward to measure and observe, 
accessibility of the DNA is required for transcription, and this is tightly controlled by epigenetic 
processes in every tissue type. Some of the recently characterized epigenetic marks are heritable, 
and all of them can affect gene expression, primarily by affecting accessibility to coding regions. 
Several of these processes are described briefly below, primarily to demonstrate how epigenetic 
mechanisms may contribute to the concept of “missing heritability”, or the idea that the observed 
proportion of population-level variability is lower than expected based on heritability 
estimates339-341; 354. 
8.3.1. DNA methylation 
DNA methylation refers to the addition of a methyl group to a cytosine preceding a 
guanine residue (cytosine-phosphodiester-guanine or CpG) by DNA methyltransferase. This 
chemical bond is heritable (i.e., it is maintained through DNA replication during mitosis), and is 
most commonly associated with repression of transcription by altering the consensus sequence of 




DNA methylation to occur (obtained via methyl donors such as choline or S-Adenosyl 
methionine), which can be obtained readily through diet, particularly in countries with foods 
fortified with iron and folate118; 227; 667; 668. DNA methylation is responsive to environmental 
exposures such as cigarette smoking, pollution, diet, and even high altitudes, risk factors which 
are also strongly associated with RBC traits 669-672. CpG sites occur throughout the genome, and 
mechanisms by which methylation sites are selected have not been fully elucidated673; 674. This 
modifiable form of structural alteration, which does not change the underlying DNA sequence, 
can change the effect magnitude of a SNP and therefore play a role in allelic heterogeneity, 
particularly when the variant changes from an A/T to C/G pair675. DNA methylation can 
therefore be important for highly regulated gene transcripts—slight reduction in binding capacity 
for a tissue-specific transcription factor can dramatically affect the amount of protein end-
product675-677.  
8.3.2.  3D chromatin structure 
Unraveled, the human chromosomes lined up would be approximately six feet long. The 
genetic sequence must be maintained across thousands of mitotic divisions over the life course, 
and environmental stresses can lead to double-stranded DNA breaks which are repaired at an 
impressive but imperfect rate. Gene expression necessarily varies by cell type, often dramatically 
with the exception of a suite of constitutively highly expressed "housekeeping" genes. 
Euchromatin refers to open stretches of chromatin, which are more accessible for the cellular 
machinery required for transcription, whereas heterochromatin, is inaccessible or has limited 
accessibility for transcription, usually because it is more densely packed678. Similar to genetic 
variants that ablate or constitutively activate transcription of a particular gene, abnormal changes 




cell function, premature apoptosis, or tumorigenesis679; 680. Related to overall 3D structure of the 
chromatin at a given genomic region are DNAseI-hypersensitivity regions (also referred to as 
DHS sites), or short, often cell-type-specific, sequences which are particularly susceptible to 
cleavage by the enzyme DNAseI681. These sites indicate of euchromatin areas that are highly 
transcribed678. Given the dramatic increase in chromatin condensation with each stage of RBC 
differentiation during erythropoiesis, culminating in nuclear- and organellar extrusion directly 
prior to terminal differentiation, genetic variation that affects chromatin structure is particularly 
relevant to RBC traits94; 682; 683.  
8.3.3. Histone modification 
Nucleosomes are octameric complexes comprising four histone dimers (named H2A, 
H2B, H3, and H4), which are proteins coded in the cell, around which 145- to 147-nucleotide 
segments of DNA are wrapped to condense chromatin that is not being transcribed. Maintenance 
of the DNA surrounding nucleosomes is controlled in part by the molecules binding to the tails 
of the histones, which—unlike the bodies of the histones—are accessible for modification in the 
nucleoplasm679; 684; 685. Methylation, acetylation, ubiquitination, and other molecular 
modifications of amino acids (frequently lysine resides) in the histone tails can affect repression 
or promotion of gene expression in the proximal DNA sequence684. Modification can be 
measured by cross-linking proteins bound to DNA from the tissue type of interest and 






8.4.   Other genetic processes  
The molecular processes occurring between RNA transcription and the folded protein 
also play a large role in the amount of final protein product. Post-transcriptional regulation, 
mRNA secondary structure, nonsense-mediated decay, and microRNA binding have all been 
demonstrated to play important roles in successful as well as aberrant erythropoiesis. The 
complex interaction of all these mechanisms highlighting the importance of considering how 
genetic variation may alter gene function in the context of epigenetic marks as well as the direct 
consequence of a nucleotide change on gene transcription690.  
8.4.1. MicroRNA 
First identified in the early 1990’s, microRNAs (22- to 24-nucleotide single-stranded 
RNAs which are also coded from DNA) have been found to be highly involved in post-
transcriptional regulation by binding to a 3’UTR consensus sequence of one or multiple 
mRNAs691. Correct functioning of this regulatory mechanism helps explain why the amount of 
transcription does not correlate 1:1 to protein translation. For example, while microRNAs are 
typically consider to function as translational repressors, recent efforts have demonstrated cases 
in which they act to stabilize mRNAs, which can then be translated multiple times prior to 
degradation692-696. Conversely, translation of mRNAs that are constitutively transcribed may 
depend heavily on post-transcriptional mechanisms such as microRNA binding and targeting to 
nonsense-mediated decay to avoid excess protein product83; 697; 698. To further complicate this 
regulatory mechanism, recent work demonstrates that microRNAs coded in one cell can be 
transferred to another cell via microvesicles, suggesting intercellular translational regulation 




Over the past decade, increasing interest has been shown in the function of microRNAs—
particularly with regard to exchange via extracellular vesicles—in erythropoiesis and 
homeostasis623. MicroRNAs are highly differentially expressed by stage of erythryopoiesis. In 
HSCs, a group of miRNAs repress erythropoietic genes (and hence continue to replenish the pool 
of HSCs in bone marrow). In committed but immature erythrocytes, miRNAs repress 
proliferation, which allows for increased transcription and translation of hemoglobin700. During 
the last stage of differentiation, one group has demonstrated the downregulation of miR191 in 
mice as playing an important role in the nuclear extrusion process701. While a reference database 
of quantitative microRNA sequencing data in different tissue types is not currently publicly 
available, the role these molecules play in gene regulation in erythropoiesis and during the life of 
the RBC is undeniable. For this reason, the coding sequences for microRNAs should therefore be 
under consideration during bioinformatic analysis of primary GWAS results.  
8.4.2. Post-translational modification  
Post-translational modification and mechanisms involved in protein maintenance can also 
affect the amount of functional protein in a cell. Faulty protein products—for example, 
membrane proteins that fail to be targeted to the membrane or shortened proteins that don't 
successfully fold into the required tertiary or quaternary structure—have been shown to be 
cleared with haste from the cytoplasm702; 703. Efficient clearance is also noteworthy because 
normal protein turnover is required for cell health and function, and genetic variants affecting the 
ability of proteins to be degraded can lead to poor performance of related pathways704-707. For 
example, “wobble bases” in the mRNA sequence are partially responsible for the secondary 
structure of the RNA and hence stability of the transcript for translation, but prediction of these 




will not be detectable in a population-based genotyping analysis without further molecular 
analysis, but implications for failure to undergo correct post-translational modification can be 



























Figure 16. Molecular processes involved in gene transcription, mRNA translation, and 
detected amounts of products from those processes (prepared by Hodonsky, 2017) 
Boxes outlined in blue indicate processes that can be directly affected by a genetic variant and would therefore be detectable 
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